[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Energetiq Technology Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":397},{"warningLetters":4,"total":396},[5,31,55,76,97,120,141,159,177,194,210,230,249,271,289,308,324,336,356,378],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},826,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-06-17T04:00:00Z\">06\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-09T04:00:00Z\">06\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freset-technology-corporation-704828-06092025\">Reset Technology Corporation\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark Teufel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Acting CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Reset Technology Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4200 West Royal Lane, Suite # 125\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irving\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75063\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 704828\u003C\u002Fp>\u003Cp>June 9, 2025\u003C\u002Fp>\u003Cp>Dear Mark Teufel:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Englewood Cliffs, NJ, from October 29, 2024, through December 20, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ResetSmile Partial Denture Device and the at-home ResetSmile Impression Kit Device. The ResetSmile Partial Denture Device is a removeable dental appliance used to replace missing teeth and the ResetSmile Impression Kit Device is an impression kit used to help make the removeable dental appliance. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Mr. Justin S. Marks, VP Clinical Operations\u002FQuality Representative, in an email dated January 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fp>\u003Cp>Specifically, you failed to define and document procedures for process validation. For example, you have no objective evidence that the following manufacturing and cleaning processes for your ResetSmile Partial Denture Devices, for which specifications such as anatomical features, mechanical strength, or residue removal cannot be verified without \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, consistently produce a result or product that meets predetermined specifications with a high degree of assurance:\u003C\u002Fp>\u003Cp>a. \u003Cu>Scanning and CAD Design\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Scanner to generate an initial 3D scan of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to develop the patient-matched CAD design from the above 3D scan of the model cast but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>b. \u003Cu>3-Dimensional (3D) Printing\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software to 3D print your ResetSmile Partial Denture Device based on the above CAD design but have no documented validations which establish the process parameter settings (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications alongside your intended use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software application.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer; \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers; or \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers to 3D print the mold to trial fit your ResetSmile Partial Denture Device but have no documented validations which establish the process parameters (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications.\u003C\u002Fp>\u003Cp>c. \u003Cu>Post-printing Quality Control (QC) Validation (i.e., Test Method)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software, as a part of finished device acceptance, to identify conforming and nonconforming areas for your finished device through comparison of the overlay of the 3D scan of your ResetSmile Partial Denture Device (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) with the initial 3D scan (via \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Scanner software) of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>d. \u003Cu>Cleaning\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to remove manufacturing material (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) applied to your ResetSmile Partial Denture Device prior to the Post-printing QC Validation above but have no documented validation that establishes the process parameter settings (e.g., clean time, water quality, degassing time, bath cycle, etc.) under which your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is able to consistently meet predefined specifications for cleanliness.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> clean your ResetSmile Partial Denture Device after \u003Cstrong>(b)(4)\u003C\u002Fstrong> but have no documented validation that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner is able to consistently meet predefined specifications for cleanliness.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You state process validations are not required as they have already been performed as part of the regulatory process for the FDA cleared materials used in your devices. You also state that you use FDA listed 3D scanners and computer assisted design and manufacturing (CAD\u002FCAM) software to manufacture each patient specific device (which has been validated by the manufacturer as part of their regulatory process) and that internal validation and verification of the patient specific device is performed as part of the QC Validation Process to ensure that the partial denture fits the patient model since each product has different patient specifications. As such, no corrective actions were identified. However, it is unclear how you are able to ensure (1) that predetermined specifications are consistently met with a high degree of assurance during the scanning, 3D printing, and post-printing quality control process steps described above for your ResetSmile Partial Denture Devices without validation of the software workflow for its intended use according to an established protocol with predefined acceptance criteria and (2) quality for all devices built in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle, \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines, where the results of a process (output specifications) cannot be fully verified by subsequent inspection and test. In addition, you did not provide a response on how you plan to address the lack of cleaning validations for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning processes to ensure that manufacturing material is able to be consistently removed, with a high degree of assurance, from your devices which present challenges for residue removal due to the complex geometry prevalent with such devices (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> with limited or no access, etc.). Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, the \"Control of Nonconformity Process\" procedure (8300-01; Rev.0; Effective: 10\u002F25\u002F24) and \"Non-Confirming Material Report\" form (8300-01-01; Rev.0; Effective: 10\u002F25\u002F24), which were implemented after the preannouncement of the FDA inspection on 10\u002F24\u002F24, are inadequate in that there are no requirements to document:\u003C\u002Fp>\u003Cp> Nonconformances in sufficient detail to describe what failed to meet specification(s);\u003Cbr> Evaluations of nonconformances to determine the need for investigations; and\u003Cbr> Dispositions of nonconformances.\u003C\u002Fp>\u003Cp>For example, there were no descriptions, evaluations for the need for investigations, and dispositions documented for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases of nonconforming product identified on the \"Internal Remakes log\" from 2\u002F2\u002F22 to 10\u002F28\u002F24 under three general categories: \"Failed print\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases); \"Fabrication error\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases); and \"Failed QC\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases).\u003C\u002Fp>\u003Cp>We reviewed your firm's response and concluded that it is not adequate. You plan to create a new procedure to include the definition of a nonconformance, visual identification of nonconforming product, and disposition instructions; develop a new disposition log; perform a statistical analysis of the rework cases to determine if additional corrective actions are needed; and schedule training on updated procedures under corrective action report # CA011 around January 31, 2025. However, you have not identified any corrective actions to ensure that (1) your procedures and forms require that nonconformances are recorded in sufficient detail to include what failed to meet specification(s) to allow determination of potential causes and evaluations of nonconformances to determine the need for investigations and (2) retrospective review of nonconformances, for a reasonable period of time, to document what failed to meet specifications, conduct evaluations to determine the need for investigations, and record dispositions. In addition, please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for rework, including retesting and reevaluation of the nonconforming product after rework to ensure that the product meets its current approved specifications and documentation of rework and reevaluation activities, including determination of any adverse effect from the rework upon the product, in the device history record (DHR), as required by 21 CFR 820.90(b)(2).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to define and document procedures for rework which include requirements to retest and reevaluate reworked devices and document the rework and reevaluation, including adverse impact assessments on reworked devices, in the DHR. Per your VP of Clinical Operations and head Dental Technician, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of manufactured ResetSmile Partial Denture Devices undergo final adjustment (rework) during the Final Quality Control (QC) step of the \"Quality Control Validation Process\" (7506-01; Rev. 0; Effective: 2\u002F19\u002F24) which states that upon completion of the scan of the finished device, where \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas indicate the need for readjustment, \"\u003Cem>***the finished device is brought to the quality control technician for final QC analysis, including possible adjustments, and cleaning***\u003C\u002Fem>.\" All eleven (11) scans of the ResetSmile Partial Denture Devices reviewed (lot #: 20022199; 20023601; 20023705; 20024773; 20025934; 20026261; 20026272; 20026352; 20021720; 20018940; 20021572) revealed that these initial scans evaluated during the final QC step contained \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas which required adjustment. However, none of the readjustments for these devices were treated as reworks which would require additional rescans and retention of the scans to confirm specifications are met before release and documented assessment of any adverse effects.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and concluded that it is not adequate. You state the QC Validation Process (7506-01) is designed to identify and adjust potentially ill-fitting partial dentures prior to delivery to the dentist and consumer which surpasses requirements of the regulation and is in contrast to relying on the prescribing dentist to perform their own post-delivery adjustments, which is a universally accepted method. As such, no corrective actions were identified. However, your firm is not meeting the requirements of 21 CFR 820.90(b)(2) with regards to the handling of adjustments (reworks). Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>4. Failure to adequately investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to investigate or adequately investigate complaints alleged to not meet specifications, as noted in the following examples:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 22952 (lot # 20021720) dated 6\u002F26\u002F24\u003C\u002Fu>: \"\u003Cem>***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>You responded to customer by sending an adjustment kit to the patient. However, there was no documented investigation into what may have caused or contributed to the device thickness.\u003C\u002Fp>\u003Cp>ii. \u003Cu>Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F24\u003C\u002Fu>: \"\u003Cem>***The partials don't t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don't fit properly***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>You requested photos and information on experienced issues from the customer and sent another impression kit to the patient for a remake. However, there was no documented investigation into what may have caused or contributed to the device fit issues.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. Your firm plans to assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR under corrective action report # CA013 around January 31, 2025. However, there were no corrective actions identified to retrospectively review and evaluate complaints, for a reasonable period of time, to determine (1) the need for an investigation (including justification when an investigation was not needed) and (2) definitively investigate any complaints which allege failures of your device, labeling, or packaging to meet any of its specifications. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>5. Failure to adequately maintain complaint files and adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your \"Complaint Handling Process\" procedure (8202-01; Rev.0; Effective: 6\u002F22\u002F22) is inadequate in that it fails to:\u003C\u002Fp>\u003Cp>a. Outline the criteria for when your follow-up questionnaire should be sent to complainants. For example, you emailed customers questionnaires (uncontrolled), which listed questions such as “\u003Cem>***Can you feel any roughness or sharp edges on the device that are contributing to sore spots in your mouth?***\u003C\u002Fem>” or “\u003Cem>***Does the device feel like it is placing too much pressure on the gums? In any specific area or overall tightness?***\u003C\u002Fem>” to attempt to obtain details on customer experienced issues for Complaints # 21161 (lot # 20026782) and # 56207 (lot # 20027010) but not for the following complaints:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 22952 (lot # 20021720) dated 06\u002F26\u002F2024\u003C\u002Fu>: “\u003Cem>***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cem>Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F2024\u003C\u002Fem>: “\u003Cem>***The partials don’t t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don’t fit properly***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>b. Ensure that complaints include evaluations of whether they represent events which require reporting to the FDA under 21 CFR 803 (Medical Device Reporting) based on sufficient information obtained from customers to determine whether the complaints meet the definition of MDR reportable events. For example, your VP of Clinical Operations acknowledged that none of your complaint records included documented evaluations on whether the complaints were reportable, including Complaints # 22952 and # 55465 above as well as the following:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 21161 (lot # 20026782) dated 10\u002F14\u002F24\u003C\u002Fu>: “\u003Cem>***The bottom is so tight, I have damaged the inside of my mouth after just one attempt. I tried again but my mouth was to [sic] sore.” The patient also stated that the device was “painful to clip in, cut me in the front of my lower teethbottom [sic]”. Your firm responded by sending an impression kit to the patient for a remake***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cu>Complaint # 56207 (lot # 20027010) dated 10\u002F23\u002F24\u003C\u002Fu>: “\u003Cem>***the bottom teeth are coming on contact with the partial causing it to move. This friction is very painful and has caused blistering… The pain that I feel goes from pressure to scratching to stabbing***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You plan to add the definition of a complaint to your MDR and complaint procedures; include a section for MDR evaluations to the complaint form; assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR; and provide training on the revised processes under corrective action report # CA013 around January 31, 2025. In addition, you reported that none of the 1,840 complaints as of 11\u002F21\u002F24 were MDR reportable. However, there were no corrective actions identified to ensure uniformity of the complaint process by establishing criteria for when complainants are sent questionnaires and ensure that sufficient information is requested from customers to determine whether complaint events meet the definition of MDR reportability under 21 CFR 820.3(o). Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your \"Corrective &amp; Preventive Action (CAPA) Process\" (8502-01; Rev. 0; 6\u002F22\u002F22) and \"Quality Objectives Management\" (5401-01; Rev. 0; 10\u002F7\u002F24) procedures are inadequate in that:\u003C\u002Fp>\u003Cp>a. 8502-01 (nor any other procedure) does not require internal remakes of your ResetSmile Partial Denture Devices, arising from issues during manufacturing, as inputs into the CAPA process to identify existing and potential causes of nonconforming product or other quality problems, as required by 21 CFR 820.100(a)(1). For example, you remade 64 devices during the month of October 2024 due to issues categorized as failed 3D printing, fabrication errors, and failed quality control but none of this data was analyzed to identify existing and potential causes of nonconforming product or other quality problems.\u003C\u002Fp>\u003Cp>b. Neither 8502-01 nor 5401-01 require appropriate statistical methodology to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example, you only evaluate complaint data by determining whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> percentage of rework (defined as the sum of adjustments kits, remakes, and refunds sent to customers divided by the number of customer orders received for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>) exceeds \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. However, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> percentage of rework calculation includes non-quality data such as refunds and lots which are different that the lots ordered for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, you do not employ appropriate statistical methodology to any of your complaints, loosely categorized as \"issue with fit in mouth;\" \"design preference;\" \"incorrect bite\u002Focclusion;\" \"fabrication error;\" \"product not aesthetically pleasing;\" \"issue with fit on model;\" \"unknown;\" and \"wrong tooth shade,\" to detect recurring quality problems.\u003C\u002Fp>\u003Cp>c. 8502-01 does not require verification or validation of the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example, you did not verify or validate that the corrective action identified under CAPA # 002 (corrected date of 11\u002F6\u002F23) to use adjustment kits, to address the observed increase in adjustments and remake rates from fit issues, were effective and did not adversely affect your ResetSmile Partial Denture Devices prior to sending them to customers.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You clarify that the quality data analysis is performed as part of the \"Quality Objectives Management\" (5401-01 Rev. 0) and \"Management Review\" (5600-M1 Rev. 0) processes and that there were no trends noted between May to October 2024 for the three (3) weeks where the value for percentage for rework was above \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As such, no corrective actions were identified. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>7. Failure to establish and maintain procedures to adequately control environmental conditions, which could reasonably be expected to have an adverse effect on product quality and periodically inspect the environmental control system to verify that the system, including necessary equipment, is adequate and functioning properly, as required by 21 CFR 820.70(c).\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>a. You failed to define and document procedures to control environmental conditions for your production area consisting of \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers, used to manufacture your ResetSmile Partial Denture Devices. For example:\u003C\u002Fp>\u003Cp>i. On 11\u002F6\u002F24, the investigator observed out of specification temperatures of 92.3℉ (33.50℃) and 92.4℉ (33.56℃) on two separate temperature and humidity monitors, which were above the \"Environment Requirements\" of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℃ specified in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide.\" In addition, the humidity value for one of the monitors was below the requirement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in this same guide. These out of specification values affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> production lots that were being printed across \u003Cstrong>(b)(4)\u003C\u002Fstrong> different \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers at the time.\u003C\u002Fp>\u003Cp>ii. On 11\u002F19\u002F24, the investigator also observed an out of specification temperature of 95.1℉ (35.06℃) and 14.4% humidity on one temperature and humidity monitor, which were outside the temperature (\u003Cstrong>(b)(4)\u003C\u002Fstrong>℃) and humidity (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) ranges specified in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide.\" This out of specification temperature and humidity affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> production lots that were being printed across \u003Cstrong>(b)(4)\u003C\u002Fstrong> different \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers at the time.\u003C\u002Fp>\u003Cp>Moreover, you do not regularly log the temperature and humidity values or regulate the temperature in the production area.\u003C\u002Fp>\u003Cp>b. You failed to periodically inspect your temperature and humidity monitors to ensure that they are suitable for their intended use and calibrated or evaluated for accuracy.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to calibrate your temperature and humidity sensor; set up alerts when values exceed specified requirements; control ambient humidity and temperature of the room; and develop an \"Environmental Requirements\" procedure under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\u003C\u002Fp>\u003Cp>8. Failure to ensure that all equipment used in the manufacturing process meets specified requirements and is appropriately designed, constructed, placed, and installed to facilitate maintenance, adjustment, cleaning, and use, as required by 21 CFR 820.70(g).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to meet specified placement requirements for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers, which are used to manufacture your ResetSmile Partial Denture Devices. For example, on 11\u002F19\u002F24, the investigator observed that the distance between the sides of 3D printers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> was approximately 8 cm and the distances between the corresponding \u003Cstrong>(b)(4)\u003C\u002Fstrong> and backs of 3D printers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were approximately 5.5 cm and 6 cm, respectively, which are all below the specified placement requirements noted in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide\" which requires that \"\u003Cem>***the distances of the left, right and back [sic] side space should be at least 20cm***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to rearrange the printers and printer racks to accommodate the recommended spacing guidelines in the manufacturer's instructions for use; reposition the \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and document these parameters in \"Environmental Requirements\" under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\u003C\u002Fp>\u003Cp>9. Failure to establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, including documentation of training, as required by 21 CFR 820.25(b).\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your \"New Hire\u002FTraining of Personnel Process\" (SOP 6202-01; Rev. 0; Effective: 6\u002F17\u002F24) which requires both acknowledgment of training on the \"Training Acknowledgment Form\" (6202-01-04; Rev. 0; Effective: none) and identification of training needs by the senior manager on the \"Training Needs Assessment\" form (6202-01-03). For example, there were no training forms completed for the following procedures:\u003C\u002Fp>\u003Cp> \"Control of Nonconformity Process\" (SOP 8300-01; Rev. 0; Effective: 10\u002F25\u002F24)\u003Cbr> \"Complaint Handling Process\" (SOP 8202-01; Rev. 0; Effective: 06\u002F22\u002F22)\u003Cbr> \"Internal Rework Process\" (SOP 8304-01; Rev. 0, Effective: 6\u002F22\u002F24)\u003Cbr> \"External Rework Process\" (SOP 8304-02; Rev. 0, Effective: 6\u002F22\u002F24)\u003C\u002Fp>\u003Cp>In addition, there was no documented training on the 6201-01-04 form from before 10\u002F28\u002F24, which is between the dates of preannouncement (10\u002F24\u002F24) and the start of the inspection (10\u002F29\u002F24) for procedures such as (but not limited to) \"QC Validation\" (7506-01), \"Device Fabrication\" (7501-01), and \"Calibration Process\" (7600-01). This applies to \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees, including your VP of Clinical Operations; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Customer Service Representatives; \u003Cstrong>(b)(4)\u003C\u002Fstrong> CAD Technician; \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printing Technicians; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Technicians; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Lab Technicians; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Shipping\u002FReceiving personnel.&nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to conduct a review in which 6202-01-03 will be completed for all employees and additional training will be scheduled for all affected personnel for procedures noted, including completion of the 6202-01-04 form under corrective action report # CA014 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA014, and any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your ResetSmile Partial Denture Devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit any report required within 10 working days of initiating a correction or removal, initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR 806.10.\u003C\u002Fp>\u003Cp>Your firm initiated a medical device correction by providing “adjustment kits” as a corrective measure, allowing customers to modify their ResetSmile Partial Denture Devices at home. This correction was initiated to remedy dentures that do not perform as intended, i.e., cause irritation or do not fit the patient. The adjustment kit is comprised of four items: a pink emery board, a blue emery board, a sanding stick, and a transfer stick to highlight problem areas. Your firm is instructing customers to use this kit to adjust the dentures that cause gum irritation or do not fit well. CDRH determined that the gum irritation being caused by the ResetSmile Partial Denture Devices may cause temporary or medically reversible adverse health consequences. Also, in some cases, there is a reasonable probability that ill-fitting dentures will cause serious adverse health consequences. Your firm’s actions thus meet the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health. Therefore, this action is a medical device correction for which your firm is required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your ResetSmile Partial Denture and the at-home ResetSmile Impression Kit Devices, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>For your ResetSmile Partial Denture Devices, the inspection determined that you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing to produce ResetSmile Partial Denture Devices, comprised of a resin denture base material and preformed plastic denture teeth. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process includes the following specific steps: customers take at-home impressions using your firm’s impression kit; a dentist virtually reviews the scans of these at-home impressions; your firm uses the resin denture base material to make the denture bases with a 3D printer; your firm chemically bonds the preformed plastic teeth to the denture bases to fabricate the dentures; and your firm ships approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> percent of these dentures directly to customers.\u003C\u002Fp>\u003Cp>We note that (1) partial denture devices and resin denture base material are class II devices classified under 21 CFR 872.3760 and require 510(k) clearance and (2) preformed plastic teeth are class II devices classified under 21 CFR 872.3590 and generally do not require 510(k) clearance. In your response, you do not identify a 510(k) clearance for your partial denture devices. Rather, your response seems to suggest that clearance for your partial denture devices is not required because your firm uses only cleared and 510(k) exempt materials in its manufacturing process and that the resin denture base material has a clearance. However, your firm did not provide a 510(k) number for the resin denture base material intended for use in a 3D printer—rather, your firm only provided a 510(k) number for preformed plastic teeth (K060507). Therefore, premarket notification or premarket approval is required for your ResetSmile Partial Denture Devices.\u003C\u002Fp>\u003Cp>Your response did not address your at-home ResetSmile Impression Kit Devices, which the inspection revealed are shipped from your headquarters facility, located in Irving TX, directly to customers for them to use without the supervision of a dentist or other practitioner to take their own impressions for the partial dentures. Specifically, your firm’s impression kits include impression material, a retractor, a tray, and instructions which explain to customers how to take their own impressions.\u003C\u002Fp>\u003Cp>Impression material is a class II device classified under 21 CFR 872.3660 and required to have 510(k) clearance, whereas retractors and trays are class I devices and generally 510(k) exempt. Your firm claims that it has a clearance for its impression material (K221668). The 510(k) summary for K221668 states that it is “intended for use with all crowns, bridges, and orthodontic impression techniques to reproduce the structure of a patient’s teeth and gums,” and is for prescription use only. Your impression material is intended to be used by customers to take their own impression without the supervision of a dentist, and thus does not fall within this cleared indication for use. This change to the device could significantly affect the safety and effectiveness of the impression material because customers who use at-home impression kits to take their own impressions may be more likely to take improper impressions—and improper impressions can lead to improper fabrication of the denture, which can cause bone loss\u002Fresorption, irritation, sores, and TMJ dysfunction. Moreover, it is unclear whether your firm is sending the impression material to customers with a prescription from a dentist—and the labeling of the impression kit does not appear to state that it is for prescription use only. Changing a device for prescription use only to a device for over the counter use also could significantly affect the safety or effectiveness of the device.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Therefore, premarket notification or premarket approval is required for your at-home ResetSmile Impression Kit Devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identification Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the ResetSmile devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for your ResetSmile Partial Denture and ResetSmile Impression Kit Devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> technology on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>In addition, your ResetSmile Partial Denture and ResetSmile Impression Kit Devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Reset Technology Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Registration and Listing Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year.\u003C\u002Fp>\u003Cp>Your response states that you are exempt from registration and listing under 21 CFR 807.65(i) because you are a dental laboratory. Your response explains that your firm “manufactures patient specific restorative devices (removable partial dentures) based upon a prescription from a licensed dentist” and “use[s] FDA cleared materials . . . to manufacture each patient specific device and do[es] not commercially distribute these devices.” Your response further explains that you previously registered as a medical device manufacturer for preformed plastic denture teeth based on incorrect information from a regulatory consultant and have since deactivated your registration with the FDA for fiscal year 2025.\u003C\u002Fp>\u003Cp>21 CFR 807.65(i), among other things, exempts from registration and listing “[p]ersons who dispense devices to the ultimate consumer or whose major responsibility is to render a service necessary to provide the consumer (i.e., patient, physician, layman, etc.) with a device or the benefits to be derived from the use of the device; for example, a…dental laboratory…whose primary responsibility to the ultimate consumer is to dispense or provide a service through the use of a previously manufactured device.” Here, your firm is not providing a service through the use of previously manufactured devices. Rather, as discussed above, your firm manufactures and distributes partial denture devices using devices that lack required approval\u002Fclearance and manufactures and distributes impression kits comprised of devices that lack required approval\u002Fclearance.\u003C\u002Fp>\u003Cp>As of this date, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2025 for your facility located in Englewood Cliffs, NJ. 21 CFR 807.22(b). Therefore, your firm’s devices at your facility located in Englewood Cliffs, NJ, are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>We also request your attendance at a virtual Regulatory Meeting to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. This meeting will also give you an opportunity to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, by email at gina.brackett@fda.hhs.gov within 5 business days to set up a date and time for the meeting.\u003C\u002Fp>\u003Cp>Your firm’s response to the Warning Letter should be addressed to Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, and sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 704828” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Justin S. Marks, VP Clinical Operations, justin@resetsmile.com\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>See\u003C\u002Fem> Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (Oct. 2017) (“FDA has found that the directions for use necessary for health care professionals to use a device safely and effectively can be significantly different from the directions for use necessary for lay users to use that same device safely and effectively. Therefore, changing a device labeled for prescription use only to a device that is labeled for OTC use typically could significantly affect the safety or effectiveness and would likely require submission of a new 510(k).”).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMark Teufel\n\nRecipient Title\n\nActing CEO\n\nReset Technology Corporation\n\n4200 West Royal Lane, Suite # 125\n\nIrving, TX 75063\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 704828\nJune 9, 2025\nDear Mark Teufel:\nDuring an inspection of your firm located in Englewood Cliffs, NJ, from October 29, 2024, through December 20, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ResetSmile Partial Denture Device and the at-home ResetSmile Impression Kit Device. The ResetSmile Partial Denture Device is a removeable dental appliance used to replace missing teeth and the ResetSmile Impression Kit Device is an impression kit used to help make the removeable dental appliance. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Mr. Justin S. Marks, VP Clinical Operations\u002FQuality Representative, in an email dated January 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you failed to define and document procedures for process validation. For example, you have no objective evidence that the following manufacturing and cleaning processes for your ResetSmile Partial Denture Devices, for which specifications such as anatomical features, mechanical strength, or residue removal cannot be verified without (b)(4) testing, consistently produce a result or product that meets predetermined specifications with a high degree of assurance:\na. Scanning and CAD Design\ni. You utilize the (b)(4) Dental Scanner to generate an initial 3D scan of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\nii. You utilize the (b)(4) to develop the patient-matched CAD design from the above 3D scan of the model cast but have no documented validation to support your intended use of this software application.\nb. 3-Dimensional (3D) Printing\ni. You utilize (b)(4) 3D Printers with the (b)(4) software to 3D print your ResetSmile Partial Denture Device based on the above CAD design but have no documented validations which establish the process parameter settings (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications alongside your intended use of the (b)(4) software application.\nii. You utilize the (b)(4) 3D Printer; (b)(4) 3D Printers; or (b)(4) 3D Printers to 3D print the mold to trial fit your ResetSmile Partial Denture Device but have no documented validations which establish the process parameters (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications.\nc. Post-printing Quality Control (QC) Validation (i.e., Test Method)\ni. You utilize the (b)(4) software, as a part of finished device acceptance, to identify conforming and nonconforming areas for your finished device through comparison of the overlay of the 3D scan of your ResetSmile Partial Denture Device ((b)(4)) with the initial 3D scan (via (b)(4) Dental Scanner software) of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\nd. Cleaning\ni. You utilize the (b)(4) to remove manufacturing material (e.g., (b)(4)) applied to your ResetSmile Partial Denture Device prior to the Post-printing QC Validation above but have no documented validation that establishes the process parameter settings (e.g., clean time, water quality, degassing time, bath cycle, etc.) under which your (b)(4) is able to consistently meet predefined specifications for cleanliness.\nii. You utilize the (b)(4) to (b)(4) clean your ResetSmile Partial Denture Device after (b)(4) but have no documented validation that this (b)(4) cleaner is able to consistently meet predefined specifications for cleanliness.\nWe reviewed your firm's response and conclude that it is not adequate. You state process validations are not required as they have already been performed as part of the regulatory process for the FDA cleared materials used in your devices. You also state that you use FDA listed 3D scanners and computer assisted design and manufacturing (CAD\u002FCAM) software to manufacture each patient specific device (which has been validated by the manufacturer as part of their regulatory process) and that internal validation and verification of the patient specific device is performed as part of the QC Validation Process to ensure that the partial denture fits the patient model since each product has different patient specifications. As such, no corrective actions were identified. However, it is unclear how you are able to ensure (1) that predetermined specifications are consistently met with a high degree of assurance during the scanning, 3D printing, and post-printing quality control process steps described above for your ResetSmile Partial Denture Devices without validation of the software workflow for its intended use according to an established protocol with predefined acceptance criteria and (2) quality for all devices built in a (b)(4) cycle, (b)(4) cycles, and (b)(4) machines, where the results of a process (output specifications) cannot be fully verified by subsequent inspection and test. In addition, you did not provide a response on how you plan to address the lack of cleaning validations for your (b)(4) and (b)(4) cleaning processes to ensure that manufacturing material is able to be consistently removed, with a high degree of assurance, from your devices which present challenges for residue removal due to the complex geometry prevalent with such devices (e.g., (b)(4) with limited or no access, etc.). Therefore, please provide a response on how you plan to address the above deficiencies.\n2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\nSpecifically, the \"Control of Nonconformity Process\" procedure (8300-01; Rev.0; Effective: 10\u002F25\u002F24) and \"Non-Confirming Material Report\" form (8300-01-01; Rev.0; Effective: 10\u002F25\u002F24), which were implemented after the preannouncement of the FDA inspection on 10\u002F24\u002F24, are inadequate in that there are no requirements to document:\n Nonconformances in sufficient detail to describe what failed to meet specification(s);\n Evaluations of nonconformances to determine the need for investigations; and\n Dispositions of nonconformances.\nFor example, there were no descriptions, evaluations for the need for investigations, and dispositions documented for (b)(4) cases of nonconforming product identified on the \"Internal Remakes log\" from 2\u002F2\u002F22 to 10\u002F28\u002F24 under three general categories: \"Failed print\" ((b)(4) cases); \"Fabrication error\" ((b)(4) cases); and \"Failed QC\" ((b)(4) cases).\nWe reviewed your firm's response and concluded that it is not adequate. You plan to create a new procedure to include the definition of a nonconformance, visual identification of nonconforming product, and disposition instructions; develop a new disposition log; perform a statistical analysis of the rework cases to determine if additional corrective actions are needed; and schedule training on updated procedures under corrective action report # CA011 around January 31, 2025. However, you have not identified any corrective actions to ensure that (1) your procedures and forms require that nonconformances are recorded in sufficient detail to include what failed to meet specification(s) to allow determination of potential causes and evaluations of nonconformances to determine the need for investigations and (2) retrospective review of nonconformances, for a reasonable period of time, to document what failed to meet specifications, conduct evaluations to determine the need for investigations, and record dispositions. In addition, please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n3. Failure to establish and maintain procedures for rework, including retesting and reevaluation of the nonconforming product after rework to ensure that the product meets its current approved specifications and documentation of rework and reevaluation activities, including determination of any adverse effect from the rework upon the product, in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, you failed to define and document procedures for rework which include requirements to retest and reevaluate reworked devices and document the rework and reevaluation, including adverse impact assessments on reworked devices, in the DHR. Per your VP of Clinical Operations and head Dental Technician, approximately (b)(4) of manufactured ResetSmile Partial Denture Devices undergo final adjustment (rework) during the Final Quality Control (QC) step of the \"Quality Control Validation Process\" (7506-01; Rev. 0; Effective: 2\u002F19\u002F24) which states that upon completion of the scan of the finished device, where (b)(4) areas indicate the need for readjustment, \"***the finished device is brought to the quality control technician for final QC analysis, including possible adjustments, and cleaning***.\" All eleven (11) scans of the ResetSmile Partial Denture Devices reviewed (lot #: 20022199; 20023601; 20023705; 20024773; 20025934; 20026261; 20026272; 20026352; 20021720; 20018940; 20021572) revealed that these initial scans evaluated during the final QC step contained (b)(4) areas which required adjustment. However, none of the readjustments for these devices were treated as reworks which would require additional rescans and retention of the scans to confirm specifications are met before release and documented assessment of any adverse effects.\nWe reviewed your firm's response and concluded that it is not adequate. You state the QC Validation Process (7506-01) is designed to identify and adjust potentially ill-fitting partial dentures prior to delivery to the dentist and consumer which surpasses requirements of the regulation and is in contrast to relying on the prescribing dentist to perform their own post-delivery adjustments, which is a universally accepted method. As such, no corrective actions were identified. However, your firm is not meeting the requirements of 21 CFR 820.90(b)(2) with regards to the handling of adjustments (reworks). Therefore, please provide a response on how you plan to address the above deficiencies.\n4. Failure to adequately investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).\nSpecifically, you failed to investigate or adequately investigate complaints alleged to not meet specifications, as noted in the following examples:\ni. Complaint # 22952 (lot # 20021720) dated 6\u002F26\u002F24: \"***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***.\"\nYou responded to customer by sending an adjustment kit to the patient. However, there was no documented investigation into what may have caused or contributed to the device thickness.\nii. Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F24: \"***The partials don't t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don't fit properly***.\"\nYou requested photos and information on experienced issues from the customer and sent another impression kit to the patient for a remake. However, there was no documented investigation into what may have caused or contributed to the device fit issues.\nWe reviewed your firm's response and conclude that it is not adequate. Your firm plans to assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR under corrective action report # CA013 around January 31, 2025. However, there were no corrective actions identified to retrospectively review and evaluate complaints, for a reasonable period of time, to determine (1) the need for an investigation (including justification when an investigation was not needed) and (2) definitively investigate any complaints which allege failures of your device, labeling, or packaging to meet any of its specifications. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n5. Failure to adequately maintain complaint files and adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).\nSpecifically, your \"Complaint Handling Process\" procedure (8202-01; Rev.0; Effective: 6\u002F22\u002F22) is inadequate in that it fails to:\na. Outline the criteria for when your follow-up questionnaire should be sent to complainants. For example, you emailed customers questionnaires (uncontrolled), which listed questions such as “***Can you feel any roughness or sharp edges on the device that are contributing to sore spots in your mouth?***” or “***Does the device feel like it is placing too much pressure on the gums? In any specific area or overall tightness?***” to attempt to obtain details on customer experienced issues for Complaints # 21161 (lot # 20026782) and # 56207 (lot # 20027010) but not for the following complaints:\ni. Complaint # 22952 (lot # 20021720) dated 06\u002F26\u002F2024: “***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***.”\nii. Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F2024: “***The partials don’t t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don’t fit properly***.”\nb. Ensure that complaints include evaluations of whether they represent events which require reporting to the FDA under 21 CFR 803 (Medical Device Reporting) based on sufficient information obtained from customers to determine whether the complaints meet the definition of MDR reportable events. For example, your VP of Clinical Operations acknowledged that none of your complaint records included documented evaluations on whether the complaints were reportable, including Complaints # 22952 and # 55465 above as well as the following:\ni. Complaint # 21161 (lot # 20026782) dated 10\u002F14\u002F24: “***The bottom is so tight, I have damaged the inside of my mouth after just one attempt. I tried again but my mouth was to [sic] sore.” The patient also stated that the device was “painful to clip in, cut me in the front of my lower teethbottom [sic]”. Your firm responded by sending an impression kit to the patient for a remake***.”\nii. Complaint # 56207 (lot # 20027010) dated 10\u002F23\u002F24: “***the bottom teeth are coming on contact with the partial causing it to move. This friction is very painful and has caused blistering… The pain that I feel goes from pressure to scratching to stabbing***.”\nWe reviewed your firm's response and conclude that it is not adequate. You plan to add the definition of a complaint to your MDR and complaint procedures; include a section for MDR evaluations to the complaint form; assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR; and provide training on the revised processes under corrective action report # CA013 around January 31, 2025. In addition, you reported that none of the 1,840 complaints as of 11\u002F21\u002F24 were MDR reportable. However, there were no corrective actions identified to ensure uniformity of the complaint process by establishing criteria for when complainants are sent questionnaires and ensure that sufficient information is requested from customers to determine whether complaint events meet the definition of MDR reportability under 21 CFR 820.3(o). Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n6. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your \"Corrective & Preventive Action (CAPA) Process\" (8502-01; Rev. 0; 6\u002F22\u002F22) and \"Quality Objectives Management\" (5401-01; Rev. 0; 10\u002F7\u002F24) procedures are inadequate in that:\na. 8502-01 (nor any other procedure) does not require internal remakes of your ResetSmile Partial Denture Devices, arising from issues during manufacturing, as inputs into the CAPA process to identify existing and potential causes of nonconforming product or other quality problems, as required by 21 CFR 820.100(a)(1). For example, you remade 64 devices during the month of October 2024 due to issues categorized as failed 3D printing, fabrication errors, and failed quality control but none of this data was analyzed to identify existing and potential causes of nonconforming product or other quality problems.\nb. Neither 8502-01 nor 5401-01 require appropriate statistical methodology to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example, you only evaluate complaint data by determining whether the (b)(4) percentage of rework (defined as the sum of adjustments kits, remakes, and refunds sent to customers divided by the number of customer orders received for the (b)(4)) exceeds (b)(4)%. However, the (b)(4) percentage of rework calculation includes non-quality data such as refunds and lots which are different that the lots ordered for the (b)(4). Therefore, you do not employ appropriate statistical methodology to any of your complaints, loosely categorized as \"issue with fit in mouth;\" \"design preference;\" \"incorrect bite\u002Focclusion;\" \"fabrication error;\" \"product not aesthetically pleasing;\" \"issue with fit on model;\" \"unknown;\" and \"wrong tooth shade,\" to detect recurring quality problems.\nc. 8502-01 does not require verification or validation of the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example, you did not verify or validate that the corrective action identified under CAPA # 002 (corrected date of 11\u002F6\u002F23) to use adjustment kits, to address the observed increase in adjustments and remake rates from fit issues, were effective and did not adversely affect your ResetSmile Partial Denture Devices prior to sending them to customers.\nWe reviewed your firm's response and conclude that it is not adequate. You clarify that the quality data analysis is performed as part of the \"Quality Objectives Management\" (5401-01 Rev. 0) and \"Management Review\" (5600-M1 Rev. 0) processes and that there were no trends noted between May to October 2024 for the three (3) weeks where the value for percentage for rework was above (b)(4). As such, no corrective actions were identified. Therefore, please provide a response on how you plan to address the above deficiencies.\n7. Failure to establish and maintain procedures to adequately control environmental conditions, which could reasonably be expected to have an adverse effect on product quality and periodically inspect the environmental control system to verify that the system, including necessary equipment, is adequate and functioning properly, as required by 21 CFR 820.70(c).\nSpecifically:\na. You failed to define and document procedures to control environmental conditions for your production area consisting of (b)(4) 3D Printers, used to manufacture your ResetSmile Partial Denture Devices. For example:\ni. On 11\u002F6\u002F24, the investigator observed out of specification temperatures of 92.3℉ (33.50℃) and 92.4℉ (33.56℃) on two separate temperature and humidity monitors, which were above the \"Environment Requirements\" of (b)(4)℃ specified in the \"(b)(4) 3D Printer User Guide.\" In addition, the humidity value for one of the monitors was below the requirement of (b)(4) in this same guide. These out of specification values affected (b)(4) production lots that were being printed across (b)(4) different (b)(4) 3D Printers at the time.\nii. On 11\u002F19\u002F24, the investigator also observed an out of specification temperature of 95.1℉ (35.06℃) and 14.4% humidity on one temperature and humidity monitor, which were outside the temperature ((b)(4)℃) and humidity ((b)(4)) ranges specified in the \"(b)(4) 3D Printer User Guide.\" This out of specification temperature and humidity affected (b)(4) production lots that were being printed across (b)(4) different (b)(4) 3D Printers at the time.\nMoreover, you do not regularly log the temperature and humidity values or regulate the temperature in the production area.\nb. You failed to periodically inspect your temperature and humidity monitors to ensure that they are suitable for their intended use and calibrated or evaluated for accuracy.\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to calibrate your temperature and humidity sensor; set up alerts when values exceed specified requirements; control ambient humidity and temperature of the room; and develop an \"Environmental Requirements\" procedure under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\n8. Failure to ensure that all equipment used in the manufacturing process meets specified requirements and is appropriately designed, constructed, placed, and installed to facilitate maintenance, adjustment, cleaning, and use, as required by 21 CFR 820.70(g).\nSpecifically, you failed to meet specified placement requirements for your (b)(4) 3D Printers, which are used to manufacture your ResetSmile Partial Denture Devices. For example, on 11\u002F19\u002F24, the investigator observed that the distance between the sides of 3D printers (b)(4) and (b)(4) and (b)(4) and (b)(4) was approximately 8 cm and the distances between the corresponding (b)(4) and backs of 3D printers (b)(4) and (b)(4) were approximately 5.5 cm and 6 cm, respectively, which are all below the specified placement requirements noted in the \"(b)(4) 3D Printer User Guide\" which requires that \"***the distances of the left, right and back [sic] side space should be at least 20cm***.\"\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to rearrange the printers and printer racks to accommodate the recommended spacing guidelines in the manufacturer's instructions for use; reposition the (b)(4); and document these parameters in \"Environmental Requirements\" under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\n9. Failure to establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, including documentation of training, as required by 21 CFR 820.25(b).\nSpecifically, you failed to implement your \"New Hire\u002FTraining of Personnel Process\" (SOP 6202-01; Rev. 0; Effective: 6\u002F17\u002F24) which requires both acknowledgment of training on the \"Training Acknowledgment Form\" (6202-01-04; Rev. 0; Effective: none) and identification of training needs by the senior manager on the \"Training Needs Assessment\" form (6202-01-03). For example, there were no training forms completed for the following procedures:\n \"Control of Nonconformity Process\" (SOP 8300-01; Rev. 0; Effective: 10\u002F25\u002F24)\n \"Complaint Handling Process\" (SOP 8202-01; Rev. 0; Effective: 06\u002F22\u002F22)\n \"Internal Rework Process\" (SOP 8304-01; Rev. 0, Effective: 6\u002F22\u002F24)\n \"External Rework Process\" (SOP 8304-02; Rev. 0, Effective: 6\u002F22\u002F24)\nIn addition, there was no documented training on the 6201-01-04 form from before 10\u002F28\u002F24, which is between the dates of preannouncement (10\u002F24\u002F24) and the start of the inspection (10\u002F29\u002F24) for procedures such as (but not limited to) \"QC Validation\" (7506-01), \"Device Fabrication\" (7501-01), and \"Calibration Process\" (7600-01). This applies to (b)(4) employees, including your VP of Clinical Operations; (b)(4) Customer Service Representatives; (b)(4) CAD Technician; (b)(4) 3D Printing Technicians; (b)(4) Dental Technicians; (b)(4) Dental Lab Technicians; and (b)(4) Shipping\u002FReceiving personnel.\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to conduct a review in which 6202-01-03 will be completed for all employees and additional training will be scheduled for all affected personnel for procedures noted, including completion of the 6202-01-04 form under corrective action report # CA014 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA014, and any supporting evidence.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your ResetSmile Partial Denture Devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\nFailure to submit any report required within 10 working days of initiating a correction or removal, initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR 806.10.\nYour firm initiated a medical device correction by providing “adjustment kits” as a corrective measure, allowing customers to modify their ResetSmile Partial Denture Devices at home. This correction was initiated to remedy dentures that do not perform as intended, i.e., cause irritation or do not fit the patient. The adjustment kit is comprised of four items: a pink emery board, a blue emery board, a sanding stick, and a transfer stick to highlight problem areas. Your firm is instructing customers to use this kit to adjust the dentures that cause gum irritation or do not fit well. CDRH determined that the gum irritation being caused by the ResetSmile Partial Denture Devices may cause temporary or medically reversible adverse health consequences. Also, in some cases, there is a reasonable probability that ill-fitting dentures will cause serious adverse health consequences. Your firm’s actions thus meet the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health. Therefore, this action is a medical device correction for which your firm is required to submit a Report of Correction or Removal to FDA.\nUnapproved Device Violation(s)\nOur inspection also revealed that your ResetSmile Partial Denture and the at-home ResetSmile Impression Kit Devices, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nFor your ResetSmile Partial Denture Devices, the inspection determined that you use (b)(4) manufacturing to produce ResetSmile Partial Denture Devices, comprised of a resin denture base material and preformed plastic denture teeth. The (b)(4) manufacturing process includes the following specific steps: customers take at-home impressions using your firm’s impression kit; a dentist virtually reviews the scans of these at-home impressions; your firm uses the resin denture base material to make the denture bases with a 3D printer; your firm chemically bonds the preformed plastic teeth to the denture bases to fabricate the dentures; and your firm ships approximately (b)(4) percent of these dentures directly to customers.\nWe note that (1) partial denture devices and resin denture base material are class II devices classified under 21 CFR 872.3760 and require 510(k) clearance and (2) preformed plastic teeth are class II devices classified under 21 CFR 872.3590 and generally do not require 510(k) clearance. In your response, you do not identify a 510(k) clearance for your partial denture devices. Rather, your response seems to suggest that clearance for your partial denture devices is not required because your firm uses only cleared and 510(k) exempt materials in its manufacturing process and that the resin denture base material has a clearance. However, your firm did not provide a 510(k) number for the resin denture base material intended for use in a 3D printer—rather, your firm only provided a 510(k) number for preformed plastic teeth (K060507). Therefore, premarket notification or premarket approval is required for your ResetSmile Partial Denture Devices.\nYour response did not address your at-home ResetSmile Impression Kit Devices, which the inspection revealed are shipped from your headquarters facility, located in Irving TX, directly to customers for them to use without the supervision of a dentist or other practitioner to take their own impressions for the partial dentures. Specifically, your firm’s impression kits include impression material, a retractor, a tray, and instructions which explain to customers how to take their own impressions.\nImpression material is a class II device classified under 21 CFR 872.3660 and required to have 510(k) clearance, whereas retractors and trays are class I devices and generally 510(k) exempt. Your firm claims that it has a clearance for its impression material (K221668). The 510(k) summary for K221668 states that it is “intended for use with all crowns, bridges, and orthodontic impression techniques to reproduce the structure of a patient’s teeth and gums,” and is for prescription use only. Your impression material is intended to be used by customers to take their own impression without the supervision of a dentist, and thus does not fall within this cleared indication for use. This change to the device could significantly affect the safety and effectiveness of the impression material because customers who use at-home impression kits to take their own impressions may be more likely to take improper impressions—and improper impressions can lead to improper fabrication of the denture, which can cause bone loss\u002Fresorption, irritation, sores, and TMJ dysfunction. Moreover, it is unclear whether your firm is sending the impression material to customers with a prescription from a dentist—and the labeling of the impression kit does not appear to state that it is for prescription use only. Changing a device for prescription use only to a device for over the counter use also could significantly affect the safety or effectiveness of the device.1 Therefore, premarket notification or premarket approval is required for your at-home ResetSmile Impression Kit Devices.\nUnique Device Identification Violation(s)\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the ResetSmile devices do not bear such a UDI.\nSpecifically, the labels for your ResetSmile Partial Denture and ResetSmile Impression Kit Devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses (b)(4) technology on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(2)).\nIn addition, your ResetSmile Partial Denture and ResetSmile Impression Kit Devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Reset Technology Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nRegistration and Listing Violation(s)\nUnder section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year.\nYour response states that you are exempt from registration and listing under 21 CFR 807.65(i) because you are a dental laboratory. Your response explains that your firm “manufactures patient specific restorative devices (removable partial dentures) based upon a prescription from a licensed dentist” and “use[s] FDA cleared materials . . . to manufacture each patient specific device and do[es] not commercially distribute these devices.” Your response further explains that you previously registered as a medical device manufacturer for preformed plastic denture teeth based on incorrect information from a regulatory consultant and have since deactivated your registration with the FDA for fiscal year 2025.\n21 CFR 807.65(i), among other things, exempts from registration and listing “[p]ersons who dispense devices to the ultimate consumer or whose major responsibility is to render a service necessary to provide the consumer (i.e., patient, physician, layman, etc.) with a device or the benefits to be derived from the use of the device; for example, a…dental laboratory…whose primary responsibility to the ultimate consumer is to dispense or provide a service through the use of a previously manufactured device.” Here, your firm is not providing a service through the use of previously manufactured devices. Rather, as discussed above, your firm manufactures and distributes partial denture devices using devices that lack required approval\u002Fclearance and manufactures and distributes impression kits comprised of devices that lack required approval\u002Fclearance.\nAs of this date, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2025 for your facility located in Englewood Cliffs, NJ. 21 CFR 807.22(b). Therefore, your firm’s devices at your facility located in Englewood Cliffs, NJ, are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nWe also request your attendance at a virtual Regulatory Meeting to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. This meeting will also give you an opportunity to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, by email at gina.brackett@fda.hhs.gov within 5 business days to set up a date and time for the meeting.\nYour firm’s response to the Warning Letter should be addressed to Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, and sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 704828” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Justin S. Marks, VP Clinical Operations, justin@resetsmile.com\n_____________________________\n1 See Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (Oct. 2017) (“FDA has found that the directions for use necessary for health care professionals to use a device safely and effectively can be significantly different from the directions for use necessary for lay users to use that same device safely and effectively. Therefore, changing a device labeled for prescription use only to a device that is labeled for OTC use typically could significantly affect the safety or effectiveness and would likely require submission of a new 510(k).”).","Reset Technology Corporation","reset-technology-corporation-704828-06092025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freset-technology-corporation-704828-06092025","2026-10-26T08:09:48.8589+00:00","Warning Letter","Issued","2025-06-17","704828","Medical Devices","Mark Teufel","2026-08-19T16:39:59.227+00:00","VIA Electronic Mail","2025-06-09",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":37,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":53,"action_taken_date":54,"medical_device_id":19,"response_letter_date":19},1204,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2024-10-22T13:20:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-01T04:00:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famnio-technology-llc-646460-10012024\">Amnio Technology, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 24-646460\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Merrill B. Stromer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Amnio Technology, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>22510 N. 18th Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85027-1363\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 1, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBER 24-646460\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nDear Dr. Stromer:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Amnio Technology, LLC, located at 22510 N. 18th Drive, Phoenix, AZ 85027, conducted between August 15, 2022, and August 29, 2022, and your storage and distribution facility, located at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, conducted between August 17, 2022, and August 29, 2022, the United States Food and Drug Administration (FDA) documented your manufacture of an amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, and an amniotic fluid derived product, PalinGen® InovōFlo® (hereinafter, your products). You have distributed your products to third-party distributors, hospitals, and medical clinics throughout the United States.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your products are intended for injection and purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and\u002For after the inspection, including information from your contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reflect that your products are intended for use in the cure, treatment or prevention of diseases or conditions, such as wound healing and\u002For are intended to affect the structure or function of the body. For example, your promotional materials for PalinGen Flow state, “PalinGen Flow contain[s] key growth factors, cytokines, amino acids… hyaluronic acid, extracellular matrix proteins and cellular components recognized as intrinsic to the complex wound healing process,” and “Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, re-epithelialization and anti-fibrotic properties.” Your promotional materials for PalinGen InovoFLo state, “Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications.”\u003C\u002Fp>\n\n\u003Cp>As a result, your products are drugs as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)(1)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Because PalinGen® Flow® contains amniotic membrane, in addition to being a drug and biological product, it is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, and are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of the materials described above, Amnio Technology, LLC does not qualify for any exception in 21 CFR 1271.15, and PalinGen® Flow® fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, PalinGen® Flow® is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>For example, PalinGen® Flow® fails to meet the minimal manipulation criterion set forth in section 1271.10(a)(1) and defined for structural tissue in section 1271.3(f)(1). During the manufacturing process for PalinGen® Flow®, amniotic membrane is processed \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a flowable form that can be administered by injection. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength, and elasticity.\u003C\u002Fp>\n\n\u003Cp>PalinGen® Flow® also fails to meet other criteria set forth in 21 CFR 1271.10(a). For example, PalinGen® Flow® fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” PalinGen® Flow® is not intended solely to perform the same basic function or functions of amniotic membrane in the recipient as in the donor (such as serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero). Rather, PalinGen® Flow® is intended, for example, for use in wound healing and tissue regeneration, which are not homologous uses of amniotic membrane as defined in 21 CFR 1271.3(c).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>PalinGen® InovōFlo® is not an HCT\u002FP. The definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted body fluids, such as amniotic fluid, are not considered HCT\u002FPs. Because PalinGen® InovōFlo® meets the definition of a drug under section 201(g) of the FD&amp;C Act and a biological product under section 351(i) of the PHS Act, your product is regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312].\u003C\u002Fp>\n\n\u003Cp>Neither PalinGen® Flow® nor PalinGen® InovōFlo® are the subject of an approved BLA or an approved application under section 505(a) of the FD&amp;C Act. Since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Amnio Technology, LLC \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>However, FDA’s inspection documented your distribution of PalinGen® Flow® for human use outside of a clinical investigation. Therefore, you are not exempt from the requirement to have an approved BLA or an approved application under section 505(a) in effect for PalinGen Flow. Further,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> PalinGen InovoFlo. Based on our review these products are unapproved new drugs, and your firm’s introduction or delivery for introduction of products into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act and section 351(a)(1) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (FDA-483), which described a number of significant CGMP deviations applicable to your products. These deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm did not validate the manufacturing processes for PalinGen® Flow® or PalinGen® InovōFlo® with respect to identity, strength, quality, and purity.Your firm’s validation protocol is insufficient as it does not include supporting data demonstrating that your firm’s manufacturing process can consistently yield expected product characteristics.. Your firm distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of PalinGen® Flow® and approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of PalinGen® InovFlo® since January 2020 to August 2022. These units were distributed without process validation for these products.\u003C\u002Fp>\n\n\u003Cp>2. \u003Cstrong>Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. \u003C\u002Fstrong>Specifically, your firm has assigned a two-year expiration date to your products without adequate data demonstrating the stability characteristics of the products. For example, in your study protocol for PalinGen® Flow® under PROT-ENG-148, only assessed \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and did not include tests for sterility.\u003C\u002Fp>\n\n\u003Cp>3. \u003Cstrong>Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].\u003C\u002Fstrong> For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical\u002Fsurgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letters dated September 16, 2022, June 7, 2023, and December 20, 2023, which respond to the FDA-483. In your response, you represent that you have corrected the deficiencies documented on the FDA-483. However, your responses and the corrective actions described are not adequate to address our concerns. For example, in your response, you reference a validation protocol completed for PalinGen® Flow; however, you failed to provide supporting data to demonstrate that your manufacturing process can consistently yield product that meets established product specifications.\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address the inventory you still have at your facility and your specific plans for the disposition of this product inventory. Nor do you describe actions you have taken or plan to take to address the impact of the above-noted deficiencies on your products that you distributed.\u003C\u002Fp>\n\n\u003Cp>Your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA statutory and regulatory requirements that cover such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR parts 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483 are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We also have concerns regarding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized amniotic fluid derived product, ProMatrX ACF®. Based on our review, this product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. It is also either a drug under section 201(g) of the FD&amp;C Act or a device under section 201(h) of the FD&amp;C Act. To lawfully market a biological product, either a valid biologics license or, as applicable, an appropriate device premarket authorization must be in effect. If you would like more information on which pathway is appropriate for this product, please contact us.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You manufacture an amniotic membrane derived product for private label customers using \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process used for Palingen Flow under product names including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, ASGFluid, Cell-ECT, Gryphon Amnio Flow, SXFluid, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The instructions for use are the same as those for PalinGen Flow. You also manufacture an amniotic membrane and amniotic fluid derived product for private label customers using the same manufacturing process used for PalinGen InovoFlo under the product name \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The instructions for use are the same as those for PalinGen InovoFlo.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, fails to meet the criterion at 21 CFR 1271.10(a)(1) and also fails to meet the criterion at 21 CFR 1271.10(a)(2), this letter does not address whether this product meets the criteria at 21 CFR 1271.10(a)(3) or (a)(4).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nCBER 24-646460\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMerrill B. Stromer\n\nRecipient Title\n\nChairman\n\nAmnio Technology, LLC\n\n22510 N. 18th Drive\n\nPhoenix, AZ 85027-1363\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nOctober 1, 2024\n\nCBER 24-646460\n\nDear Dr. Stromer:\n\nDuring an inspection of your firm, Amnio Technology, LLC, located at 22510 N. 18th Drive, Phoenix, AZ 85027, conducted between August 15, 2022, and August 29, 2022, and your storage and distribution facility, located at (b)(4), conducted between August 17, 2022, and August 29, 2022, the United States Food and Drug Administration (FDA) documented your manufacture of an amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, and an amniotic fluid derived product, PalinGen® InovōFlo® (hereinafter, your products). You have distributed your products to third-party distributors, hospitals, and medical clinics throughout the United States.1 Your products are intended for injection and purported to be sterile.\n\nInformation and records gathered prior to, during, and\u002For after the inspection, including information from your contract manufacturer, (b)(4), reflect that your products are intended for use in the cure, treatment or prevention of diseases or conditions, such as wound healing and\u002For are intended to affect the structure or function of the body. For example, your promotional materials for PalinGen Flow state, “PalinGen Flow contain[s] key growth factors, cytokines, amino acids… hyaluronic acid, extracellular matrix proteins and cellular components recognized as intrinsic to the complex wound healing process,” and “Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, re-epithelialization and anti-fibrotic properties.” Your promotional materials for PalinGen InovoFLo state, “Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications.”\n\nAs a result, your products are drugs as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)(1)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nBecause PalinGen® Flow® contains amniotic membrane, in addition to being a drug and biological product, it is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, and are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of the materials described above, Amnio Technology, LLC does not qualify for any exception in 21 CFR 1271.15, and PalinGen® Flow® fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, PalinGen® Flow® is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nFor example, PalinGen® Flow® fails to meet the minimal manipulation criterion set forth in section 1271.10(a)(1) and defined for structural tissue in section 1271.3(f)(1). During the manufacturing process for PalinGen® Flow®, amniotic membrane is processed (b)(4) to a flowable form that can be administered by injection. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength, and elasticity.\n\nPalinGen® Flow® also fails to meet other criteria set forth in 21 CFR 1271.10(a). For example, PalinGen® Flow® fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” PalinGen® Flow® is not intended solely to perform the same basic function or functions of amniotic membrane in the recipient as in the donor (such as serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero). Rather, PalinGen® Flow® is intended, for example, for use in wound healing and tissue regeneration, which are not homologous uses of amniotic membrane as defined in 21 CFR 1271.3(c).2\n\nPalinGen® InovōFlo® is not an HCT\u002FP. The definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted body fluids, such as amniotic fluid, are not considered HCT\u002FPs. Because PalinGen® InovōFlo® meets the definition of a drug under section 201(g) of the FD&C Act and a biological product under section 351(i) of the PHS Act, your product is regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval.\n\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312].\n\nNeither PalinGen® Flow® nor PalinGen® InovōFlo® are the subject of an approved BLA or an approved application under section 505(a) of the FD&C Act. Since (b)(4), Amnio Technology, LLC (b)(4) However, FDA’s inspection documented your distribution of PalinGen® Flow® for human use outside of a clinical investigation. Therefore, you are not exempt from the requirement to have an approved BLA or an approved application under section 505(a) in effect for PalinGen Flow. Further, (b)(4) PalinGen InovoFlo. Based on our review these products are unapproved new drugs, and your firm’s introduction or delivery for introduction of products into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (FDA-483), which described a number of significant CGMP deviations applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm did not validate the manufacturing processes for PalinGen® Flow® or PalinGen® InovōFlo® with respect to identity, strength, quality, and purity.Your firm’s validation protocol is insufficient as it does not include supporting data demonstrating that your firm’s manufacturing process can consistently yield expected product characteristics.. Your firm distributed approximately (b)(4) units of PalinGen® Flow® and approximately (b)(4) units of PalinGen® InovFlo® since January 2020 to August 2022. These units were distributed without process validation for these products.\n\n2. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a two-year expiration date to your products without adequate data demonstrating the stability characteristics of the products. For example, in your study protocol for PalinGen® Flow® under PROT-ENG-148, only assessed (b)(4) and (b)(4) and did not include tests for sterility.\n\n3. Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]. For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical\u002Fsurgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.\n\nWe acknowledge receipt of your letters dated September 16, 2022, June 7, 2023, and December 20, 2023, which respond to the FDA-483. In your response, you represent that you have corrected the deficiencies documented on the FDA-483. However, your responses and the corrective actions described are not adequate to address our concerns. For example, in your response, you reference a validation protocol completed for PalinGen® Flow; however, you failed to provide supporting data to demonstrate that your manufacturing process can consistently yield product that meets established product specifications.\n\nYour response also does not adequately address the inventory you still have at your facility and your specific plans for the disposition of this product inventory. Nor do you describe actions you have taken or plan to take to address the impact of the above-noted deficiencies on your products that you distributed.\n\nYour response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA statutory and regulatory requirements that cover such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR parts 312].\n\nNeither this letter nor the observations noted on the FDA-483 are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe also have concerns regarding your (b)(4) sterilized amniotic fluid derived product, ProMatrX ACF®. Based on our review, this product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. It is also either a drug under section 201(g) of the FD&C Act or a device under section 201(h) of the FD&C Act. To lawfully market a biological product, either a valid biologics license or, as applicable, an appropriate device premarket authorization must be in effect. If you would like more information on which pathway is appropriate for this product, please contact us.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\nCc:\n\n(b)(4)\n\n_________________________\n\n1 You manufacture an amniotic membrane derived product for private label customers using (b)(4) manufacturing process used for Palingen Flow under product names including (b)(4), ASGFluid, Cell-ECT, Gryphon Amnio Flow, SXFluid, and (b)(4). The instructions for use are the same as those for PalinGen Flow. You also manufacture an amniotic membrane and amniotic fluid derived product for private label customers using the same manufacturing process used for PalinGen InovoFlo under the product name (b)(4). The instructions for use are the same as those for PalinGen InovoFlo.\n\n2 Because your amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, fails to meet the criterion at 21 CFR 1271.10(a)(1) and also fails to meet the criterion at 21 CFR 1271.10(a)(2), this letter does not address whether this product meets the criteria at 21 CFR 1271.10(a)(3) or (a)(4).","Amnio Technology, LLC","amnio-technology-llc-646460-10012024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famnio-technology-llc-646460-10012024","2026-10-26T08:07:55.44972+00:00","2024-10-22","646460","Biologics","Merrill B. Stromer","2026-08-19T21:55:18.541+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","CBER 24-646460","2024-10-01",{"id":56,"raw":57,"subject":12,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":69,"posted_date":70,"marcs_cms_no":71,"product_type":26,"closeout_date":72,"issuing_office":11,"recipient_name":73,"body_fetched_at":74,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},2051,[58,59,60,11,12,13,61,13],"\u003Ctime datetime=\"2023-06-20T13:20:00Z\">06\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-12T04:00:00Z\">06\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-06122023\">Vitang Technology LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-07232024\">\u003Ctime datetime=\"2024-07-31T04:00:00Z\">07\u002F31\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ronald Jiang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vitang Technology LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14662 Franklin Ave Ste H\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tustin\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92780-7224\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ron@vitangtechnology.com\"> ron@vitangtechnology.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER \u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CMS # 653455\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 12, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jiang:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Vitang Technology LLC. (Vitang or “the firm”), located in Tustin, CA on January 24, 2023 through January 31, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of The UniSmile Clear Aligner, a Class II dental aligner, cleared under 510(k) K191837and marketed as both the “UniSmile Clear Aligner System” and “2usmiles” on your firm’s websites. For example, your website (https:\u002F\u002Funismile.us\u002F) promotes the device name Unismile. Additionally, your website (https:\u002F\u002Fwww.2usmiles.com\u002F) promotes the device name 2usmiles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the UniSmile Clear Aligner System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>We received your response, dated February 20, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded and\u002For Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm currently holds a 510(k) clearance for the “UniSmile Clear Aligner System.” This device was cleared on January 30, 2020, under K191837 for, among other things, treatment of tooth malocclusion in patients with permanent dentition by way of continuous gentle force. Your 510(k) summary dated January 29, 2020 states that “Software is used to design treatment plans. The software used with UniSmile Clear Aligner System is the Orchestrate 3D (K181112) software, version OrthoRx 4”.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm made changes to the device without submission of a new 510(k). On November 26, 2019 you changed from using the cleared Orchestrate 3D to the non-cleared iRok OrthoRx 4.0 for the development of the treatment plans for your UniSmile Clear Aligner System. You indicated that you performed verification and validation activities on iRok OrthoRx 4.0 and concluded that this software is “similar in designing clear aligner treatment plans” as Orchestrate 3D (K181112). However, note that verification and validation requirements apply for all devices subject to 21 CFR 820.30, and must be conducted regardless of whether submission of a new 510(k) is required. A change in orthodontic treatment planning software is a change that could significantly affect the safety and effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Specifically, a change from Orchestrate 3D to iRok OrthoRx 4.0 has the potential to affect the proposed treatment protocol as well as the dimensions, configurations, and applied forces of the UniSmile Clear Aligners, and affect the clinical outcome. Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified UniSmile Clear Aligner System. You did not submit any new 510(k) for the referenced modification to the UniSmile Clear Aligner System.\u003C\u002Fp>\n\n\u003Cp>Therefore, your devices are misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). Your devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the UniSmile Clear Aligner System is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>Specifically, our inspection revealed that your firm has failed to establish and maintain procedures for (1) determining whether a complaint is reportable to the FDA under part 803, (2) investigating the possible failure of a device to meet any of its specifications, and (3) receiving complaints outside of your firm's complaint management system, including oral complaints. Instead, your procedure,\u003Cem> Customer complaints and refinements\u003C\u002Fem>, is used to only to provide refinement services, (e.g., rescans). For example, 11 out of 13 complaint records reviewed during our inspection did not include an evaluation for MDR reportability nor an evaluation to determine if an investigation was necessary. In addition, you did not perform an investigation into reports of broken aligners.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response, and it is inadequate. Although you stated that you recognize that your procedure lacks specific steps to report death or serious injuries, and that you will review and update procedures to comply with MDR reporting requirements within 6 weeks of your response and conduct training, you have not provided evidence of the corrective and preventive actions. Further, your response is also inadequate because it did not address corrective actions that you have taken or plan to take to establish procedures for investigating the possible failure of a device to meet any of its specifications or receiving complaints outside of your firm's complaint management system, including oral complaints.\u003C\u002Fp>\n\n\u003Cp>2. Failure to validate software used as part of the quality system for its intended use according to an established protocol, as required by 21 CFR 820.70(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, you failed to validate your complaint handling system software. Your Ruby on Rails server-side web application framework, using the programming language Ruby and found at unismile.us, is used to maintain complaint files. However, your firm has failed to validate the software for its intended use.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. In your response, your firm stated that your complaint handling system has been in use for a few years and has “proven to be effective.” However, your firm has not provided evidence of the effectiveness of this complaint handling system. Additionally, your firm stated that you initiated an action plan to validate the complaint handling system. You committed to generate a software validation report, approach, testing methodology, and results of the validation within 6 weeks of your response to FDA. You have not provided a response with evidence of the corrective and preventive actions relevant to the complaint handling system effectiveness.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluation of suppliers, contractors, and consultants, as required by 21 CFR 820.50(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, you are not defining the type and extent of control to be exercised over supplier services. When our investigator asked for an evaluation of your firm’s suppliers, you only provided a Manufacturing and Supply Agreement with Xi’an Henghui Technologies Co., Ltd. The August 27, 2021, manufacturing agreement with Henghui, the Chinese contract manufacturer and supplier for the uncleared software you use in the design of the dental aligners, does not identify the roles and responsibilities of both companies. Henghui has contract manufactured your devices since 2019.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you conducted comprehensive inspections of your critical supplier, Henghui, including site visits, and documented the results. You stated to look at an Attachment A. However, the response did not contain an Attachment A. Further, all supporting documents in the response are in Chinese and cannot be reviewed or assessed. You stated that you plan to review the supplier evaluation process and update necessary documents as soon as possible, and conduct auditing of all suppliers, within 12 weeks of the response. You have not provided a response with evidence of the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR § 820.75(b), and failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, including the validation of major equipment, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your \u003Cem>Validation of Process\u003C\u002Fem> procedure refers to “approval of equipment” but does not address equipment qualification to show that equipment is appropriately designed, constructed, placed, and installed. You stated during the inspection that you have documents in Chinese from the supplier that show the installation and qualifications of your 3D printer. However, since they were not in English, we were unable to verify this statement nor if your firm validated the 3D printing process used to manufacture the UniSmile Clear Aligner System. In addition, your firm’s General Manager and Engineering Manager stated that your firm documents the installation of the printers and the operational and performance qualification in the HeyGears Ultracraft A2D Quasi-Industrial Grade DLP 3D Printer operation manual when an installation occurs. However, that manual does not indicate when the qualification occurred or include evidence that it was performed.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that your response is inadequate. Your firm has not provided a procedure that addresses major equipment qualification or process validation for your 3D printing process. You stated that you will complete the necessary updates to the equipment qualification documents for all equipment within 12 weeks of the response and conduct training. We request that you provide evidence that your 3D printing process has been qualified and validated.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, the Equipment Calibration List in your firm’s \u003Cem>Control of Monitoring and Measuring Equipment’s\u003C\u002Fem> procedure states that the 3D Printer should be calibrated monthly, but your firm could only provide a record of quarterly maintenance. You are not documenting the next calibration due date for your 3D printers used in the manufacture of dental aligners. Records are not readily available to the personnel using such equipment as you do not keep the records at the firm. Instead, your firm stated that they are kept with the 3D printer supplier\u002Fcalibrator.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that the equipment has been calibrated but, due to a manpower shortage, some of the records were not available. You also stated this was compounded by deficiencies in forms and procedures. You stated that you will review your forms and procedures relating to calibration and update as necessary within 10 weeks of the response. You have not provided calibration records to show all equipment was calibrated on the required schedule and have not provided a response with evidence of the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish procedures for device history records as required by 21 CFR 820.184.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm does not have a device history record (DHR) procedure. For example, a review of 11 out of 13 device history records (DHRs) for dental aligners did not include nor make reference to the primary identification label and labeling used for each production unit. In addition, the device history records do not contain any UDI information on its label or labeling. During our inspection, you stated that the procedure is being held at the supplier in China.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you reviewed Henghui’s procedures and quality documents and deemed them equivalent to your firm’s procedure in Attachment B. You stated that you can obtain documents from Henghui upon request and then referenced an Attachment C. Both attachments are in Chinese, and we are unable to review them. You stated that the DHR does not include or refer to the location of any UDI or UPC as you believed the devices were custom-made and exempt. In your response you stated that you plan to conduct a review and update of device history process procedures with 8 weeks of the response and provide guidance to all employees; and you will review and update shipping documentation within 4 weeks of the response and then conduct training. You stated that you will update your DHRs with regard to UDI\u002FUPC within 6 weeks of the response and provide training to employees.\u003C\u002Fp>\n\n\u003Cp>7. Failure to document the results and\u002For dates of management reviews as required by 21 CFR 820.20(c).\u003Cbr>\n\u003Cbr>\nSpecifically, you firm has no record of management reviews. Your \u003Cem>Quality Manual and Management Responsibility\u003C\u002Fem> documents both make references to the required conduct of management reviews. You provided a memo on 01\u002F30\u002F2023 that they have been conducted. However, it is generalized as to the topics covered and there are no dates of reviews documented.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate because it does not address this observation.\u003C\u002Fp>\n\n\u003Cp>8. Failure to document personnel training as required by 21 CFR 820.25(b).\u003C\u002Fp>\n\n\u003Cp>Your firm has failed to document training records. Specifically, you were unable to provide training records for General\u002FEngineering Manager and the CEO\u002FVice President of Operations\u002FHead of Shipment Tracking and Handling.\u003C\u002Fp>\n\n\u003Cp>However, your procedure that we did review indicates that new employees attend an orientation that includes training on the quality system, the quality policy, the importance of meeting regulatory, statutory and customer requirements, and the relevance and importance of their activities and how they contribute to the achievement of the quality objective. However, there is no documentation of this orientation.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate because it does not address your firm’s failure to document personnel training.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Representations that Create an Impression of FDA Approval\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The UniSmile Clear Aligner System is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because a representation on your website creates an impression of official approval of the device and is misleading. In addition, 21 CFR 807.97 states that any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Your website contains such representations. Specifically, your website at https:\u002F\u002Fwww.2usmiles.com\u002Fwhy-2usmiles states: “FDA APPROVED.” and incorporates the FDA logo. Statements about having active status with the FDA, and display of the FDA logo near images of and information about the respective products, is misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>In addition, we offer the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>We note that we are unable to identify whether the device covered by the above-referenced 510(k) clearance is the same as the 2usmiles your firm is currently marketing. We request that you provide to us in writing with your firm’s basis for determining the 2usmiles is the same device described in K191837.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implantation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 653455 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRonald Jiang\n\nRecipient Title\n\nOwner & CEO\n\nVitang Technology LLC\n\n14662 Franklin Ave Ste H\n\nTustin, CA 92780-7224\n\nUnited States\n\nron@vitangtechnology.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 653455\n\nJune 12, 2023\n\nDear Mr. Jiang:\n\nDuring an inspection of your firm, Vitang Technology LLC. (Vitang or “the firm”), located in Tustin, CA on January 24, 2023 through January 31, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of The UniSmile Clear Aligner, a Class II dental aligner, cleared under 510(k) K191837and marketed as both the “UniSmile Clear Aligner System” and “2usmiles” on your firm’s websites. For example, your website (https:\u002F\u002Funismile.us\u002F) promotes the device name Unismile. Additionally, your website (https:\u002F\u002Fwww.2usmiles.com\u002F) promotes the device name 2usmiles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the UniSmile Clear Aligner System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nWe received your response, dated February 20, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nMisbranded and\u002For Unapproved Device Violations\n\nOur inspection revealed that your firm currently holds a 510(k) clearance for the “UniSmile Clear Aligner System.” This device was cleared on January 30, 2020, under K191837 for, among other things, treatment of tooth malocclusion in patients with permanent dentition by way of continuous gentle force. Your 510(k) summary dated January 29, 2020 states that “Software is used to design treatment plans. The software used with UniSmile Clear Aligner System is the Orchestrate 3D (K181112) software, version OrthoRx 4”.\n\nOur inspection revealed that your firm made changes to the device without submission of a new 510(k). On November 26, 2019 you changed from using the cleared Orchestrate 3D to the non-cleared iRok OrthoRx 4.0 for the development of the treatment plans for your UniSmile Clear Aligner System. You indicated that you performed verification and validation activities on iRok OrthoRx 4.0 and concluded that this software is “similar in designing clear aligner treatment plans” as Orchestrate 3D (K181112). However, note that verification and validation requirements apply for all devices subject to 21 CFR 820.30, and must be conducted regardless of whether submission of a new 510(k) is required. A change in orthodontic treatment planning software is a change that could significantly affect the safety and effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Specifically, a change from Orchestrate 3D to iRok OrthoRx 4.0 has the potential to affect the proposed treatment protocol as well as the dimensions, configurations, and applied forces of the UniSmile Clear Aligners, and affect the clinical outcome. Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified UniSmile Clear Aligner System. You did not submit any new 510(k) for the referenced modification to the UniSmile Clear Aligner System.\n\nTherefore, your devices are misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). Your devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulation (QSR) Violations\n\nOur inspection also revealed that the UniSmile Clear Aligner System is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198.\n\nSpecifically, our inspection revealed that your firm has failed to establish and maintain procedures for (1) determining whether a complaint is reportable to the FDA under part 803, (2) investigating the possible failure of a device to meet any of its specifications, and (3) receiving complaints outside of your firm's complaint management system, including oral complaints. Instead, your procedure, Customer complaints and refinements, is used to only to provide refinement services, (e.g., rescans). For example, 11 out of 13 complaint records reviewed during our inspection did not include an evaluation for MDR reportability nor an evaluation to determine if an investigation was necessary. In addition, you did not perform an investigation into reports of broken aligners.\n\nWe reviewed your firm’s response, and it is inadequate. Although you stated that you recognize that your procedure lacks specific steps to report death or serious injuries, and that you will review and update procedures to comply with MDR reporting requirements within 6 weeks of your response and conduct training, you have not provided evidence of the corrective and preventive actions. Further, your response is also inadequate because it did not address corrective actions that you have taken or plan to take to establish procedures for investigating the possible failure of a device to meet any of its specifications or receiving complaints outside of your firm's complaint management system, including oral complaints.\n\n2. Failure to validate software used as part of the quality system for its intended use according to an established protocol, as required by 21 CFR 820.70(i).\n\nSpecifically, you failed to validate your complaint handling system software. Your Ruby on Rails server-side web application framework, using the programming language Ruby and found at unismile.us, is used to maintain complaint files. However, your firm has failed to validate the software for its intended use.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. In your response, your firm stated that your complaint handling system has been in use for a few years and has “proven to be effective.” However, your firm has not provided evidence of the effectiveness of this complaint handling system. Additionally, your firm stated that you initiated an action plan to validate the complaint handling system. You committed to generate a software validation report, approach, testing methodology, and results of the validation within 6 weeks of your response to FDA. You have not provided a response with evidence of the corrective and preventive actions relevant to the complaint handling system effectiveness.\n\n3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluation of suppliers, contractors, and consultants, as required by 21 CFR 820.50(a).\n\nSpecifically, you are not defining the type and extent of control to be exercised over supplier services. When our investigator asked for an evaluation of your firm’s suppliers, you only provided a Manufacturing and Supply Agreement with Xi’an Henghui Technologies Co., Ltd. The August 27, 2021, manufacturing agreement with Henghui, the Chinese contract manufacturer and supplier for the uncleared software you use in the design of the dental aligners, does not identify the roles and responsibilities of both companies. Henghui has contract manufactured your devices since 2019.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you conducted comprehensive inspections of your critical supplier, Henghui, including site visits, and documented the results. You stated to look at an Attachment A. However, the response did not contain an Attachment A. Further, all supporting documents in the response are in Chinese and cannot be reviewed or assessed. You stated that you plan to review the supplier evaluation process and update necessary documents as soon as possible, and conduct auditing of all suppliers, within 12 weeks of the response. You have not provided a response with evidence of the corrective and preventive actions.\n\n4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR § 820.75(b), and failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, including the validation of major equipment, as required by 21 CFR 820.75(a).\n\nSpecifically, your Validation of Process procedure refers to “approval of equipment” but does not address equipment qualification to show that equipment is appropriately designed, constructed, placed, and installed. You stated during the inspection that you have documents in Chinese from the supplier that show the installation and qualifications of your 3D printer. However, since they were not in English, we were unable to verify this statement nor if your firm validated the 3D printing process used to manufacture the UniSmile Clear Aligner System. In addition, your firm’s General Manager and Engineering Manager stated that your firm documents the installation of the printers and the operational and performance qualification in the HeyGears Ultracraft A2D Quasi-Industrial Grade DLP 3D Printer operation manual when an installation occurs. However, that manual does not indicate when the qualification occurred or include evidence that it was performed.\n\nWe reviewed your firm’s response and concluded that your response is inadequate. Your firm has not provided a procedure that addresses major equipment qualification or process validation for your 3D printing process. You stated that you will complete the necessary updates to the equipment qualification documents for all equipment within 12 weeks of the response and conduct training. We request that you provide evidence that your 3D printing process has been qualified and validated.\n\n5. Failure to adequately establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\n\nSpecifically, the Equipment Calibration List in your firm’s Control of Monitoring and Measuring Equipment’s procedure states that the 3D Printer should be calibrated monthly, but your firm could only provide a record of quarterly maintenance. You are not documenting the next calibration due date for your 3D printers used in the manufacture of dental aligners. Records are not readily available to the personnel using such equipment as you do not keep the records at the firm. Instead, your firm stated that they are kept with the 3D printer supplier\u002Fcalibrator.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that the equipment has been calibrated but, due to a manpower shortage, some of the records were not available. You also stated this was compounded by deficiencies in forms and procedures. You stated that you will review your forms and procedures relating to calibration and update as necessary within 10 weeks of the response. You have not provided calibration records to show all equipment was calibrated on the required schedule and have not provided a response with evidence of the corrective and preventive actions.\n\n6. Failure to establish procedures for device history records as required by 21 CFR 820.184.\n\nSpecifically, your firm does not have a device history record (DHR) procedure. For example, a review of 11 out of 13 device history records (DHRs) for dental aligners did not include nor make reference to the primary identification label and labeling used for each production unit. In addition, the device history records do not contain any UDI information on its label or labeling. During our inspection, you stated that the procedure is being held at the supplier in China.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you reviewed Henghui’s procedures and quality documents and deemed them equivalent to your firm’s procedure in Attachment B. You stated that you can obtain documents from Henghui upon request and then referenced an Attachment C. Both attachments are in Chinese, and we are unable to review them. You stated that the DHR does not include or refer to the location of any UDI or UPC as you believed the devices were custom-made and exempt. In your response you stated that you plan to conduct a review and update of device history process procedures with 8 weeks of the response and provide guidance to all employees; and you will review and update shipping documentation within 4 weeks of the response and then conduct training. You stated that you will update your DHRs with regard to UDI\u002FUPC within 6 weeks of the response and provide training to employees.\n\n7. Failure to document the results and\u002For dates of management reviews as required by 21 CFR 820.20(c).\n\nSpecifically, you firm has no record of management reviews. Your Quality Manual and Management Responsibility documents both make references to the required conduct of management reviews. You provided a memo on 01\u002F30\u002F2023 that they have been conducted. However, it is generalized as to the topics covered and there are no dates of reviews documented.\n\nYour firm’s response is inadequate because it does not address this observation.\n\n8. Failure to document personnel training as required by 21 CFR 820.25(b).\n\nYour firm has failed to document training records. Specifically, you were unable to provide training records for General\u002FEngineering Manager and the CEO\u002FVice President of Operations\u002FHead of Shipment Tracking and Handling.\n\nHowever, your procedure that we did review indicates that new employees attend an orientation that includes training on the quality system, the quality policy, the importance of meeting regulatory, statutory and customer requirements, and the relevance and importance of their activities and how they contribute to the achievement of the quality objective. However, there is no documentation of this orientation.\n\nYour firm’s response is inadequate because it does not address your firm’s failure to document personnel training.\n\nRepresentations that Create an Impression of FDA Approval\n\nThe UniSmile Clear Aligner System is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because a representation on your website creates an impression of official approval of the device and is misleading. In addition, 21 CFR 807.97 states that any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Your website contains such representations. Specifically, your website at https:\u002F\u002Fwww.2usmiles.com\u002Fwhy-2usmiles states: “FDA APPROVED.” and incorporates the FDA logo. Statements about having active status with the FDA, and display of the FDA logo near images of and information about the respective products, is misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nIn addition, we offer the following comment:\n\nWe note that we are unable to identify whether the device covered by the above-referenced 510(k) clearance is the same as the 2usmiles your firm is currently marketing. We request that you provide to us in writing with your firm’s basis for determining the 2usmiles is the same device described in K191837.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implantation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 653455 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest","Vitang Technology LLC","vitang-technology-llc-653455-06122023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-06122023","2026-10-26T08:10:28.614825+00:00","Closed Out","2023-06-20","653455","2024-07-31","Ronald Jiang","2026-08-20T01:02:45.663+00:00","2023-06-12",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":66,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},2156,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2023-03-21T13:20:00Z\">03\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-16T04:00:00Z\">03\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarina-technology-llc-652997-03162023\">Marina Technology LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nicholas Gollust and Robert Sunderland\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Marina Technology LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6080 Center Drive, Floor 6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Los Angeles\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90045\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nick@marinatech.com\"> nick@marinatech.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@marinatech.co\"> info@marinatech.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 16, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Nicholas Gollust and Robert Sunderland:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.marinatech.co and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.marinatech.co revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Aquabar Berry Blast, Aquabar Peach Ice, and Aquabar Rainbow Ice.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301909, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003Cbr>\n\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nMarina Technology, LLC\u003Cbr>\nAttn: Sam Rosenberg and Nicholas\u003Cbr>\nsam@marinavape.com\u003Cbr>\nnick@marinavape.com\u003C\u002Fp>\n\n\u003Cp>Marina Vape LLC\u003Cbr>\nAttn: Nebil Kabir\u003Cbr>\n4943 McConnell Ave Ste N\u003Cbr>\nLos Angeles, CA 90066\u003Cbr>\ninfo@marinatech.co\u003C\u002Fp>\n\n\u003Cp>Key-Systems GmbH\u003Cbr>\nabuse@key-systems.net\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\u003Cp>Element Vape\u003Cbr>\n300 W. Valley Blvd, Unit 23\u003Cbr>\nAlhambra, CA 91803\u003Cbr>\ncustomerservice@elementvape.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nNicholas Gollust and Robert Sunderland\n\nMarina Technology LLC\n\n6080 Center Drive, Floor 6\n\nLos Angeles, CA 90045\n\nUnited States\n\nnick@marinatech.com\n\ninfo@marinatech.co\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 16, 2023\n\nWARNING LETTER\n\nDear Nicholas Gollust and Robert Sunderland:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.marinatech.co and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.marinatech.co revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Aquabar Berry Blast, Aquabar Peach Ice, and Aquabar Rainbow Ice.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301909, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nMarina Technology, LLC\n\nAttn: Sam Rosenberg and Nicholas\n\nsam@marinavape.com\n\nnick@marinavape.com\n\nMarina Vape LLC\n\nAttn: Nebil Kabir\n\n4943 McConnell Ave Ste N\n\nLos Angeles, CA 90066\n\ninfo@marinatech.co\n\nKey-Systems GmbH\n\nabuse@key-systems.net\n\nShopify, Inc.\n\nabuse@shopify.com\n\nElement Vape\n\n300 W. Valley Blvd, Unit 23\n\nAlhambra, CA 91803\n\ncustomerservice@elementvape.com","Marina Technology LLC","marina-technology-llc-652997-03162023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarina-technology-llc-652997-03162023","2026-10-26T08:09:20.478436+00:00","2023-03-21","652997","Tobacco","Nicholas Gollust and Robert Sunderland","2026-08-20T01:11:27.55+00:00","VIA UPS and Electronic Mail","2023-03-16",{"id":98,"raw":99,"subject":104,"body_html":105,"body_text":106,"firm_name":107,"letter_id":108,"created_at":109,"fei_number":19,"letter_url":110,"updated_at":111,"action_type":22,"case_status":23,"posted_date":112,"marcs_cms_no":113,"product_type":114,"closeout_date":19,"issuing_office":103,"recipient_name":115,"body_fetched_at":116,"delivery_method":117,"recipient_title":19,"reference_number":118,"action_taken_date":119,"medical_device_id":19,"response_letter_date":19},171,[100,101,102,103,104,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-22T04:00:00Z\">04\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Festar-technologies-ltd-716831-04222026\">Estar Technologies Ltd\u003C\u002Fa>","Center for Biologics Evaluation and Research","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-716831\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Aaron Esteron\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and Founder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Estar Technologies Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15, Ha-Merkava\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Holon\u003C\u002Fspan> \u003Cspan>5885111\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Israel\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Aaron@estar-medical.com\"> Aaron@estar-medical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-716831\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Esteron:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is offering for sale the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit (hereafter, “your devices”) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), your devices are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your websites at https:\u002F\u002Fwww.tropocells.com and https:\u002F\u002Festar-medical.com\u002F (last visited April 2026), your devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your introduction or delivery for introduction of your devices into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the Act, 21 U.S.C. § 331(a). Your devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce your devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a).\u003C\u002Fp>\u003Cp>Of note, the TropoCells® PRP kit was cleared under premarket notification (510(k)) submission number BK110035 with the following indication, “safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft and\u002For allograft bone prior to application to a bony defect for improving handling characteristics.” However, you include statements such as the following on your website, https:\u002F\u002Fwww.tropocells.com, regarding the uses of the Tropocells® PRP kit:\u003C\u002Fp>\u003Cp>“Tropocells® PRP is the ideal autologous technology for the healing of: musculoskeletal injuries, joint and osteoarthritis treatment, sports injuries, wound healing, ophthalmology, dentistry and oral surgery, and post-surgical recovery.”\u003C\u002Fp>\u003Cp>These represent major changes or modifications to the intended uses for this device and are changes or modifications that could significantly affect its safety or effectiveness. Therefore, premarket notification for this device is required. See 21 CFR 807.81(a)(3).\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA. 21 C.F.R. § 807.81(b). The kind of information that you need to submit in order to obtain approval or clearance for your devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Estar Technologies Ltd. should cease any activities that result in the misbranding or adulteration of the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit, such as the commercial distribution of the devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify our office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actionsyour firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your devices are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: Mr. Irving L. Wiesen, Esq\u003Cbr>US Agent\u003Cbr>Law Offices of Irving L. Wiesen PC.\u003Cbr>420 Lexington Avenue, Suite 2400\u003Cbr>New York, New York 10170\u003Cbr>lwiesen@Wiesenlaw.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-716831\n\nProduct:\n\nBiologics\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAaron Esteron\n\nRecipient Title\n\nChief Executive Officer and Founder\n\nEstar Technologies Ltd\n\n15, Ha-Merkava\n\nHolon 5885111\n\nIsrael\n\nAaron@estar-medical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nApril 22, 2026\nCBER 26-716831\nDear Mr. Esteron:\nThe United States Food and Drug Administration (FDA) has learned that your firm is offering for sale the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit (hereafter, “your devices”) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), your devices are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or any function of the body.\nBased on information and records reviewed by FDA, including your websites at https:\u002F\u002Fwww.tropocells.com and https:\u002F\u002Festar-medical.com\u002F (last visited April 2026), your devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your introduction or delivery for introduction of your devices into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the Act, 21 U.S.C. § 331(a). Your devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce your devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a).\nOf note, the TropoCells® PRP kit was cleared under premarket notification (510(k)) submission number BK110035 with the following indication, “safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft and\u002For allograft bone prior to application to a bony defect for improving handling characteristics.” However, you include statements such as the following on your website, https:\u002F\u002Fwww.tropocells.com, regarding the uses of the Tropocells® PRP kit:\n“Tropocells® PRP is the ideal autologous technology for the healing of: musculoskeletal injuries, joint and osteoarthritis treatment, sports injuries, wound healing, ophthalmology, dentistry and oral surgery, and post-surgical recovery.”\nThese represent major changes or modifications to the intended uses for this device and are changes or modifications that could significantly affect its safety or effectiveness. Therefore, premarket notification for this device is required. See 21 CFR 807.81(a)(3).\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA. 21 C.F.R. § 807.81(b). The kind of information that you need to submit in order to obtain approval or clearance for your devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nConclusion\nEstar Technologies Ltd. should cease any activities that result in the misbranding or adulteration of the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit, such as the commercial distribution of the devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify our office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actionsyour firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your devices are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc: Mr. Irving L. Wiesen, Esq\nUS Agent\nLaw Offices of Irving L. Wiesen PC.\n420 Lexington Avenue, Suite 2400\nNew York, New York 10170\nlwiesen@Wiesenlaw.com","Estar Technologies Ltd","estar-technologies-ltd-716831-04222026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Festar-technologies-ltd-716831-04222026","2026-10-26T08:08:36.3981+00:00","2026-05-12","716831","BiologicsMedical Devices","Aaron Esteron","2026-08-19T04:42:21.534+00:00","Via UPS and EMAIL","CBER 26-716831","2026-04-22",{"id":121,"raw":122,"subject":128,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":44,"fei_number":19,"letter_url":133,"updated_at":134,"action_type":22,"case_status":23,"posted_date":135,"marcs_cms_no":136,"product_type":137,"closeout_date":19,"issuing_office":126,"recipient_name":138,"body_fetched_at":139,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":140,"medical_device_id":19,"response_letter_date":19},1348,[123,124,125,126,127,13,13,13],"\u003Ctime datetime=\"2024-07-23T13:20:00Z\">07\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-09T04:00:00Z\">07\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fformulation-technology-inc-672905-07092024\">Formulation Technology, Inc.\u003C\u002Fa>","Division of Human and Animal Food Operations West V","New Drugs\u002FDietary Supplements\u002FFood Labeling\u002FMisbranded\u003Cbr \u002F>\r\n","New Drugs\u002FDietary Supplements\u002FFood Labeling\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Matthew D. McBride\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCo-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Formulation Technology, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>571 Armstrong Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oakdale\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95361\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 9, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL 672905\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McBride:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 571 Armstrong Way, Oakdale, CA, from October 24 through November 9, 2023.\u003C\u002Fp>\n\n\u003Cp>Based on inspectional findings and review of the product labeling collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations.\u003C\u002Fp>\n\n\u003Cp>You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov. At the conclusion of the inspection on November 9, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response dated December 5, 2023, and we address your responses below.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed product labeling for \u003Cstrong>(b)(4)\u003C\u002Fstrong> product following the inspection of your facility between October 24 and November 9, 2023. The claims on the product labeling establish that the product \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a drug under section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)], because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims that provide evidence that the product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Product name, \u003Cstrong>(b)(4)\u003C\u002Fstrong>: The product name implies the product is intended to cure, mitigate, treat, or prevent migraines.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the finished product label for \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fli>\n\t\u003Cli>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility on October 24, 2023, through November 9, 2023, identified significant violations of the FDA’s regulations for Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, Title 21, Code of Federal Regulations Part 111 (21 CFR Part 111). These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements. Specifically, these violations cause the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act. Also, in addition to being an unapproved new drug, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is likewise an adulterated dietary supplement for the same reason.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of dietary supplement cGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish component specifications for each component that you used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement, as required under 21 CFR 111.70(b).\u003C\u002Fp>\n\n\u003Cp>Specifically, during the inspection, the investigator noted that you failed to establish limits on those types of contamination that may adulterate or that may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(3). Notably, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> component specification sheets are lacking heavy metal specifications. These two components, which are used to manufacture the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, are botanicals and are at risk for heavy metal contamination.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish product specifications for strength of the finished batch for each dietary supplement that you manufacture to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e).\u003C\u002Fp>\n\n\u003Cp>Specifically, as observed during the inspection, you failed to establish product specification for strength for each finished batch of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. We received and reviewed your December 5, 2023 written response and determined it inadequate. Your finished product specification sheet for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is lacking adequate strength specifications. The method listed on the finished product specification sheet for determining the strength of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the finished product is by “input.” While measuring input may be a useful process control, it is not an appropriate test method for determining the strength specification of these ingredients in the finished batch of dietary supplement.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>We reviewed product labels collected during the inspection and have determined the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products you manufacture are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements. Thus, in addition to being an unapproved new drug, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is also a misbranded dietary supplement. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. 343(q)(1)(A)] because the serving size declared on the label is incorrect. The terms \"serving\" or \"serving size\" for a dietary supplement are defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2, as the maximum amount recommended on the label for consumption per eating occasion. For example, the serving size declared in the Supplement Facts label for all intended groups is 2 caplets, whereas the recommended use is one caplet twice a day with food for children \u003Cstrong>(b)(4)\u003C\u002Fstrong> years. Furthermore, there is no correlation between the serving size for children ages&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> years that appears in the Supplement Facts label and the recommended use that appears on the product labeling.\u003C\u002Fp>\n\n\u003Cp>2. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are misbranded within the meaning of 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The title, “Supplement Facts”, is not set at full width of the nutrition label in accordance with 21 CFR 101.36(e)(1).\u003C\u002Fli>\n\t\u003Cli>A light bar is not placed beneath the heading “Amount Per Serving”, which as not in accordance with 21 CFR 101.36(e)(7).\u003C\u002Fli>\n\t\u003Cli>The subheading “Servings Per Container” does not appear under the subheading “Serving Size”, which is not in accordance with 21 CFR 101.36(b)(1)(ii).\u003C\u002Fli>\n\t\u003Cli>The dietary ingredients that comprise the proprietary blend do not appear to be indented, which is not in accordance with 21 CFR 101.36(c)(2).\u003C\u002Fli>\n\t\u003Cli>There is no provision in the regulation for the footnote symbol *** to link to a statement within the Supplement Facts label that describes the constituents of the proprietary blend.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A heavy bar is not placed beneath the final (b)(2)-dietary ingredient, which is not in accordance with 21 CFR 101.36(e)(6)(ii).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comment:\u003C\u002Fp>\n\n\u003Cp>1. We note that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished product specification for Lead is &lt; \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm and for Arsenic is &lt; \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Your batch record for \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> reports lead results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Under 21 CFR 111.70(e), you must establish specifications for limits on those types of contamination that may adulterate, or may lead to adulteration of, the finished batch of dietary supplement to ensure the quality of the dietary supplement. We request that your response address the scientific basis for setting a specification for lead at &lt; \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm as a level that will not adulterate the dietary supplement.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your firm’s response to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\nFormulation Technology, Inc.\u003Cbr>\n1201 Harbor Bay Parkway\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number CMS #672905 when replying.\u003C\u002Fp>\n\n\u003Cp>If you prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. Matthew D. McBride\n\nRecipient Title\n\nPresident\u002FCo-Owner\n\nFormulation Technology, Inc.\n\n571 Armstrong Way\n\nOakdale, CA 95361\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nJuly 9, 2024\n\nWL 672905\n\nDear Mr. McBride:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 571 Armstrong Way, Oakdale, CA, from October 24 through November 9, 2023.\n\nBased on inspectional findings and review of the product labeling collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations.\n\nYou can find the Act and FDA regulations through links on FDA's home page at www.fda.gov. At the conclusion of the inspection on November 9, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483).\n\nWe acknowledge receipt of your response dated December 5, 2023, and we address your responses below.\n\nUnapproved New Drug\n\nFDA reviewed product labeling for (b)(4) product following the inspection of your facility between October 24 and November 9, 2023. The claims on the product labeling establish that the product (b)(4) is a drug under section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)], because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the claims that provide evidence that the product is intended for use as a drug include:\n\nProduct name, (b)(4): The product name implies the product is intended to cure, mitigate, treat, or prevent migraines.\n\nOn the finished product label for (b)(4):\n\n“(b)(4).”\n\n“(b)(4).”\n\nThe (b)(4) product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nAdulterated Dietary Supplements\n\nThe inspection of your facility on October 24, 2023, through November 9, 2023, identified significant violations of the FDA’s regulations for Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, Title 21, Code of Federal Regulations Part 111 (21 CFR Part 111). These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements. Specifically, these violations cause the (b)(4) product manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act. Also, in addition to being an unapproved new drug, your (b)(4) product is likewise an adulterated dietary supplement for the same reason.\n\nYour significant violations of dietary supplement cGMP requirements are as follows:\n\n1. You failed to establish component specifications for each component that you used in the manufacture of your (b)(4) dietary supplement, as required under 21 CFR 111.70(b).\n\nSpecifically, during the inspection, the investigator noted that you failed to establish limits on those types of contamination that may adulterate or that may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(3). Notably, your (b)(4) and (b)(4) component specification sheets are lacking heavy metal specifications. These two components, which are used to manufacture the (b)(4) product, are botanicals and are at risk for heavy metal contamination.\n\n2. You failed to establish product specifications for strength of the finished batch for each dietary supplement that you manufacture to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e).\n\nSpecifically, as observed during the inspection, you failed to establish product specification for strength for each finished batch of your (b)(4) product. We received and reviewed your December 5, 2023 written response and determined it inadequate. Your finished product specification sheet for your (b)(4) product is lacking adequate strength specifications. The method listed on the finished product specification sheet for determining the strength of (b)(4), and (b)(4) in the finished product is by “input.” While measuring input may be a useful process control, it is not an appropriate test method for determining the strength specification of these ingredients in the finished batch of dietary supplement.\n\nMisbranded Dietary Supplements\n\nWe reviewed product labels collected during the inspection and have determined the (b)(4) and (b)(4) products you manufacture are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements. Thus, in addition to being an unapproved new drug, your (b)(4) product is also a misbranded dietary supplement. Specifically, we identified the following:\n\n1. The (b)(4) product is misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. 343(q)(1)(A)] because the serving size declared on the label is incorrect. The terms \"serving\" or \"serving size\" for a dietary supplement are defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2, as the maximum amount recommended on the label for consumption per eating occasion. For example, the serving size declared in the Supplement Facts label for all intended groups is 2 caplets, whereas the recommended use is one caplet twice a day with food for children (b)(4) years. Furthermore, there is no correlation between the serving size for children ages (b)(4) years that appears in the Supplement Facts label and the recommended use that appears on the product labeling.\n\n2. The (b)(4) and (b)(4) products are misbranded within the meaning of 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36. For example:\n\na. (b)(4)\n\nThe title, “Supplement Facts”, is not set at full width of the nutrition label in accordance with 21 CFR 101.36(e)(1).\n\nA light bar is not placed beneath the heading “Amount Per Serving”, which as not in accordance with 21 CFR 101.36(e)(7).\n\nThe subheading “Servings Per Container” does not appear under the subheading “Serving Size”, which is not in accordance with 21 CFR 101.36(b)(1)(ii).\n\nThe dietary ingredients that comprise the proprietary blend do not appear to be indented, which is not in accordance with 21 CFR 101.36(c)(2).\n\nThere is no provision in the regulation for the footnote symbol *** to link to a statement within the Supplement Facts label that describes the constituents of the proprietary blend.\n\nb. (b)(4)\n\nA heavy bar is not placed beneath the final (b)(2)-dietary ingredient, which is not in accordance with 21 CFR 101.36(e)(6)(ii).\n\nThis letter is not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also offer the following comment:\n\n1. We note that the (b)(4) finished product specification for Lead is \u003C (b)(4) ppm and for Arsenic is \u003C (b)(4) ppm. Your batch record for (b)(4) batch (b)(4) reports lead results of (b)(4) ppm. Under 21 CFR 111.70(e), you must establish specifications for limits on those types of contamination that may adulterate, or may lead to adulteration of, the finished batch of dietary supplement to ensure the quality of the dietary supplement. We request that your response address the scientific basis for setting a specification for lead at \u003C (b)(4) ppm as a level that will not adulterate the dietary supplement.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your firm’s response to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\nFormulation Technology, Inc.\n\n1201 Harbor Bay Parkway\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number CMS #672905 when replying.\n\nIf you prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5","Formulation Technology, Inc.","formulation-technology-inc-672905-07092024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fformulation-technology-inc-672905-07092024","2026-10-26T08:08:42.764022+00:00","2024-07-23","672905","Dietary Supplements","Mr. Matthew D. McBride","2026-08-19T23:56:35.01+00:00","2024-07-09",{"id":142,"raw":143,"subject":83,"body_html":147,"body_text":148,"firm_name":149,"letter_id":150,"created_at":151,"fei_number":19,"letter_url":152,"updated_at":153,"action_type":22,"case_status":23,"posted_date":154,"marcs_cms_no":155,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":19,"body_fetched_at":156,"delivery_method":29,"recipient_title":19,"reference_number":157,"action_taken_date":158,"medical_device_id":19,"response_letter_date":19},1723,[144,145,146,82,83,13,13,13],"\u003Ctime datetime=\"2023-11-28T14:20:00Z\">11\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-21T05:00:00Z\">11\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-ijoy-technology-co-ltd-672190-11212023\">Shenzhen IJOY Technology Co., LTD.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2302063\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Shenzhen IJOY Technology Co., LTD.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:service@ijoycig.com\"> service@ijoycig.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 21, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.ijoycig.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.ijoycig.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following ENDS products without a marketing authorization order, including: IJOY Bar IC8000 Disposable, Apple Juice; and IJOY Bar SD10000, Blue Razz Ice.\u003Cbr>\n\u003Cbr>\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2302063, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nShenzhen IJOY Technology Co.\u003Cbr>\nsales@ijoycig.com\u003Cbr>\nmarketing@ijoycig.com\u003C\u002Fp>\n\n\u003Cp>Element Vape\u003Cbr>\ncustomerservice@elementvape.com\u003C\u002Fp>\n\n\u003Cp>22net, Inc.\u003Cbr>\nAbuse@22.cn\u003C\u002Fp>\n\n\u003Cp>Alicoud-US\u003Cbr>\nIntl-abuse@list.alibaba-inc.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\nRW2302063\n\nProduct:\n\nTobacco\n\nRecipient:\n\nShenzhen IJOY Technology Co., LTD.\n\nChina\n\nservice@ijoycig.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 21, 2023\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.ijoycig.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.ijoycig.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following ENDS products without a marketing authorization order, including: IJOY Bar IC8000 Disposable, Apple Juice; and IJOY Bar SD10000, Blue Razz Ice.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2302063, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nShenzhen IJOY Technology Co.\n\nsales@ijoycig.com\n\nmarketing@ijoycig.com\n\nElement Vape\n\ncustomerservice@elementvape.com\n\n22net, Inc.\n\nAbuse@22.cn\n\nAlicoud-US\n\nIntl-abuse@list.alibaba-inc.com","Shenzhen IJOY Technology Co., LTD.","shenzhen-ijoy-technology-co-ltd-672190-11212023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-ijoy-technology-co-ltd-672190-11212023","2026-10-26T08:09:56.493138+00:00","2023-11-28","672190","2026-08-20T00:29:09.972+00:00","RW2302063","2023-11-21",{"id":160,"raw":161,"subject":83,"body_html":165,"body_text":166,"firm_name":167,"letter_id":168,"created_at":44,"fei_number":19,"letter_url":169,"updated_at":170,"action_type":22,"case_status":23,"posted_date":171,"marcs_cms_no":172,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":173,"body_fetched_at":174,"delivery_method":95,"recipient_title":19,"reference_number":175,"action_taken_date":176,"medical_device_id":19,"response_letter_date":19},1303,[162,163,164,82,83,13,13,13],"\u003Ctime datetime=\"2024-08-27T13:20:00Z\">08\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-16T04:00:00Z\">08\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapollo-future-technology-inc-690452-08162024\">Apollo Future Technology, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402185\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Lawrence Robert Ciardella\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Apollo Future Technology, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4460 W Reno Ave Ste H-I\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89118\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Support@apolloecigs.com\"> Support@apolloecigs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 16, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Lawrence Robert Ciardella:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fapolloecigs.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1,] and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: FLUM Gio 3000 puff Disposable Vape - Power Bull and Brez Pods 4-Pack Breeze.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402185, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\u003Cp>United States Corporation Agents, Inc.\u003Cbr>\n6605 Grand Montecito Pkwy, Suite 100\u003Cbr>\nLas Vegas, NV 89149\u003Cbr>\nramanagement@legalzoom.com\u003C\u002Fp>\n\n\u003Cp>Apollo Future Technology, Inc.\u003Cbr>\nAttn: Richard Zhu\u003Cbr>\n30 Lindbergh Ave.\u003Cbr>\nLivermore, CA 94551\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402185\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nLawrence Robert Ciardella\n\nApollo Future Technology, Inc.\n\n4460 W Reno Ave Ste H-I\n\nLas Vegas, NV 89118\n\nUnited States\n\nSupport@apolloecigs.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 16, 2024\n\nWARNING LETTER\n\nDear Lawrence Robert Ciardella:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fapolloecigs.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1,] and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: FLUM Gio 3000 puff Disposable Vape - Power Bull and Brez Pods 4-Pack Breeze.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402185, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com\n\nUnited States Corporation Agents, Inc.\n\n6605 Grand Montecito Pkwy, Suite 100\n\nLas Vegas, NV 89149\n\nramanagement@legalzoom.com\n\nApollo Future Technology, Inc.\n\nAttn: Richard Zhu\n\n30 Lindbergh Ave.\n\nLivermore, CA 94551","Apollo Future Technology, Inc.","apollo-future-technology-inc-690452-08162024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapollo-future-technology-inc-690452-08162024","2026-10-26T08:07:56.512387+00:00","2024-08-27","690452","Lawrence Robert Ciardella","2026-08-19T23:52:03.53+00:00","RW2402185","2024-08-16",{"id":178,"raw":179,"subject":83,"body_html":183,"body_text":184,"firm_name":185,"letter_id":186,"created_at":151,"fei_number":19,"letter_url":187,"updated_at":188,"action_type":22,"case_status":23,"posted_date":189,"marcs_cms_no":190,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":19,"body_fetched_at":191,"delivery_method":29,"recipient_title":19,"reference_number":192,"action_taken_date":193,"medical_device_id":19,"response_letter_date":19},1712,[180,181,182,82,83,13,13,13],"\u003Ctime datetime=\"2023-12-12T14:20:00Z\">12\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-01T05:00:00Z\">12\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzovoo-technology-co-ltd-shenzhen-672760-12012023\">ZOVOO Technology Co., Ltd. Shenzhen\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2302065\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>ZOVOO Technology Co., Ltd. Shenzhen\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@izovoo.com\"> sales@izovoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 1, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.izovoo.com and determined that the electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including smokeless nicotine products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.izovoo.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: ZOVOO Dragbar F8000 Disposable, Strawberry Orange Mango; ZOVOO Dragbar R6000 Disposable, Watermelon Cherry; and ZOVOO Dragbar 6500 Disposable, Sour Berry.\u003Cbr>\n\u003Cbr>\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this warning letter These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2302065, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nZOVOO (Shenzhen) Technology Co Ltd.\u003Cbr>\nsupport@izovoo.com\u003Cbr>\nmarketing@izovoo.com\u003Cbr>\nsales@zovoo.com.cn\u003C\u002Fp>\n\n\u003Cp>ZOVOO (Shenzhen) Technology Co Ltd.\u003Cbr>\nAttn: William Tang\u003Cbr>\nregulation@zovoo.com.cn\u003C\u002Fp>\n\n\u003Cp>Chemular Inc.\u003Cbr>\nAttn: Bryan Burd\u003Cbr>\n103 W Main St\u003Cbr>\nHudson, MI 49247\u003Cbr>\nbryan.burd@chemular.com\u003C\u002Fp>\n\n\u003Cp>Alibaba Cloud Computing (Beijing) Co., Ltd.\u003Cbr>\nDomainAbuse@service.aliyun.com\u003C\u002Fp>\n\n\u003Cp>ALICLOUD-US\u003Cbr>\nabuse@alibaba-inc.com\u003Cbr>\nintl-abuse@list.alibaba-inc.com\u003C\u002Fp>\n\n\u003Cp>Element Vape\u003Cbr>\ncustomerservice@elementvape.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\nRW2302065\n\nProduct:\n\nTobacco\n\nRecipient:\n\nZOVOO Technology Co., Ltd. Shenzhen\n\nChina\n\nsales@izovoo.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDecember 1, 2023\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.izovoo.com and determined that the electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including smokeless nicotine products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.izovoo.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: ZOVOO Dragbar F8000 Disposable, Strawberry Orange Mango; ZOVOO Dragbar R6000 Disposable, Watermelon Cherry; and ZOVOO Dragbar 6500 Disposable, Sour Berry.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this warning letter These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nIt is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2302065, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002Fs\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nZOVOO (Shenzhen) Technology Co Ltd.\n\nsupport@izovoo.com\n\nmarketing@izovoo.com\n\nsales@zovoo.com.cn\n\nZOVOO (Shenzhen) Technology Co Ltd.\n\nAttn: William Tang\n\nregulation@zovoo.com.cn\n\nChemular Inc.\n\nAttn: Bryan Burd\n\n103 W Main St\n\nHudson, MI 49247\n\nbryan.burd@chemular.com\n\nAlibaba Cloud Computing (Beijing) Co., Ltd.\n\nDomainAbuse@service.aliyun.com\n\nALICLOUD-US\n\nabuse@alibaba-inc.com\n\nintl-abuse@list.alibaba-inc.com\n\nElement Vape\n\ncustomerservice@elementvape.com","ZOVOO Technology Co., Ltd. Shenzhen","zovoo-technology-co-ltd-shenzhen-672760-12012023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzovoo-technology-co-ltd-shenzhen-672760-12012023","2026-10-26T08:10:39.873177+00:00","2023-12-12","672760","2026-08-20T00:28:11.422+00:00","RW2302065","2023-12-01",{"id":195,"raw":196,"subject":83,"body_html":200,"body_text":201,"firm_name":202,"letter_id":203,"created_at":66,"fei_number":19,"letter_url":204,"updated_at":205,"action_type":22,"case_status":23,"posted_date":206,"marcs_cms_no":207,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":208,"body_fetched_at":209,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":206,"medical_device_id":19,"response_letter_date":19},2344,[197,198,199,82,83,13,13,13],"\u003Ctime datetime=\"2022-11-16T15:35:00Z\">11\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-16T05:00:00Z\">11\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-fumot-technology-co-ltd-645183-11162022\">Shenzhen Fumot Technology Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Xiochuan Chen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Shenzhen Fumot Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@fumot-tech.com\"> info@fumot-tech.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@randmvape.com\"> sales@randmvape.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>November 16, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Xiochuan Chen:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the websites https:\u002F\u002Fwww.fumot-tech.com and https:\u002F\u002Frandmvape.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.fumot-tech.com and https:\u002F\u002Frandmvape.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Fumot Original RandM Max Pro Rechargeable 3600 Puff Disposable Vape Pen Pod Device; Fumot Original RandM Squid Bar 2500 Puffs Disposable Vape Pen Device; Fumot Original RandM Squid Box 5200 Puffs Disposable Vape Pod Device; RandM Switch 2in1 Disposable Pod Device (Cartoon Design 2400 Puffs); Fumot Original RandM Dazzle 5000 RGB Glowing Disposable Vape Pod Device; and Fumot Original RandM Dazzle Pro 2600 Puffs RGB Glowing Disposable Vape Pod Device.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds your products particularly concerning because the product labeling and\u002For advertising for the RandM products (see Exhibits A) are likely to promote use of the products by youth by imitating popular TV shows and movies (see Exhibits B). FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products. FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645183%20Bart%20Simpson_0.PNG\" alt=\"Bart skate\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645183.jpg\" alt=\"Squid game\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645183Pict.jpg\" alt=\"Doll Squid\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645183Mini.jpg\" alt=\"Minions \">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645183Family.jpg\" alt=\"Family simpsons\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645183Rick.jpg\" alt=\"Rick and Morty\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201876, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Alibaba Cloud Computing (Beijing) Co., Ltd.\u003Cbr>\nDomainAbuse@service.aliyun.com\u003C\u002Fp>\n\n\u003Cp>Alibaba.com LLC\u003Cbr>\nintl-abuse@list.alibaba-inc.com\u003Cbr>\nabuse@alibaba-inc.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nXiochuan Chen\n\nShenzhen Fumot Technology Co., Ltd.\n\nChina\n\ninfo@fumot-tech.com\n\nsales@randmvape.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 16, 2022\n\nWARNING LETTER\n\nDear Xiochuan Chen:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the websites https:\u002F\u002Fwww.fumot-tech.com and https:\u002F\u002Frandmvape.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.fumot-tech.com and https:\u002F\u002Frandmvape.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Fumot Original RandM Max Pro Rechargeable 3600 Puff Disposable Vape Pen Pod Device; Fumot Original RandM Squid Bar 2500 Puffs Disposable Vape Pen Device; Fumot Original RandM Squid Box 5200 Puffs Disposable Vape Pod Device; RandM Switch 2in1 Disposable Pod Device (Cartoon Design 2400 Puffs); Fumot Original RandM Dazzle 5000 RGB Glowing Disposable Vape Pod Device; and Fumot Original RandM Dazzle Pro 2600 Puffs RGB Glowing Disposable Vape Pod Device.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nAdditional Considerations\n\nFDA finds your products particularly concerning because the product labeling and\u002For advertising for the RandM products (see Exhibits A) are likely to promote use of the products by youth by imitating popular TV shows and movies (see Exhibits B). FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products. FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201876, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nAlibaba Cloud Computing (Beijing) Co., Ltd.\n\nDomainAbuse@service.aliyun.com\n\nAlibaba.com LLC\n\nintl-abuse@list.alibaba-inc.com\n\nabuse@alibaba-inc.com\n\nShopify, Inc.\n\nabuse@shopify.com","Shenzhen Fumot Technology Co., Ltd.","shenzhen-fumot-technology-co-ltd-645183-11162022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-fumot-technology-co-ltd-645183-11162022","2026-10-26T08:09:56.337642+00:00","2022-11-16","645183","Xiochuan Chen","2026-08-20T01:26:18.335+00:00",{"id":211,"raw":212,"subject":104,"body_html":217,"body_text":218,"firm_name":219,"letter_id":220,"created_at":221,"fei_number":19,"letter_url":222,"updated_at":223,"action_type":22,"case_status":69,"posted_date":224,"marcs_cms_no":225,"product_type":26,"closeout_date":226,"issuing_office":11,"recipient_name":227,"body_fetched_at":228,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":229,"medical_device_id":19,"response_letter_date":19},3458,[213,214,215,11,104,13,216,13],"\u003Ctime datetime=\"2021-03-16T04:00:00Z\">03\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-11T05:00:00Z\">03\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-weifa-technology-co-ltd-609828-03112021\">Shenzhen Weifa Technology Co., Ltd\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-weifa-technology-co-ltd-609828-09272021\">\u003Ctime datetime=\"2021-09-27T04:00:00Z\">09\u002F27\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Huaquan Yu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Shenzhen Weifa Technology Co., Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Room 403, Building 117, Sungang Village, Baogang Road, Sungang Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>518100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@starkit.com\"> info@starkit.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: March 11, 2021\u003C\u002Fp>\n\n\u003Cp>Re: FFP1 3-ply Non-Woven EarLoop Mask and N95\u002FFFP2 Respirator\u003C\u002Fp>\n\n\u003Cp>Dear Huaquan Yu:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the Internet address www.starkit.com, on February 2, 2021, where you offered the “FFP1 3-ply Non-Woven EarLoop Mask” and “N95\u002FFFP2 Respirator” for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The FFP1 3-ply Non-Woven EarLoop Mask and the N95\u002FFFP2 Respirator\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> are being offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, the FFP1 3-ply Non-Woven EarLoop Mask and N95\u002FFFP2 Respirator are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. The devices are not “FDA certificated” and so express statements to the contrary are false. Moreover, FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to your firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the N95\u002FFFP2 Respirator are misleading and constitute misbranding. \u003Cem>See\u003C\u002Fem> 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false and\u002For misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Stating that the devices are “FDA certificated” and that the devices are “official certificated…FDA.”\u003Cbr>\n• Unauthorized display of FDA’s logo\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> alongside the devices’ product information.\u003Cbr>\n• Displaying a “Certification of FDA Registration” (Certification) issued by “Shenzhen CCT Testing Technology Co. Ltd.” alongside N95\u002FFFP2 Respirator product information. The Certification “certifies that Shenzhen Weifa Technology Co., Ltd … has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” and incorporates, unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>To date, FDA has not “certificated” the FFP1 3-ply Non-Woven EarLoop Mask and the N95\u002FFFP2 Respirators, and statements to the contrary are false. In addition, taken together, display of the FDA logo and Certification positioned near images of and information about the N95\u002FFFP2 Respirator are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the N95\u002FFFP2 Respirator and\u002For establishment based on the existence of your firm’s registration and possession of a registration number. Although the Certification contains language that appears to be intended to function as a disclaimer, including a statement that the Certification does not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of the language could be easily overlooked and do not limit or otherwise mitigate the misleading impression created by the use of the Certification. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the N95\u002FFFP2 Respirator has been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue any type of device registration certificates to medical device establishments, including sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database does not denote anything other than that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the product or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen 15 business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 609828 or CTS Number CPT2000946 when replying. We remind you that only written communication is considered as official.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector Division of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Angla Li\u003Cbr>\nUS Agent\u003Cbr>\n4402 Gertrude Dr\u003Cbr>\nFremont, CA 94536 xv393fbhh@sina.cn\u003C\u002Fp>\n\n\u003Cp>Alan Lin\u003Cbr>\nShenzhen CCT Testing Technology Co. Ltd.\u003Cbr>\n6F, Fazhan Building, No.04, Shangwu Road,\u003Cbr>\nShiyan Town, Bao'an District, Shenzhen, Guangdong, 518108 China\u003Cbr>\nfda@fda-test.com\u003C\u002Fp>\n\n\u003Cp>Fei Leng\u003Cbr>\nGaomishi Zhonghexiang Labor Products Industry &amp; Trade Company\u003Cbr>\n2th.Zhilan Village, Chaoyang District, Gaomi City,\u003Cbr>\nShandong Province, Weifang Shandong, CN 261500\u003C\u002Fp>\n\n\u003Cp>Medical Facility Company\u003Cbr>\nUS Agent\u003Cbr>\n555 Lexington Avenue\u003Cbr>\nFort George, NY 10040\u003Cbr>\nSpecifyA@163.com\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your website indicates the N95\u002FFFP2 Respirator is manufactured by “Gaomishi Zhonghexiang labor products industry &amp;Trade Co., Ltd.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHuaquan Yu\n\nShenzhen Weifa Technology Co., Ltd\n\nRoom 403, Building 117, Sungang Village, Baogang Road, Sungang Street\n\nShenzhen Shi\n\nGuangdong Sheng, 518100\n\nChina\n\ninfo@starkit.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: March 11, 2021\n\nRe: FFP1 3-ply Non-Woven EarLoop Mask and N95\u002FFFP2 Respirator\n\nDear Huaquan Yu:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the Internet address www.starkit.com, on February 2, 2021, where you offered the “FFP1 3-ply Non-Woven EarLoop Mask” and “N95\u002FFFP2 Respirator” for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe FFP1 3-ply Non-Woven EarLoop Mask and the N95\u002FFFP2 Respirator1 are being offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, the FFP1 3-ply Non-Woven EarLoop Mask and N95\u002FFFP2 Respirator are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. The devices are not “FDA certificated” and so express statements to the contrary are false. Moreover, FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to your firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the N95\u002FFFP2 Respirator are misleading and constitute misbranding. See 21 CFR 807.39.\n\nYour website contains a number of false and\u002For misleading representations, including but not limited to:\n\n• Stating that the devices are “FDA certificated” and that the devices are “official certificated…FDA.”\n\n• Unauthorized display of FDA’s logo2 alongside the devices’ product information.\n\n• Displaying a “Certification of FDA Registration” (Certification) issued by “Shenzhen CCT Testing Technology Co. Ltd.” alongside N95\u002FFFP2 Respirator product information. The Certification “certifies that Shenzhen Weifa Technology Co., Ltd … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” and incorporates, unauthorized use of the FDA logo2.\n\nTo date, FDA has not “certificated” the FFP1 3-ply Non-Woven EarLoop Mask and the N95\u002FFFP2 Respirators, and statements to the contrary are false. In addition, taken together, display of the FDA logo and Certification positioned near images of and information about the N95\u002FFFP2 Respirator are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the N95\u002FFFP2 Respirator and\u002For establishment based on the existence of your firm’s registration and possession of a registration number. Although the Certification contains language that appears to be intended to function as a disclaimer, including a statement that the Certification does not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of the language could be easily overlooked and do not limit or otherwise mitigate the misleading impression created by the use of the Certification. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the N95\u002FFFP2 Respirator has been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue any type of device registration certificates to medical device establishments, including sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database does not denote anything other than that the establishment has provided certain information to FDA.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the product or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them.\n\nPlease notify this office in writing within fifteen 15 business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 609828 or CTS Number CPT2000946 when replying. We remind you that only written communication is considered as official.\n\nIf you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector Division of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nAngla Li\n\nUS Agent\n\n4402 Gertrude Dr\n\nFremont, CA 94536 xv393fbhh@sina.cn\n\nAlan Lin\n\nShenzhen CCT Testing Technology Co. Ltd.\n\n6F, Fazhan Building, No.04, Shangwu Road,\n\nShiyan Town, Bao'an District, Shenzhen, Guangdong, 518108 China\n\nfda@fda-test.com\n\nFei Leng\n\nGaomishi Zhonghexiang Labor Products Industry & Trade Company\n\n2th.Zhilan Village, Chaoyang District, Gaomi City,\n\nShandong Province, Weifang Shandong, CN 261500\n\nMedical Facility Company\n\nUS Agent\n\n555 Lexington Avenue\n\nFort George, NY 10040\n\nSpecifyA@163.com\n\n_____________________\n\n1 Your website indicates the N95\u002FFFP2 Respirator is manufactured by “Gaomishi Zhonghexiang labor products industry &Trade Co., Ltd.”\n\n2 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).","Shenzhen Weifa Technology Co., Ltd","shenzhen-weifa-technology-co-ltd-609828-03112021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-weifa-technology-co-ltd-609828-03112021","2026-10-26T08:09:56.748503+00:00","2021-03-16","609828","2021-09-27","Huaquan Yu","2026-08-20T03:16:48.496+00:00","2021-03-11",{"id":231,"raw":232,"subject":236,"body_html":238,"body_text":239,"firm_name":240,"letter_id":241,"created_at":221,"fei_number":19,"letter_url":242,"updated_at":243,"action_type":22,"case_status":69,"posted_date":244,"marcs_cms_no":245,"product_type":26,"closeout_date":246,"issuing_office":11,"recipient_name":247,"body_fetched_at":248,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":244,"medical_device_id":19,"response_letter_date":19},3488,[233,234,235,11,236,13,237,13],"\u003Ctime datetime=\"2021-03-04T21:30:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-sunell-technology-corporation-613563-03042021\">Shenzhen Sunell Technology Corporation\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-sunell-technology-corporation-613563-07202023\">\u003Ctime datetime=\"2023-07-27T04:00:00Z\">07\u002F27\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ann Wu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Shenzhen Sunell Technology Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4 Aerospace Micromoto Bldg 2 Floor 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Ann Wu\u003Cbr>\nShenzhen Sunell Technology Corporation\u003Cbr>\nAliases: Sunell Technology, Sunell Security\u003Cbr>\n4 Aerospace Micromoto Bldg 2 Floor 5\u003Cbr>\nShenzhen\u003Cbr>\nCHINA\u003C\u002Fp>\n\n\u003Cp>sales@sunellsecurity.com, support@sunellsecurity.com\u003Cbr>\n&nbsp;&nbsp;\u003Cbr>\nRE:&nbsp;&nbsp;&nbsp;&nbsp; Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Sirs,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.sunellsecurity.com\u002F on February 26, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the Bi-Spectrum Fever Screening Network Camera (SN-T5P-F), Temperature Screening Thermographic Network Bullet Camera (SN-F22-B), AI Fever Screening Network Camera With Integrated Blackbody (SN-T5H-P-F), and Fever Screening Body Temperature Measurement Network Camera Accurate ±0.3℃ (SN-T5\u002FF) (collectively, “Screening Cameras”), for sale in the United States. Based on our review, these products are intended to mitigate, prevent, treat, diagnose or cure COVID-19&nbsp; in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the Screening Cameras are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“At the start-up of 2020, Covid-19 had been sweeping through the mainland of China, and now is getting threatening worldwide. From the occurrence of the epidemic to today, Sunell's ''panda camera'' -- Body Temperature Measurement System played an important role in the work of prevention and control of epidemic. It has become the guardians for thousands of prevention and control site and points worldwide.” and “FIGHTING CORONAVIRUS WE ARE AT THE FRONTIER!” [Both statements published in their article, “History of Sunell Body Temperature Measurement System”, https:\u002F\u002Fwww.sunellsecurity.com\u002Fhistory-of-sunell-body-temperature-measurement-system_n231]\u003C\u002Fp>\n\n\u003Cp>The Screening Cameras are offered for sale in the United States without marketing approval, clearance, or authorization from FDA.&nbsp; Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[ ] In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.[ ] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment.&nbsp; These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.sunellsecurity.com\u002F, includes statements that the Screening Cameras are intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“High efficiency on temperature detection, up to 45 Targets” and “Temperature screening for multiple people at the same time” [Both statements published on your Bi-Spectrum Fever Screening Network Camera webpage, https:\u002F\u002Fwww.sunellsecurity.com\u002Fbi-spectrum-fever-screening-network-camera_p16.html]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Body temperature measurement up to 30 Targets”, “High efficiency on temperature detection, up to 30Targets”, and “Temperature screening for multiple people at the same time” [All statements published on your Temperature Screening Thermographic Network Bullet Camera webpage, https:\u002F\u002Fwww.sunellsecurity.com\u002Ftemperature-screening-thermographic-network-bullet-camera_p144.html]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Body temperature measurement up to 45 Targets”, “High efficiency on temperature detection, up to 45 Targets”, and “Temperature screening for multiple people at the same time” [All statements published on your AI Fever Screening Network Camera With Integrated Blackbody webpage, https:\u002F\u002Fwww.sunellsecurity.com\u002Fai-fever-screening-network-camera-with-integrated-blackbody_p141.html]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Body temperature measurement up to 45 Targets”, “High efficiency on temperature detection, up to 45 Targets”, and “Temperature screening for multiple people at the same time” [All statements published on your Fever Screening Body Temperature Measurement Network Camera Accurate ±0.3℃ webpage, https:\u002F\u002Fwww.sunellsecurity.com\u002Ffever-screening-body-temperature-measurement-network-camera-accurate-0-3_p13.html]\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”[ ] provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to \u003C\u002Fstrong>COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613563 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective action.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fa>.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp;&nbsp;&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAnn Wu\n\nShenzhen Sunell Technology Corporation\n\n4 Aerospace Micromoto Bldg 2 Floor 5\n\nShenzhen\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nAnn Wu\n\nShenzhen Sunell Technology Corporation\n\nAliases: Sunell Technology, Sunell Security\n\n4 Aerospace Micromoto Bldg 2 Floor 5\n\nShenzhen\n\nCHINA\n\nsales@sunellsecurity.com, support@sunellsecurity.com\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Sirs,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.sunellsecurity.com\u002F on February 26, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the Bi-Spectrum Fever Screening Network Camera (SN-T5P-F), Temperature Screening Thermographic Network Bullet Camera (SN-F22-B), AI Fever Screening Network Camera With Integrated Blackbody (SN-T5H-P-F), and Fever Screening Body Temperature Measurement Network Camera Accurate ±0.3℃ (SN-T5\u002FF) (collectively, “Screening Cameras”), for sale in the United States. Based on our review, these products are intended to mitigate, prevent, treat, diagnose or cure COVID-19 in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Screening Cameras are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\n\n• “At the start-up of 2020, Covid-19 had been sweeping through the mainland of China, and now is getting threatening worldwide. From the occurrence of the epidemic to today, Sunell's ''panda camera'' -- Body Temperature Measurement System played an important role in the work of prevention and control of epidemic. It has become the guardians for thousands of prevention and control site and points worldwide.” and “FIGHTING CORONAVIRUS WE ARE AT THE FRONTIER!” [Both statements published in their article, “History of Sunell Body Temperature Measurement System”, https:\u002F\u002Fwww.sunellsecurity.com\u002Fhistory-of-sunell-body-temperature-measurement-system_n231]\n\nThe Screening Cameras are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[ ] In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.[ ] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.sunellsecurity.com\u002F, includes statements that the Screening Cameras are intended to scan multiple individuals simultaneously, including:\n\n• “High efficiency on temperature detection, up to 45 Targets” and “Temperature screening for multiple people at the same time” [Both statements published on your Bi-Spectrum Fever Screening Network Camera webpage, https:\u002F\u002Fwww.sunellsecurity.com\u002Fbi-spectrum-fever-screening-network-camera_p16.html]\n\n• “Body temperature measurement up to 30 Targets”, “High efficiency on temperature detection, up to 30Targets”, and “Temperature screening for multiple people at the same time” [All statements published on your Temperature Screening Thermographic Network Bullet Camera webpage, https:\u002F\u002Fwww.sunellsecurity.com\u002Ftemperature-screening-thermographic-network-bullet-camera_p144.html]\n\n• “Body temperature measurement up to 45 Targets”, “High efficiency on temperature detection, up to 45 Targets”, and “Temperature screening for multiple people at the same time” [All statements published on your AI Fever Screening Network Camera With Integrated Blackbody webpage, https:\u002F\u002Fwww.sunellsecurity.com\u002Fai-fever-screening-network-camera-with-integrated-blackbody_p141.html]\n\n• “Body temperature measurement up to 45 Targets”, “High efficiency on temperature detection, up to 45 Targets”, and “Temperature screening for multiple people at the same time” [All statements published on your Fever Screening Body Temperature Measurement Network Camera Accurate ±0.3℃ webpage, https:\u002F\u002Fwww.sunellsecurity.com\u002Ffever-screening-body-temperature-measurement-network-camera-accurate-0-3_p13.html]\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”[ ] provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\n\nYou should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613563 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective action.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Shenzhen Sunell Technology Corporation","shenzhen-sunell-technology-corporation-613563-03042021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-sunell-technology-corporation-613563-03042021","2026-10-26T08:09:56.686107+00:00","2021-03-04","613563","2023-07-27","Ann Wu","2026-08-20T03:19:25.621+00:00",{"id":250,"raw":251,"subject":256,"body_html":257,"body_text":258,"firm_name":259,"letter_id":260,"created_at":66,"fei_number":19,"letter_url":261,"updated_at":262,"action_type":22,"case_status":23,"posted_date":263,"marcs_cms_no":264,"product_type":265,"closeout_date":19,"issuing_office":266,"recipient_name":267,"body_fetched_at":268,"delivery_method":269,"recipient_title":19,"reference_number":19,"action_taken_date":270,"medical_device_id":19,"response_letter_date":19},2144,[252,253,254,255,256,13,13,13],"\u003Ctime datetime=\"2023-03-28T13:20:00Z\">03\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-13T04:00:00Z\">03\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnugeneration-technologies-llc-645821-03132023\">NuGeneration Technologies LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations IV ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Donato B. Polignone\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u002FFounder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NuGeneration Technologies LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1155 Park Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Emeryville\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dpolignone@nugentec.com\"> dpolignone@nugentec.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations IV \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 13, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Polignone:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, NuGeneration Technologies LLC., FEI 3004943112, at 1155 Park Avenue in Emeryville, California from September 14 to September 22, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 12, 2022 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to conduct adequate release testing of your NuRinse Hand Sanitizer drug product\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. You only conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing prior to release. Full release testing, which includes strength and identity testing of the active ingredient (e.g., ethanol), and appropriate impurity and microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test incoming active pharmaceutical ingredients (API) (e.g., ethanol) and other components (e.g., deionized (DI) water) used to manufacture over-the-counter drug products to determine their identity, purity, strength, and other appropriate quality attributes. Additionally, you have not shown that your water system can consistently produce water suitable for drug manufacturing, and, at a minimum, meets the USP monograph for Purified Water and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>\u003Cem>Inadequate API Testing\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm relied on the COA from unqualified suppliers of ethanol. This component is used as an active ingredient in the manufacture of your NuRinse Hand Sanitizer drug product. CGMP requires identity testing for each component lot used in drug product manufacturing, and you can only rely on the COA for other component attributes by appropriately validating the supplier’s test results at appropriate intervals. You also failed to appropriately test your incoming ethanol, used as an active ingredient, for methanol.\u003C\u002Fp>\n\n\u003Cp>The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Inadequate Component Water\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm has not shown that your DI water is suitable for aqueous-based dosage form drug product manufacturing, and, at a minimum, meets the USP Purified Water monograph and appropriate microbials limits. Your firm lacked sufficient testing of your DI water system. For example, you failed to appropriately test for total organic carbon or microbial organisms, and you failed to ensure that your conductivity results are accurate and recorded.\u003C\u002Fp>\n\n\u003Cp>Without routine water monitoring of an appropriately designed system, you cannot ensure that your water meets minimum microbiological and chemical standards suitable for the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked stability data to support the expiration dates for your NuRinse Hand Sanitizer drug product currently in distribution. Without an adequate stability program, you cannot confirm that your drug product will meet established specifications and all pre-determined quality criteria throughout their shelf life.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o&nbsp; Stability-indicating methods\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o&nbsp; An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your water system design, control, and maintenance.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o&nbsp; Detailed definition of the specific attributes to be tested at each station(timepoint)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to validate the manufacturing process for NuRinse Hand Sanitizer drug product currently in distribution.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>Timelines for completed process performance qualification for marketed drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier \u003Cstrong>645821\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have any further questions, please contact Compliance Officer Nayan J. Patel by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven E. Porter, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>____________________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). Because NuGeneration Technologies LLC.’s hand sanitizer products were not prepared under the circumstances described in this guidance, they do not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDonato B. Polignone\n\nRecipient Title\n\nChief Executive Officer\u002FFounder\n\nNuGeneration Technologies LLC\n\n1155 Park Avenue\n\nEmeryville, CA 94608\n\nUnited States\n\ndpolignone@nugentec.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nMarch 13, 2023\n\nDear Mr. Polignone:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, NuGeneration Technologies LLC., FEI 3004943112, at 1155 Park Avenue in Emeryville, California from September 14 to September 22, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 12, 2022 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm failed to conduct adequate release testing of your NuRinse Hand Sanitizer drug product1. You only conducted (b)(4), and (b)(4) testing prior to release. Full release testing, which includes strength and identity testing of the active ingredient (e.g., ethanol), and appropriate impurity and microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide:\n\nA list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and211.84(d)(2)).\n\nYour firm failed to test incoming active pharmaceutical ingredients (API) (e.g., ethanol) and other components (e.g., deionized (DI) water) used to manufacture over-the-counter drug products to determine their identity, purity, strength, and other appropriate quality attributes. Additionally, you have not shown that your water system can consistently produce water suitable for drug manufacturing, and, at a minimum, meets the USP monograph for Purified Water and appropriate microbial limits.\n\nInadequate API Testing\n\nYour firm relied on the COA from unqualified suppliers of ethanol. This component is used as an active ingredient in the manufacture of your NuRinse Hand Sanitizer drug product. CGMP requires identity testing for each component lot used in drug product manufacturing, and you can only rely on the COA for other component attributes by appropriately validating the supplier’s test results at appropriate intervals. You also failed to appropriately test your incoming ethanol, used as an active ingredient, for methanol.\n\nThe use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nInadequate Component Water\n\nYour firm has not shown that your DI water is suitable for aqueous-based dosage form drug product manufacturing, and, at a minimum, meets the USP Purified Water monograph and appropriate microbials limits. Your firm lacked sufficient testing of your DI water system. For example, you failed to appropriately test for total organic carbon or microbial organisms, and you failed to ensure that your conductivity results are accurate and recorded.\n\nWithout routine water monitoring of an appropriately designed system, you cannot ensure that your water meets minimum microbiological and chemical standards suitable for the manufacture of your drug products.\n\nIn response to this letter, provide:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\n\nRegarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYour firm lacked stability data to support the expiration dates for your NuRinse Hand Sanitizer drug product currently in distribution. Without an adequate stability program, you cannot confirm that your drug product will meet established specifications and all pre-determined quality criteria throughout their shelf life.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability-indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\nA comprehensive, independent assessment of your water system design, control, and maintenance.\n\no Detailed definition of the specific attributes to be tested at each station(timepoint)\n\nAll procedures that describe these and other elements of your remediated stability program.\n\n4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to validate the manufacturing process for NuRinse Hand Sanitizer drug product currently in distribution.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate process performance qualification for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\nTimelines for completed process performance qualification for marketed drug products.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your response with unique identifier 645821.\n\nIf you have any further questions, please contact Compliance Officer Nayan J. Patel by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven E. Porter, Jr.\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations IV\n\n____________________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because NuGeneration Technologies LLC.’s hand sanitizer products were not prepared under the circumstances described in this guidance, they do not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","NuGeneration Technologies LLC","nugeneration-technologies-llc-645821-03132023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnugeneration-technologies-llc-645821-03132023","2026-10-26T08:09:35.725918+00:00","2023-03-28","645821","Drugs","Division of Pharmaceutical Quality Operations IV","Donato B. Polignone","2026-08-20T01:10:36.39+00:00","Via Email","2023-03-13",{"id":272,"raw":273,"subject":12,"body_html":277,"body_text":278,"firm_name":279,"letter_id":280,"created_at":66,"fei_number":19,"letter_url":281,"updated_at":282,"action_type":22,"case_status":23,"posted_date":283,"marcs_cms_no":284,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":285,"body_fetched_at":286,"delivery_method":287,"recipient_title":19,"reference_number":19,"action_taken_date":288,"medical_device_id":19,"response_letter_date":19},2068,[274,275,276,11,12,13,13,13],"\u003Ctime datetime=\"2023-06-06T13:20:00Z\">06\u002F06\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-19T04:00:00Z\">05\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsteiner-biotechnology-llc-651802-05192023\">Steiner Biotechnology, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gregory G. Steiner, DDS\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Steiner Biotechnology, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1051 Olsen Street, Suite 3611\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Henderson\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89011\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #651802\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 19, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Steiner:\u003C\u002Fp>\n\n\u003Cp>During inspections of your firm located at 1051 Olsen Street, Suite 3611, Henderson, NV 89011 on August 15–19, 2022 and November 3-8, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bone grafting materials including, the Socket Graft, Socket Graft Plus, Socket Graft Injectable, OsseoConduct, OsseoConduct Micron, Ridge Graft Kit, Immediate Graft, and Oral Bond. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Quality System Regulation Provisions and Regulations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspections revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from you dated November 21, 2022, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). For example,\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures various implantable bone grafting materials, including the OsseoConduct, Socket Graft, Immediate Graft, and Socket Graft Injectable, which require design controls and you have not established design control procedures.\u003C\u002Fp>\n\n\u003Cp>a. Your firm’s “Quality Management Systems Manual,” dated June 1, 2017, includes high level requirements indicating design activities will be conducted and meet the requirements outlined in 21 CFR 820.30; however, this manual does not include procedures on describing how these activities will be conducted or documented.\u003C\u002Fp>\n\n\u003Cp>b. You verbally confirmed your firm’s only design control procedures were your “Design Input Requirements,” SOP 010-02, dated June 1, 2017. However, these procedures do not include procedures for design output, design reviews, design verification, design validation, design transfer, or changes, as required by 21 CFR 820.30(d) through (i).\u003C\u002Fp>\n\n\u003Cp>c. Your firm’s “Design Input Requirements,” SOP 010-02, dated June 1, 2017, does not include a mechanism for addressing ambiguous, incomplete, or conflicting requirements, as required by 21 CFR 820.30(c).\u003C\u002Fp>\n\n\u003Cp>d. Your firm has not established and maintained procedures for design verification, as required by 21 CFR 820.30(f). For example, your firm’s “Quality Management Systems Manual,” dated June 1, 2017, states design verification will be conducted to ensure design outputs have satisfied design input requirements. The product labeling for your OsseoConduct device identifies the following design inputs:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, you did not provide procedures for confirming that design output meets the design input requirements. You also did not provide documentation showing these design inputs have been verified. This is a repeat observation from the previous December 10-13, 2018, FDA inspection and a violation listed on the Untitled Letter issued to your firm on April 3, 2019. Your November 21, 2022 response is inadequate because, although you provided images of histological results, you did not provide supporting data or records, including pyrogen testing, to support what the test methods and records are purported to be.\u003Cbr>\n\u003Cbr>\ne. Your firm has not established and maintained adequate design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\u003C\u002Fp>\n\n\u003Cp>i. Your firm’s “Quality Management Systems Manual,” dated June 1, 2017, requires design validation to ensure that the resulting product is capable of fulfilling the requirements for the specified or known intended use or application. The labeling for your OsseoConduct bone grafting material states that this product was developed to meet the following criteria:\u003C\u002Fp>\n\n\u003Cp>&nbsp; 1. Does not elicit an inflammatory response\u003Cbr>\n&nbsp; 2. Produce bone with normal form and function\u003Cbr>\n&nbsp; 3. Be significantly resorbed in 3 months\u003Cbr>\n&nbsp; 4. Be able to handle reasonable load in order to resist deformation during the remodeling phase\u003Cbr>\n&nbsp; 5. Allow ease of application\u003Cbr>\n&nbsp; 6. Be designed to prevent bacterial colonization\u003C\u002Fp>\n\n\u003Cp>However, your firm did not provide procedures to ensure that devices conform to defined user needs and intended uses that include testing of production units under actual or simulated use conditions. You also did not provide documentation to demonstrate the OsseoConduct device was validated to ensure it conforms to these user needs. Your November 21, 2022 response is inadequate because, although you provided images of histological results, you did not provide supporting data or records, including pyrogen testing, to support what the test methods and records are purported to be.\u003C\u002Fp>\n\n\u003Cp>ii. Your firm has not established adequate procedures for risk analysis, as required by 21 CFR 820.30(g). Specifically, your firm manufactures the OsseoConduct bone graft material which is labeled to be an implantable, sterile, biocompatible, and pyrogen free device. However, the risk analysis documented in your Design History File dated June 1, 2017, does not identify any foreseeable hazards associated with the use of this device. Your November 21, 2022 response is inadequate because the “Risk Management Plan” you provided does not identify reasonably foreseeable hazards with your implantable sterile device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your firm’s response states your firm has conducted histology and biocompatibility studies which support the validation and verification of your OsseoConduct device. However, the records you provided to support this assertion do not show these studies were conducted using the OsseoConduct device. Additionally, the histology data provided does not include the study protocol or methods used to generate the data. Further, your response does not address the lack of adequate design control procedures or how you plan to correct this deficiency.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\u003C\u002Fp>\n\n\u003Cp>a. Your firm’s “Process Validation,” SOP 018, revision 2, dated June 1, 2017, establishes high level requirements for process validation; however, these procedures do not establish any specific requirements for the sterilization process validation for each of your devices.\u003C\u002Fp>\n\n\u003Cp>b. Your firm uses a \u003Cstrong>(b)(4)\u003C\u002Fstrong> process to sterilize your Oral Bond and Socket Graft devices. Your firm does not have records demonstrating these processes were validated as set forth in your firm’s “Process Validation,” SOP 018 and as required by 21 CFR 820.75(b)(1).\u003C\u002Fp>\n\n\u003Cp>c. Your firm uses a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process to sterilize your OsseoConduct device. Your firm does not have records demonstrating this process has been validated as set forth in your firm’s “Process Validation,” SOP 018 and as required by 21 CFR 820.75(b)(1).\u003C\u002Fp>\n\n\u003Cp>This is a repeat observation from the FDA inspection conducted December 10-13, 2018, and a violation listed on the Untitled Letter issued to your firm on April 3, 2019. We reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response is limited to a description of \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities purportedly conducted; however, it does not describe the specific processes used or include a protocol indicating critical process parameters to support the process is validated. Additionally, your response does not include a systemic evaluation of your firm’s manufacturing processes to ensure all processes requiring validation have been validated. Finally, your response did not include procedures establishing any specific requirements for the sterilization process validation for each of your devices.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain adequate procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. For example,\u003Cbr>\n\u003Cbr>\nYour firm’s “Purchasing &amp; Suppliers,” SOP 410, Version 0, dated June 1, 2017, requires suppliers to be evaluated and reviewed as part of a continuous and iterative process. However, your firm did not provide any records to support that these activities have been conducted.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response states all suppliers have been evaluated to meet standards and be in compliance with “SOP 140 00.” Your response also provided a supplier evaluation form, stating it will be used moving forward. However, your response does not include your revised procedures describing how this form will be used or records of training for the new process as required by 21 CFR 820.25. Additionally, your response is unclear if the supplier evaluation form is a requirement of your revised procedures and if so, whether the form has been completed for all suppliers or if this corrective action is ongoing. In response to this letter, we request you provided the most current purchasing control procedures showing compliance with 21 CFR 820.50, which addresses the use of the supplier evaluation form.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain adequate procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a). For example,\u003C\u002Fp>\n\n\u003Cp>Section 9 of your device history records (DHR) identifies specific acceptance criteria for each device. However, you do not have records required by 21 CFR 820.80(e) demonstrating these acceptance activities were conducted or documented for eight out of nine DHRs reviewed, as follows:\u003C\u002Fp>\n\n\u003Cp>a. Socket Graft Plus lot 061422\u003Cbr>\nb. OsseoConduct lot 060822\u003Cbr>\nc. BioDensification lot 072622\u003Cbr>\nd. Ridge Graft lot 060922\u003Cbr>\ne. Immediate Graft lot 100322\u003Cbr>\nf. Sinus Graft lot 072622\u003Cbr>\ng. Socket Graft lot 061322\u003Cbr>\nh. Socket Graft Injectable lot 090722\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response states you will analyze the criteria for acceptability for each device prior to the time of release and ensure appropriate documentation has been generated. However, your response does not include a retrospective review of previous lots to evaluate if previously release lots were deficient. Additionally, your response does not address any procedural corrective actions or revisions you are taking to ensure appropriate acceptance activities are conducted.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain adequate procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained, and to include provisions for handling, preservation, and storage of equipment, so that its accuracy and fitness for use are maintained, as required by 21 CFR 820.72(a). For example,\u003C\u002Fp>\n\n\u003Cp>Your firm uses a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilizion of your OsseoConduct device; however, your firm’s Laboratory Manager verbally confirmed this \u003Cstrong>(b)(4)\u003C\u002Fstrong> has not been calibrated and there are no records for calibration.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response states you have established an equipment list that identifies all production equipment requiring calibration. However, your response did not provide evidence the referenced&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> has been calibrated.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain procedures to adequately control environmental conditions that could reasonably be expected to have an adverse effect on product quality and failure to periodically inspect environmental control systems to verify that the system is adequate and functioning properly, as required by 21 CFR 820.70(c). For example,\u003C\u002Fp>\n\n\u003Cp>Your firm conducts manufacturing and packaging operations in ISO 7 certified cleanrooms both \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your dental graft material devices. Your firm does not have established written procedures for the environmental monitoring of these cleanrooms. Additionally, our investigators observed a box fan inside cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong> which may disrupt unidirectional airflow. Further, our investigators observed the area surrounding the cleanrooms to be dusty and contain miscellaneous items such as exercise equipment and a motorcycle. Your firm’s Laboratory Manager stated she gowns in this area prior to entering the ISO 7 cleanroom. Lastly, our review of the certification report for cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, documented the cleanroom failed the high average particle count specification. Your firm did not have a justification or investigation into this failed result.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response states the box fan has been removed from cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response does not address the other aspects of the observation or describe the corrective actions you have taken to address the lack of adequate environmental monitoring procedures.\u003C\u002Fp>\n\n\u003Cp>7. Failure to establish and maintain adequate procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system.\u003C\u002Fp>\n\n\u003Cp>These quality audits shall be conducted by individuals who do not have direct responsibility for the matters being audited, as required by 21 CFR 820.22. For example,\u003C\u002Fp>\n\n\u003Cp>Your firm’s “Audit,” SOP 023, revision 2, dated June 1, 2017, states general audits will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm has not conducted audits which meet the requirements of 21 CFR 820.22. Your firm’s Vice President of Marketing provided MDSAP task audit form templates for 2020, 2021, and 2022; however, these templates were limited to design control coverage and did not include coverage of other quality system requirements.\u003C\u002Fp>\n\n\u003Cp>This is a repeat observation from the previous December 10-13, 2018, FDA inspection and a violation listed on the Untitled Letter issued to your firm on April 3, 2019. We have reviewed your firm’s response dated November 21, 2022 and cannot determine the adequacy at this time. Your response states you have purchased auditing tools which will assist in generating and conducting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> audits. However, your response does not include a timeframe of the implementation of these tools or procedures describing their use for compliance with 21 CFR 820.22. Additionally, we remind you that any software used as part of the quality system shall be validated for its intended use, as required by 21 CFR 820.70(i).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Premarket Submission Requirements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Ridge Graft Kit, and Immediate Graft devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>1. Specifically, Socket Graft was cleared under K052493 and K113049 for use in dental extraction sockets that have all walls remaining. The earliest time point for implant placement in sockets grafted with Socket Graft is at 8 weeks.\u003C\u002Fp>\n\n\u003Cp>Based on evidence obtained from your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fsocket-graft\u002F) as of May 10, 2023, your firm is marketing Socket Graft for a different intended use, namely for use at an earlier time point than 8 weeks for implant placement. For example, your firm’s website states the following:\u003C\u002Fp>\n\n\u003Cp>“A faster and healthier bone regeneration sequence allows for an implant to be placed sooner than if other bone grafts were used. Implant placement at 4 weeks, 6 weeks, 12 weeks or more can now be achieved with predictable results.”\u003C\u002Fp>\n\n\u003Cp>However, there is no information in K052493 or K113049 to support an indication for placement at 4 or 6 weeks. This change in Indications for Use constitutes a significant change requiring a new premarket submission to modify the proposed indications for this device. Furthermore, promoting Socket Graft for use with implants earlier than what the data supported could significantly affect the safety or effectiveness of the device for implant to abutment compatibility, resulting in potential osseointegration complications of the dental implant bodies for patients. If you have data to support these indications, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>2. Additionally, based on evidence obtained from your website (https:\u002F\u002Fwww.steinerbio.com\u002Fregenerative-products\u002Fsocket-graft\u002F) as of May 10, 2023, several performance statements related to the use of Socket Graft appear to be unsupported. We have conducted a review of our files and are unable to identify an additional FDA clearance or approval supporting these performance statements. For example, your website includes the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“This innovative delivery system allows for ease of application, but most importantly, produces superior bone quality with bone to implant integration due to its osteogenic properties.” There is no information in K052493 or K113049 demonstrating that Socket Graft is superior to other bone graft material.\u003C\u002Fli>\n\t\u003Cli>“Socket Graft is a dual phase calcium phosphate based synthetic bone graft material designed to quickly treat the extraction socket, retain alveolar bone, stimulate bone formation, reduce post-operative complications, and resorb quickly and completely.” There is no information in K052493 or K113049 demonstrating that use of Socket Graft results in an accelerated healing response.\u003C\u002Fli>\n\t\u003Cli>“No allergic reaction” and “No inflammatory response.” There is no information in K052493 or K113049 demonstrating that use of Socket Graft results in no possibility of these adverse reactions occurring. In your June 14, 2022, response to our May 27, 2022, letter, you referenced external vendor \u003Cstrong>(b)(4)\u003C\u002Fstrong>, wherein testing per ISO 10993-1 evaluated safety and performance of the device; however, the testing results do not substantiate these performance statements. Your written response dated November 22, 2022, to our FDA 483, Inspectional Observations, included a biocompatibility study, which you also included in your June 14, 2022, response. You purport that this study supports the above performance statements. However, the biocompatibility study does not support these performance statements because the study data shows that an inflammatory response occurred.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We are not aware of any new data supporting such statements. These statements were communicated to you in our letter dated May 27, 2022. In your response to this letter dated June 14, 2022, you committed to removing or modifying some of these statements; however, to date, they have not been revised. Marketing the Socket Graft with these performance statements represent significant changes to the cleared device that require a new premarket submission. These assertions of performance characteristics identify new risk in affecting the timeline of patient treatment, treatment considerations, and effectiveness of the received treatment, that require additional performance testing and\u002For clinical testing in a new premarket submission. If you have data demonstrating these performance characteristics, please provide that information to the agency.\u003C\u002Fp>\n\n\u003Cp>3. Further, the OsseoConduct device was cleared under K101718 and intended to fill, augment or reconstruct periodontal or bony defects of the oral and maxillofacial region. Specifically, for the augmentation of deficient maxillary and mandibular alveolar ridges and the treatment of oral, maxillofacial, and dental intraosseous defects including ridge augmentation, sinus lifts, craniofacial augmentation, filling of defects of endodontic origin, filling of cystic defects, filling of extraction sites, filling of lesions of periodontal origin, repair of traumatic defects of the alveolar ridge, filling of resection defects from bone tumors, cysts or other osseous defects, and a substitute for autogenous or allogenic bone grafts. The device is fully resorbed in 6 months.\u003C\u002Fp>\n\n\u003Cp>However, based on evidence obtained on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Fregenerative-products\u002Fosseoconduct\u002F) as of May 10, 2023, several performance statements related to the use of OsseoConduct appear to be unsupported. We have conducted a review of our files and are unable to identify an additional FDA clearance or approval supporting these performance statements. For example, your website includes the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Be designed to prevent bacterial colonization.” There is no information in K101718 demonstrating that OsseoConduct prevents bacterial colonization.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>During our inspection conducted November 3-8, 2022, our investigators requested any data or studies that were conducted to support this statement, as would be required under 21 CFR 820.30. You stated that an external vendor \u003Cstrong>(b)(4)\u003C\u002Fstrong> conducted extensive biocompatibility studies for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of OsseoConduct. However, the the \u003Cstrong>(b)(4)\u003C\u002Fstrong> reports did not include adequate data, such as a prospective, long-term, statistically relevant clinical study to support this claim. Further, in your June 14, 2022, response to FDA’s May 27, 2022, letter, you agreed that the statement is not supported by the clearance and would remove the statement from your website; however as of May 10, 2023, the statement has not been removed.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Be significantly resorbed in 3 months.” There is no information in K101718 demonstrating that OsseoConduct is significantly resorbed in 3 months. The data show that full resorption occurs in \u003Cstrong>(b)(4)\u003C\u002Fstrong> months. Your June 14, 2022, response to FDA’s May 27, 2022, letter, asserts that the clearance establishes this statement. Your June 14, 2022, response also agreed to modify or remove this statement from your website; however as of May 10, 2023, the statement has not been modified or removed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We are not aware of any new data supporting the above statements. Promoting this device with these performance statements constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. These assertions of performance characteristics identify new risks in affecting the timeline of patient treatment, treatment considerations, and effectiveness of the received treatment, which may lead to a need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, these statements impact the intended use and performance of the device and require additional performance testing and\u002For clinical testing in a new premarket submission. If you have data demonstrating these performance characteristics, please provide that information to the agency.\u003C\u002Fp>\n\n\u003Cp>4. Your firm is currently marketing the Ridge Graft Kit, which appears to be a combination of the Socket Graft and OsseoConduct devices. Based on evidence obtained from your website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fridge-graft-kit\u002F) as of May 10, 2023, the Ridge Graft Kit is packaged in syringes. However, this form of packaging was not previously cleared in K101718, which describes OsseoConduct as being distributed in single-use pouch packaging. Evaluation of a product’s packaging and shelf-life for devices provided sterile is necessary to ensure the sterilization methods used in manufacturing settings adhere to FDA’s Quality System (QS) regulation requirements, 21 CFR part 820. Assurance of sterility is important to prevent a serious risk to human health because of the risk of infection. Additionally, packaging and sterility assurance, including delivery mechanisms such as syringes, are considered part of the finished device that must be assessed for safety (e.g., biocompatibility testing per ISO 10993-1). The interactions of packaging and the effects of sterilization can have direct and potentially negative impacts on a product’s biocompatibility; this may lead to a need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, use of different packaging and materials require additional performance testing and\u002For clinical testing as these changes could affect the safety and effectiveness of the devices and require submission of a new premarket submission. If you have data to support the new packaging, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>5. In addition, your firm is marketing the Socket Graft Plus, which appears to be a combination of your firm’s Socket Graft and OsseoConduct devices. Based on evidence obtained from your website (https:\u002F\u002Fwww.steinerbio.com\u002Fregenerative-products\u002Fsocket-graft-plus\u002F) as of May 10, 2023, the Socket Graft Plus is intended for use as “a bone graft material appropriate for all socket grafting situations” and is used to “integrate immediate implants.” We have reviewed our files and are unable to identify FDA clearance or approval for a product with this indication.\u003C\u002Fp>\n\n\u003Cp>In your response dated June 14, 2022 to our letter dated May 27, 2022, you state the Socket Graft Plus is cleared under K113049 and K101718 due to references being made to Socket Graft being used in conjunction with OsseoConduct in your 510(k) submissions. However, these 510(k) clearances do not include clearance for use as a single formulation without socket walls remaining, and for immediate implantation. Specifically, there is no information demonstrating the sterilization validation methods performed for the combined materials. In addition, the indications for use in these 510(k)s do not support the combination of these two devices, which is limited to use in dental extraction sockets that have all walls remaining; whereas the Socket Graft Plus indicates the device may be used for defects with missing walls. Further, grafts for immediate implants were not cleared in either of the Socket Graft or OsseoConduct submissions. The use of the product as described creates the risk of ineffective bone formation, infection, or non-biocompatible responses, which may lead to a need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, these changes impact the intended use, sterilization, and performance of the device and require additional performance testing and\u002For clinical testing in a new premarket submission. If you have data to support the sterilization validation method performed and additional indication, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>6. Further, your firm is currently marketing the Immediate Graft, which appears to be a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on evidence obtained from your website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fimmediate-graft\u002F) as of May 10, 2023, Immediate Graft is a dental bone grafting material intended to fill defects and achieve implant integration. Your firm’s website indicates this product is “proven to produce integration to immediate implants.” We have reviewed our files and are unable to identify FDA clearance or approval for a product with this indication.\u003C\u002Fp>\n\n\u003Cp>In your response dated June 14, 2022, to our letter dated May 27, 2022, you state the Immediate Graft is cleared under K113049 and K101718 due to references being made to Socket Graft being used in conjunction with OsseoConduct in your 510(k) submissions. However, these 510(k) clearances do not include clearance for use as a single formulation and as grafts for immediate implants. The use of the product as described creates the risk of ineffective bone formation, infection, or non-biocompatible responses, which may lead to a need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, these changes impact the intended use and performance of the device and require additional performance testing and\u002For clinical testing in a new premarket submission. Specifically, there is no information demonstrating the performance of your device (i.e., sterilization validation, biocompatibility, resorption\u002Fnew bone formation) for the combined materials. If you have data to support the indication, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>7. Additionally, based on evidence obtained during our November 3-8, 2022 inspection and evidence on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fosseoconduct\u002F) as of May 10, 2023, you are marketing the OsseoConduct Micron device for “Treating Peri-Implantitis with βTCP Air Abrasion.” There is no information in K101718 demonstrating that OsseoConduct is cleared for this intended treatment.\u003C\u002Fp>\n\n\u003Cp>Your June 14, 2022 response to FDA’s May 27, 2022 letter, states you are only marketing the device for the abrasive cleaning of dental appliances; however, as identified above, your firm’s website markets the device for the treatment of disease. This change in Indications for Use constitutes a significant change requiring a new premarket submission to modify the proposed indications for this device. Furthermore, promoting OsseoConduct for treatment of a new disease creates the risk of ineffective bone formation, infection, or non-biocompatible responses. If you have data to support this indication, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>8. Additionally, based on evidence obtained on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fsocket-graft-plus\u002F) as of May 10, 2023, you are marketing the Socket Graft in a new ‘petal’ form with silicone trays. This form and packaging were not previously cleared in K052439 and K113049, which describe Socket Graft as being distributed in single use syringes or in a pouch with single use packets in powder form. Evaluation of a product’s packaging for devices provided sterile is necessary to ensure the sterilization methods used in manufacturing settings adhere to FDA’s Quality System (QS) regulation requirements, 21 CFR part 820. Assurance of sterility is important to prevent a serious risk to human health because of the risk of infection. Additionally, packaging and sterility assurance, including delivery mechanisms such as syringes or trays, are considered part of the finished device that must be assessed for safety (e.g., biocompatibility testing per ISO 10993-1). The interactions of packaging and the effects of sterilization can have direct and potentially negative impacts on a product’s biocompatibility. As such, use of different packaging and materials require additional performance testing and\u002For clinical testing as these changes could affect the safety and effectiveness of the devices and require submission of a new premarket submission. If you have data to support the new form and packaging, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>9. Further, based on evidence obtained on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fsocket-graft-plus\u002F) as of May 10, 2023, you are marketing the Socket Graft for use with a drug. For example, the instructions for use document (https:\u002F\u002Fwww.steinerbio.com\u002Fwp-content\u002Fuploads\u002F2022\u002F08\u002FDFU-Socket-Graft-2022.pdf) for the Socket Graft in a new ‘petal’ form states “Add moisture by applying a few drops of local anesthesia to the petals of graft for a manageable putty.” This new indication was not previously cleared in K052439 or K113049. We have reviewed our files and are unable to identify FDA clearance or approval of a product for use in combining anesthetics with the device. Additional data is required to assess if the combination of the two products can influence effectiveness of one or the other material components. These changes could significantly affect the safety and effectiveness of these devices requiring a new premarket submission because the previous clearances have not provided data that show this preparation and use of Socket Graft does not negatively impact bone formation, healing, or biocompatibility of the product.\u003C\u002Fp>\n\n\u003Cp>10. Additionally, based on evidence obtained on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fridge-graft-kit\u002F) as of May 10, 2023, you are marketing OsseoConduct βTCP 3D-Printed Grafts device for “Custom 3D-printed beta tricalcium bone grafts designed to be used for lateral and vertical ridge augmentation with implant placement ridge augmentation”. There is no information in K101718 demonstrating that OsseoConduct is cleared for this intended treatment which is manufactured using a new additive manufacturing process that is outside the scope of the manufacturing process that was cleared in K101718. This major manufacturing change is a modification that could significantly affect the safety or effectiveness of the device and requires the submission of a new premarket submission. The use of the product as described creates the risk of ineffective bone formation, infection, or non-biocompatible responses, which may lead to the need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, these changes impact the performance of the device and require additional performance testing and\u002For clinical testing in a new premarket submission.\u003C\u002Fp>\n\n\u003Cp>If you have data to support the new manufacturing method, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>The OsseoConduct is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Fregenerative-products\u002Fosseoconduct\u002F) as of May 10, 2023, that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device and competing devices. For example, your website states: “Unlike allografts and xenografts, OsseoConduct produces bone with normal physiology and architecture.”\u003C\u002Fp>\n\n\u003Cp>We are not aware of any new data supporting this statement. This statement is false or misleading because allograft bone, which is human derived, represents normal physiology and architecture, and data do not demonstrate that the OsseoConduct is superior to other bone grafting materials such as allograft or xenograft. This comparison may mislead consumers about the effectiveness of OsseoConduct by implying less effectiveness of other bone grafting materials that may be equally advantageous. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating factors, which may lead to patient harm. These claims therefore constitute misleading representations with respect to another device. If you have data demonstrating that OsseoConduct is more effective than other bone grafting materials, please provide that information to the agency.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Other Regulations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition to being a manufacturer of devices including the Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Ridge Graft Kit, Immediate Graft, and Oral Bond, the inspection of November 3-8, 2022, revealed your firm is a “labeler” of these devices as defined in 21 CFR 801.3 and 21 CFR 830.3. The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), in that your firm failed to have on the label or labeling of the device information that is required by or under the authority of this Act. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR part 801, subpart B, and 21 CFR part 830. The labels of these devices do not bear such a UDI. In addition, your devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure to furnish material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR part 830, subpart E, for each version or model required to bear a UDI. Your firm has not submitted to GUDID any information required by 21 CFR part 830, subpart E, respecting these devices. Furthermore, it is a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B), to fail to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i.\u003C\u002Fp>\n\n\u003Cp>These violations include the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to ensure that the label of every medical device shall bear a UDI that meets the requirements of 21 CFR part 801, subpart B, and 21 CFR part 830, as required by 21 CFR 801.20(a). For example,\u003C\u002Fp>\n\n\u003Cp>The labels for the Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Immediate Bond, and Oral Bond do not include a UDI. Class II devices manufactured and labeled after September 24, 2016, must bear a UDI, unless an exception or alternative applies.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> No exception or alternative to the requirements of 21 CFR part 801, subpart B, and 21 CFR part 830 applies to the Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Immediate Graft, and Oral Bond manufactured and labeled after September 24, 2016.\u003C\u002Fp>\n\n\u003Cp>This is a repeat observation from the previous FDA inspection of December 10-13, 2018. During our inspection conducted November 3-8, 2022, your Director of Marketing committed to generating a UDI and updating your labels accordingly. However, you have not provided any additional updates to this proposed corrective action. In response to this letter, please provide evidence of implementation of the following documents: records to verify identification and traceability controls, a copy of the revised labeling to verify that requirements have been met, training records, updated SOP which includes the requirements for developing and assigning UDIs to your devices, the requirements for printing labels that contain the UDI for all devices, label verification procedures, and recordkeeping.\u003C\u002Fp>\n\n\u003Cp>2. Failure to provide required information to GUDID as required by 21 CFR 830.300(a). For example:\u003C\u002Fp>\n\n\u003Cp>Labelers of devices required to bear a UDI are required to submit specific data pertaining to these devices to FDA’s GUDID on or before September 24, 2016. Your firm has failed to submit the information required under 21 CFR part 830, subpart E, for each version or model required to bear a UDI, as specified by 21 CFR 830.300(a).\u003C\u002Fp>\n\n\u003Cp>This is a repeat observation from the previous FDA inspection of December 10-13, 2018. During our inspection conducted November 3-8, 2022, your Director of Marketing committed to registering UDIs to the GUDID. However, you have not provided any updates to this corrective action and to date there are no records pertaining to your Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Immediate Graft, and Oral Bond devices that have been submitted.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS # 651802 when replying. If you have any questions about the contents of this letter, please contact: Jeff Wooley, Compliance Officer at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh Program Division Director\u003Cbr>\nOffice of Medical Devices and Radiological\u003Cbr>\nHealth, Division III\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina Eydelman\u003Cbr>\nDirector\u003Cbr>\nOHT 1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT &amp; Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See the UDI Final Rule, 78 FR 58786 (September 24, 2013) at 58815-58816. More information about compliance dates for UDI requirements can be found at FDA’s website (https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Funique-device-identification-system-udi-system\u002Fudi-compliance-policies-and-udi-rule-compliance-dates).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGregory G. Steiner, DDS\n\nRecipient Title\n\nCEO\n\nSteiner Biotechnology, LLC\n\n1051 Olsen Street, Suite 3611\n\nHenderson, NV 89011\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS #651802\n\nMay 19, 2023\n\nDear Dr. Steiner:\n\nDuring inspections of your firm located at 1051 Olsen Street, Suite 3611, Henderson, NV 89011 on August 15–19, 2022 and November 3-8, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bone grafting materials including, the Socket Graft, Socket Graft Plus, Socket Graft Injectable, OsseoConduct, OsseoConduct Micron, Ridge Graft Kit, Immediate Graft, and Oral Bond. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nObservations Pertaining to Quality System Regulation Provisions and Regulations\n\nThe inspections revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from you dated November 21, 2022, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). For example,\n\nYour firm manufactures various implantable bone grafting materials, including the OsseoConduct, Socket Graft, Immediate Graft, and Socket Graft Injectable, which require design controls and you have not established design control procedures.\n\na. Your firm’s “Quality Management Systems Manual,” dated June 1, 2017, includes high level requirements indicating design activities will be conducted and meet the requirements outlined in 21 CFR 820.30; however, this manual does not include procedures on describing how these activities will be conducted or documented.\n\nb. You verbally confirmed your firm’s only design control procedures were your “Design Input Requirements,” SOP 010-02, dated June 1, 2017. However, these procedures do not include procedures for design output, design reviews, design verification, design validation, design transfer, or changes, as required by 21 CFR 820.30(d) through (i).\n\nc. Your firm’s “Design Input Requirements,” SOP 010-02, dated June 1, 2017, does not include a mechanism for addressing ambiguous, incomplete, or conflicting requirements, as required by 21 CFR 820.30(c).\n\nd. Your firm has not established and maintained procedures for design verification, as required by 21 CFR 820.30(f). For example, your firm’s “Quality Management Systems Manual,” dated June 1, 2017, states design verification will be conducted to ensure design outputs have satisfied design input requirements. The product labeling for your OsseoConduct device identifies the following design inputs:\n\n(b)(4)\n\nHowever, you did not provide procedures for confirming that design output meets the design input requirements. You also did not provide documentation showing these design inputs have been verified. This is a repeat observation from the previous December 10-13, 2018, FDA inspection and a violation listed on the Untitled Letter issued to your firm on April 3, 2019. Your November 21, 2022 response is inadequate because, although you provided images of histological results, you did not provide supporting data or records, including pyrogen testing, to support what the test methods and records are purported to be.\n\ne. Your firm has not established and maintained adequate design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\n\ni. Your firm’s “Quality Management Systems Manual,” dated June 1, 2017, requires design validation to ensure that the resulting product is capable of fulfilling the requirements for the specified or known intended use or application. The labeling for your OsseoConduct bone grafting material states that this product was developed to meet the following criteria:\n\n1. Does not elicit an inflammatory response\n\n2. Produce bone with normal form and function\n\n3. Be significantly resorbed in 3 months\n\n4. Be able to handle reasonable load in order to resist deformation during the remodeling phase\n\n5. Allow ease of application\n\n6. Be designed to prevent bacterial colonization\n\nHowever, your firm did not provide procedures to ensure that devices conform to defined user needs and intended uses that include testing of production units under actual or simulated use conditions. You also did not provide documentation to demonstrate the OsseoConduct device was validated to ensure it conforms to these user needs. Your November 21, 2022 response is inadequate because, although you provided images of histological results, you did not provide supporting data or records, including pyrogen testing, to support what the test methods and records are purported to be.\n\nii. Your firm has not established adequate procedures for risk analysis, as required by 21 CFR 820.30(g). Specifically, your firm manufactures the OsseoConduct bone graft material which is labeled to be an implantable, sterile, biocompatible, and pyrogen free device. However, the risk analysis documented in your Design History File dated June 1, 2017, does not identify any foreseeable hazards associated with the use of this device. Your November 21, 2022 response is inadequate because the “Risk Management Plan” you provided does not identify reasonably foreseeable hazards with your implantable sterile device.\n\nWe reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your firm’s response states your firm has conducted histology and biocompatibility studies which support the validation and verification of your OsseoConduct device. However, the records you provided to support this assertion do not show these studies were conducted using the OsseoConduct device. Additionally, the histology data provided does not include the study protocol or methods used to generate the data. Further, your response does not address the lack of adequate design control procedures or how you plan to correct this deficiency.\n\n2. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\n\na. Your firm’s “Process Validation,” SOP 018, revision 2, dated June 1, 2017, establishes high level requirements for process validation; however, these procedures do not establish any specific requirements for the sterilization process validation for each of your devices.\n\nb. Your firm uses a (b)(4) process to sterilize your Oral Bond and Socket Graft devices. Your firm does not have records demonstrating these processes were validated as set forth in your firm’s “Process Validation,” SOP 018 and as required by 21 CFR 820.75(b)(1).\n\nc. Your firm uses a (b)(4) sterilization process to sterilize your OsseoConduct device. Your firm does not have records demonstrating this process has been validated as set forth in your firm’s “Process Validation,” SOP 018 and as required by 21 CFR 820.75(b)(1).\n\nThis is a repeat observation from the FDA inspection conducted December 10-13, 2018, and a violation listed on the Untitled Letter issued to your firm on April 3, 2019. We reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response is limited to a description of (b)(4) activities purportedly conducted; however, it does not describe the specific processes used or include a protocol indicating critical process parameters to support the process is validated. Additionally, your response does not include a systemic evaluation of your firm’s manufacturing processes to ensure all processes requiring validation have been validated. Finally, your response did not include procedures establishing any specific requirements for the sterilization process validation for each of your devices.\n\n3. Failure to establish and maintain adequate procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. For example,\n\nYour firm’s “Purchasing & Suppliers,” SOP 410, Version 0, dated June 1, 2017, requires suppliers to be evaluated and reviewed as part of a continuous and iterative process. However, your firm did not provide any records to support that these activities have been conducted.\n\nWe reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response states all suppliers have been evaluated to meet standards and be in compliance with “SOP 140 00.” Your response also provided a supplier evaluation form, stating it will be used moving forward. However, your response does not include your revised procedures describing how this form will be used or records of training for the new process as required by 21 CFR 820.25. Additionally, your response is unclear if the supplier evaluation form is a requirement of your revised procedures and if so, whether the form has been completed for all suppliers or if this corrective action is ongoing. In response to this letter, we request you provided the most current purchasing control procedures showing compliance with 21 CFR 820.50, which addresses the use of the supplier evaluation form.\n\n4. Failure to establish and maintain adequate procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a). For example,\n\nSection 9 of your device history records (DHR) identifies specific acceptance criteria for each device. However, you do not have records required by 21 CFR 820.80(e) demonstrating these acceptance activities were conducted or documented for eight out of nine DHRs reviewed, as follows:\n\na. Socket Graft Plus lot 061422\n\nb. OsseoConduct lot 060822\n\nc. BioDensification lot 072622\n\nd. Ridge Graft lot 060922\n\ne. Immediate Graft lot 100322\n\nf. Sinus Graft lot 072622\n\ng. Socket Graft lot 061322\n\nh. Socket Graft Injectable lot 090722\n\nWe reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response states you will analyze the criteria for acceptability for each device prior to the time of release and ensure appropriate documentation has been generated. However, your response does not include a retrospective review of previous lots to evaluate if previously release lots were deficient. Additionally, your response does not address any procedural corrective actions or revisions you are taking to ensure appropriate acceptance activities are conducted.\n\n5. Failure to establish and maintain adequate procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained, and to include provisions for handling, preservation, and storage of equipment, so that its accuracy and fitness for use are maintained, as required by 21 CFR 820.72(a). For example,\n\nYour firm uses a (b)(4) for (b)(4) sterilizion of your OsseoConduct device; however, your firm’s Laboratory Manager verbally confirmed this (b)(4) has not been calibrated and there are no records for calibration.\n\nWe reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response states you have established an equipment list that identifies all production equipment requiring calibration. However, your response did not provide evidence the referenced (b)(4) has been calibrated.\n\n6. Failure to establish and maintain procedures to adequately control environmental conditions that could reasonably be expected to have an adverse effect on product quality and failure to periodically inspect environmental control systems to verify that the system is adequate and functioning properly, as required by 21 CFR 820.70(c). For example,\n\nYour firm conducts manufacturing and packaging operations in ISO 7 certified cleanrooms both (b)(4) of your dental graft material devices. Your firm does not have established written procedures for the environmental monitoring of these cleanrooms. Additionally, our investigators observed a box fan inside cleanroom (b)(4) which may disrupt unidirectional airflow. Further, our investigators observed the area surrounding the cleanrooms to be dusty and contain miscellaneous items such as exercise equipment and a motorcycle. Your firm’s Laboratory Manager stated she gowns in this area prior to entering the ISO 7 cleanroom. Lastly, our review of the certification report for cleanroom (b)(4) dated (b)(4), documented the cleanroom failed the high average particle count specification. Your firm did not have a justification or investigation into this failed result.\n\nWe have reviewed your firm’s response dated November 21, 2022, and conclude it is not adequate. Your response states the box fan has been removed from cleanroom (b)(4). However, your response does not address the other aspects of the observation or describe the corrective actions you have taken to address the lack of adequate environmental monitoring procedures.\n\n7. Failure to establish and maintain adequate procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system.\n\nThese quality audits shall be conducted by individuals who do not have direct responsibility for the matters being audited, as required by 21 CFR 820.22. For example,\n\nYour firm’s “Audit,” SOP 023, revision 2, dated June 1, 2017, states general audits will be conducted (b)(4). However, your firm has not conducted audits which meet the requirements of 21 CFR 820.22. Your firm’s Vice President of Marketing provided MDSAP task audit form templates for 2020, 2021, and 2022; however, these templates were limited to design control coverage and did not include coverage of other quality system requirements.\n\nThis is a repeat observation from the previous December 10-13, 2018, FDA inspection and a violation listed on the Untitled Letter issued to your firm on April 3, 2019. We have reviewed your firm’s response dated November 21, 2022 and cannot determine the adequacy at this time. Your response states you have purchased auditing tools which will assist in generating and conducting the (b)(4) audits. However, your response does not include a timeframe of the implementation of these tools or procedures describing their use for compliance with 21 CFR 820.22. Additionally, we remind you that any software used as part of the quality system shall be validated for its intended use, as required by 21 CFR 820.70(i).\n\nObservations Pertaining to Premarket Submission Requirements\n\nOur inspection also revealed that the Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Ridge Graft Kit, and Immediate Graft devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\n\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\n1. Specifically, Socket Graft was cleared under K052493 and K113049 for use in dental extraction sockets that have all walls remaining. The earliest time point for implant placement in sockets grafted with Socket Graft is at 8 weeks.\n\nBased on evidence obtained from your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fsocket-graft\u002F) as of May 10, 2023, your firm is marketing Socket Graft for a different intended use, namely for use at an earlier time point than 8 weeks for implant placement. For example, your firm’s website states the following:\n\n“A faster and healthier bone regeneration sequence allows for an implant to be placed sooner than if other bone grafts were used. Implant placement at 4 weeks, 6 weeks, 12 weeks or more can now be achieved with predictable results.”\n\nHowever, there is no information in K052493 or K113049 to support an indication for placement at 4 or 6 weeks. This change in Indications for Use constitutes a significant change requiring a new premarket submission to modify the proposed indications for this device. Furthermore, promoting Socket Graft for use with implants earlier than what the data supported could significantly affect the safety or effectiveness of the device for implant to abutment compatibility, resulting in potential osseointegration complications of the dental implant bodies for patients. If you have data to support these indications, please submit that data to FDA for review.\n\n2. Additionally, based on evidence obtained from your website (https:\u002F\u002Fwww.steinerbio.com\u002Fregenerative-products\u002Fsocket-graft\u002F) as of May 10, 2023, several performance statements related to the use of Socket Graft appear to be unsupported. We have conducted a review of our files and are unable to identify an additional FDA clearance or approval supporting these performance statements. For example, your website includes the following:\n\n“This innovative delivery system allows for ease of application, but most importantly, produces superior bone quality with bone to implant integration due to its osteogenic properties.” There is no information in K052493 or K113049 demonstrating that Socket Graft is superior to other bone graft material.\n\n“Socket Graft is a dual phase calcium phosphate based synthetic bone graft material designed to quickly treat the extraction socket, retain alveolar bone, stimulate bone formation, reduce post-operative complications, and resorb quickly and completely.” There is no information in K052493 or K113049 demonstrating that use of Socket Graft results in an accelerated healing response.\n\n“No allergic reaction” and “No inflammatory response.” There is no information in K052493 or K113049 demonstrating that use of Socket Graft results in no possibility of these adverse reactions occurring. In your June 14, 2022, response to our May 27, 2022, letter, you referenced external vendor (b)(4), wherein testing per ISO 10993-1 evaluated safety and performance of the device; however, the testing results do not substantiate these performance statements. Your written response dated November 22, 2022, to our FDA 483, Inspectional Observations, included a biocompatibility study, which you also included in your June 14, 2022, response. You purport that this study supports the above performance statements. However, the biocompatibility study does not support these performance statements because the study data shows that an inflammatory response occurred.\n\nWe are not aware of any new data supporting such statements. These statements were communicated to you in our letter dated May 27, 2022. In your response to this letter dated June 14, 2022, you committed to removing or modifying some of these statements; however, to date, they have not been revised. Marketing the Socket Graft with these performance statements represent significant changes to the cleared device that require a new premarket submission. These assertions of performance characteristics identify new risk in affecting the timeline of patient treatment, treatment considerations, and effectiveness of the received treatment, that require additional performance testing and\u002For clinical testing in a new premarket submission. If you have data demonstrating these performance characteristics, please provide that information to the agency.\n\n3. Further, the OsseoConduct device was cleared under K101718 and intended to fill, augment or reconstruct periodontal or bony defects of the oral and maxillofacial region. Specifically, for the augmentation of deficient maxillary and mandibular alveolar ridges and the treatment of oral, maxillofacial, and dental intraosseous defects including ridge augmentation, sinus lifts, craniofacial augmentation, filling of defects of endodontic origin, filling of cystic defects, filling of extraction sites, filling of lesions of periodontal origin, repair of traumatic defects of the alveolar ridge, filling of resection defects from bone tumors, cysts or other osseous defects, and a substitute for autogenous or allogenic bone grafts. The device is fully resorbed in 6 months.\n\nHowever, based on evidence obtained on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Fregenerative-products\u002Fosseoconduct\u002F) as of May 10, 2023, several performance statements related to the use of OsseoConduct appear to be unsupported. We have conducted a review of our files and are unable to identify an additional FDA clearance or approval supporting these performance statements. For example, your website includes the following:\n\n“Be designed to prevent bacterial colonization.” There is no information in K101718 demonstrating that OsseoConduct prevents bacterial colonization.\n\nDuring our inspection conducted November 3-8, 2022, our investigators requested any data or studies that were conducted to support this statement, as would be required under 21 CFR 820.30. You stated that an external vendor (b)(4) conducted extensive biocompatibility studies for the (b)(4) used in the manufacture of OsseoConduct. However, the the (b)(4) reports did not include adequate data, such as a prospective, long-term, statistically relevant clinical study to support this claim. Further, in your June 14, 2022, response to FDA’s May 27, 2022, letter, you agreed that the statement is not supported by the clearance and would remove the statement from your website; however as of May 10, 2023, the statement has not been removed.\n\n“Be significantly resorbed in 3 months.” There is no information in K101718 demonstrating that OsseoConduct is significantly resorbed in 3 months. The data show that full resorption occurs in (b)(4) months. Your June 14, 2022, response to FDA’s May 27, 2022, letter, asserts that the clearance establishes this statement. Your June 14, 2022, response also agreed to modify or remove this statement from your website; however as of May 10, 2023, the statement has not been modified or removed.\n\nWe are not aware of any new data supporting the above statements. Promoting this device with these performance statements constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. These assertions of performance characteristics identify new risks in affecting the timeline of patient treatment, treatment considerations, and effectiveness of the received treatment, which may lead to a need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, these statements impact the intended use and performance of the device and require additional performance testing and\u002For clinical testing in a new premarket submission. If you have data demonstrating these performance characteristics, please provide that information to the agency.\n\n4. Your firm is currently marketing the Ridge Graft Kit, which appears to be a combination of the Socket Graft and OsseoConduct devices. Based on evidence obtained from your website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fridge-graft-kit\u002F) as of May 10, 2023, the Ridge Graft Kit is packaged in syringes. However, this form of packaging was not previously cleared in K101718, which describes OsseoConduct as being distributed in single-use pouch packaging. Evaluation of a product’s packaging and shelf-life for devices provided sterile is necessary to ensure the sterilization methods used in manufacturing settings adhere to FDA’s Quality System (QS) regulation requirements, 21 CFR part 820. Assurance of sterility is important to prevent a serious risk to human health because of the risk of infection. Additionally, packaging and sterility assurance, including delivery mechanisms such as syringes, are considered part of the finished device that must be assessed for safety (e.g., biocompatibility testing per ISO 10993-1). The interactions of packaging and the effects of sterilization can have direct and potentially negative impacts on a product’s biocompatibility; this may lead to a need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, use of different packaging and materials require additional performance testing and\u002For clinical testing as these changes could affect the safety and effectiveness of the devices and require submission of a new premarket submission. If you have data to support the new packaging, please submit that data to FDA for review.\n\n5. In addition, your firm is marketing the Socket Graft Plus, which appears to be a combination of your firm’s Socket Graft and OsseoConduct devices. Based on evidence obtained from your website (https:\u002F\u002Fwww.steinerbio.com\u002Fregenerative-products\u002Fsocket-graft-plus\u002F) as of May 10, 2023, the Socket Graft Plus is intended for use as “a bone graft material appropriate for all socket grafting situations” and is used to “integrate immediate implants.” We have reviewed our files and are unable to identify FDA clearance or approval for a product with this indication.\n\nIn your response dated June 14, 2022 to our letter dated May 27, 2022, you state the Socket Graft Plus is cleared under K113049 and K101718 due to references being made to Socket Graft being used in conjunction with OsseoConduct in your 510(k) submissions. However, these 510(k) clearances do not include clearance for use as a single formulation without socket walls remaining, and for immediate implantation. Specifically, there is no information demonstrating the sterilization validation methods performed for the combined materials. In addition, the indications for use in these 510(k)s do not support the combination of these two devices, which is limited to use in dental extraction sockets that have all walls remaining; whereas the Socket Graft Plus indicates the device may be used for defects with missing walls. Further, grafts for immediate implants were not cleared in either of the Socket Graft or OsseoConduct submissions. The use of the product as described creates the risk of ineffective bone formation, infection, or non-biocompatible responses, which may lead to a need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, these changes impact the intended use, sterilization, and performance of the device and require additional performance testing and\u002For clinical testing in a new premarket submission. If you have data to support the sterilization validation method performed and additional indication, please submit that data to FDA for review.\n\n6. Further, your firm is currently marketing the Immediate Graft, which appears to be a (b)(4). Based on evidence obtained from your website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fimmediate-graft\u002F) as of May 10, 2023, Immediate Graft is a dental bone grafting material intended to fill defects and achieve implant integration. Your firm’s website indicates this product is “proven to produce integration to immediate implants.” We have reviewed our files and are unable to identify FDA clearance or approval for a product with this indication.\n\nIn your response dated June 14, 2022, to our letter dated May 27, 2022, you state the Immediate Graft is cleared under K113049 and K101718 due to references being made to Socket Graft being used in conjunction with OsseoConduct in your 510(k) submissions. However, these 510(k) clearances do not include clearance for use as a single formulation and as grafts for immediate implants. The use of the product as described creates the risk of ineffective bone formation, infection, or non-biocompatible responses, which may lead to a need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, these changes impact the intended use and performance of the device and require additional performance testing and\u002For clinical testing in a new premarket submission. Specifically, there is no information demonstrating the performance of your device (i.e., sterilization validation, biocompatibility, resorption\u002Fnew bone formation) for the combined materials. If you have data to support the indication, please submit that data to FDA for review.\n\n7. Additionally, based on evidence obtained during our November 3-8, 2022 inspection and evidence on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fosseoconduct\u002F) as of May 10, 2023, you are marketing the OsseoConduct Micron device for “Treating Peri-Implantitis with βTCP Air Abrasion.” There is no information in K101718 demonstrating that OsseoConduct is cleared for this intended treatment.\n\nYour June 14, 2022 response to FDA’s May 27, 2022 letter, states you are only marketing the device for the abrasive cleaning of dental appliances; however, as identified above, your firm’s website markets the device for the treatment of disease. This change in Indications for Use constitutes a significant change requiring a new premarket submission to modify the proposed indications for this device. Furthermore, promoting OsseoConduct for treatment of a new disease creates the risk of ineffective bone formation, infection, or non-biocompatible responses. If you have data to support this indication, please submit that data to FDA for review.\n\n8. Additionally, based on evidence obtained on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fsocket-graft-plus\u002F) as of May 10, 2023, you are marketing the Socket Graft in a new ‘petal’ form with silicone trays. This form and packaging were not previously cleared in K052439 and K113049, which describe Socket Graft as being distributed in single use syringes or in a pouch with single use packets in powder form. Evaluation of a product’s packaging for devices provided sterile is necessary to ensure the sterilization methods used in manufacturing settings adhere to FDA’s Quality System (QS) regulation requirements, 21 CFR part 820. Assurance of sterility is important to prevent a serious risk to human health because of the risk of infection. Additionally, packaging and sterility assurance, including delivery mechanisms such as syringes or trays, are considered part of the finished device that must be assessed for safety (e.g., biocompatibility testing per ISO 10993-1). The interactions of packaging and the effects of sterilization can have direct and potentially negative impacts on a product’s biocompatibility. As such, use of different packaging and materials require additional performance testing and\u002For clinical testing as these changes could affect the safety and effectiveness of the devices and require submission of a new premarket submission. If you have data to support the new form and packaging, please submit that data to FDA for review.\n\n9. Further, based on evidence obtained on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fsocket-graft-plus\u002F) as of May 10, 2023, you are marketing the Socket Graft for use with a drug. For example, the instructions for use document (https:\u002F\u002Fwww.steinerbio.com\u002Fwp-content\u002Fuploads\u002F2022\u002F08\u002FDFU-Socket-Graft-2022.pdf) for the Socket Graft in a new ‘petal’ form states “Add moisture by applying a few drops of local anesthesia to the petals of graft for a manageable putty.” This new indication was not previously cleared in K052439 or K113049. We have reviewed our files and are unable to identify FDA clearance or approval of a product for use in combining anesthetics with the device. Additional data is required to assess if the combination of the two products can influence effectiveness of one or the other material components. These changes could significantly affect the safety and effectiveness of these devices requiring a new premarket submission because the previous clearances have not provided data that show this preparation and use of Socket Graft does not negatively impact bone formation, healing, or biocompatibility of the product.\n\n10. Additionally, based on evidence obtained on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Ffor-professionals\u002Fregenerative-products\u002Fridge-graft-kit\u002F) as of May 10, 2023, you are marketing OsseoConduct βTCP 3D-Printed Grafts device for “Custom 3D-printed beta tricalcium bone grafts designed to be used for lateral and vertical ridge augmentation with implant placement ridge augmentation”. There is no information in K101718 demonstrating that OsseoConduct is cleared for this intended treatment which is manufactured using a new additive manufacturing process that is outside the scope of the manufacturing process that was cleared in K101718. This major manufacturing change is a modification that could significantly affect the safety or effectiveness of the device and requires the submission of a new premarket submission. The use of the product as described creates the risk of ineffective bone formation, infection, or non-biocompatible responses, which may lead to the need for additional surgical procedures, increased healing time, and unnecessary cost to patients. As such, these changes impact the performance of the device and require additional performance testing and\u002For clinical testing in a new premarket submission.\n\nIf you have data to support the new manufacturing method, please submit that data to FDA for review.\n\nThe OsseoConduct is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your firm’s website (https:\u002F\u002Fwww.steinerbio.com\u002Fregenerative-products\u002Fosseoconduct\u002F) as of May 10, 2023, that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device and competing devices. For example, your website states: “Unlike allografts and xenografts, OsseoConduct produces bone with normal physiology and architecture.”\n\nWe are not aware of any new data supporting this statement. This statement is false or misleading because allograft bone, which is human derived, represents normal physiology and architecture, and data do not demonstrate that the OsseoConduct is superior to other bone grafting materials such as allograft or xenograft. This comparison may mislead consumers about the effectiveness of OsseoConduct by implying less effectiveness of other bone grafting materials that may be equally advantageous. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating factors, which may lead to patient harm. These claims therefore constitute misleading representations with respect to another device. If you have data demonstrating that OsseoConduct is more effective than other bone grafting materials, please provide that information to the agency.\n\nObservations Pertaining to Other Regulations\n\nIn addition to being a manufacturer of devices including the Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Ridge Graft Kit, Immediate Graft, and Oral Bond, the inspection of November 3-8, 2022, revealed your firm is a “labeler” of these devices as defined in 21 CFR 801.3 and 21 CFR 830.3. The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), in that your firm failed to have on the label or labeling of the device information that is required by or under the authority of this Act. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR part 801, subpart B, and 21 CFR part 830. The labels of these devices do not bear such a UDI. In addition, your devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure to furnish material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR part 830, subpart E, for each version or model required to bear a UDI. Your firm has not submitted to GUDID any information required by 21 CFR part 830, subpart E, respecting these devices. Furthermore, it is a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B), to fail to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i.\n\nThese violations include the following:\n\n1. Failure to ensure that the label of every medical device shall bear a UDI that meets the requirements of 21 CFR part 801, subpart B, and 21 CFR part 830, as required by 21 CFR 801.20(a). For example,\n\nThe labels for the Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Immediate Bond, and Oral Bond do not include a UDI. Class II devices manufactured and labeled after September 24, 2016, must bear a UDI, unless an exception or alternative applies.1 No exception or alternative to the requirements of 21 CFR part 801, subpart B, and 21 CFR part 830 applies to the Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Immediate Graft, and Oral Bond manufactured and labeled after September 24, 2016.\n\nThis is a repeat observation from the previous FDA inspection of December 10-13, 2018. During our inspection conducted November 3-8, 2022, your Director of Marketing committed to generating a UDI and updating your labels accordingly. However, you have not provided any additional updates to this proposed corrective action. In response to this letter, please provide evidence of implementation of the following documents: records to verify identification and traceability controls, a copy of the revised labeling to verify that requirements have been met, training records, updated SOP which includes the requirements for developing and assigning UDIs to your devices, the requirements for printing labels that contain the UDI for all devices, label verification procedures, and recordkeeping.\n\n2. Failure to provide required information to GUDID as required by 21 CFR 830.300(a). For example:\n\nLabelers of devices required to bear a UDI are required to submit specific data pertaining to these devices to FDA’s GUDID on or before September 24, 2016. Your firm has failed to submit the information required under 21 CFR part 830, subpart E, for each version or model required to bear a UDI, as specified by 21 CFR 830.300(a).\n\nThis is a repeat observation from the previous FDA inspection of December 10-13, 2018. During our inspection conducted November 3-8, 2022, your Director of Marketing committed to registering UDIs to the GUDID. However, you have not provided any updates to this corrective action and to date there are no records pertaining to your Socket Graft, Socket Graft Plus, OsseoConduct, OsseoConduct Micron, Immediate Graft, and Oral Bond devices that have been submitted.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS # 651802 when replying. If you have any questions about the contents of this letter, please contact: Jeff Wooley, Compliance Officer at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nShari J. Shambaugh Program Division Director\n\nOffice of Medical Devices and Radiological\n\nHealth, Division III\n\n\u002FS\u002F\n\nMalvina Eydelman\n\nDirector\n\nOHT 1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT & Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n__________________\n\n1 See the UDI Final Rule, 78 FR 58786 (September 24, 2013) at 58815-58816. More information about compliance dates for UDI requirements can be found at FDA’s website (https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Funique-device-identification-system-udi-system\u002Fudi-compliance-policies-and-udi-rule-compliance-dates).","Steiner Biotechnology, LLC","steiner-biotechnology-llc-651802-05192023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsteiner-biotechnology-llc-651802-05192023","2026-10-26T08:10:05.698384+00:00","2023-06-06","651802","Gregory G. Steiner, DDS","2026-08-20T01:04:13.173+00:00","VIA UNITED PARCEL SERVICE","2023-05-19",{"id":290,"raw":291,"subject":104,"body_html":296,"body_text":297,"firm_name":298,"letter_id":299,"created_at":151,"fei_number":19,"letter_url":300,"updated_at":301,"action_type":22,"case_status":23,"posted_date":302,"marcs_cms_no":303,"product_type":26,"closeout_date":19,"issuing_office":304,"recipient_name":305,"body_fetched_at":306,"delivery_method":287,"recipient_title":19,"reference_number":19,"action_taken_date":307,"medical_device_id":19,"response_letter_date":19},2000,[292,293,294,295,104,13,13,13],"\u003Ctime datetime=\"2023-07-11T13:20:00Z\">07\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-21T04:00:00Z\">06\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyto-technologies-inc-652316-06212023\">ZYTO Technologies, Inc.\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations West","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Vaughn R. Cook\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman and Owner\u002FFounder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ZYTO Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1172 W. 700 N., Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lindon\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84042\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 652316\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 21, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Cook,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Lindon, UT on December 5 through 13, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ZYTO Hand Cradle Galvanic Skin Response (GSR) device and associated proprietary software used to scan a patient to identify “stressors” and “balancers.” Your website refers to using the ZYTO as part of a “journey to wellness.\" However, some of the “stressors” identified or diagnosed by the ZYTO Hand cradle and associated proprietary software include diseases and conditions such as Alzheimer’s disease, human immunodeficiency virus (HIV), Parkinson’s disease and melanoma, and some of the “balancers” recommended by the software represent specific treatments or mitigations for a given “stressor.” Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the ZYTO Hand Cradle GSR and associated proprietary software is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. 352(o), because you did not notify the agency of your intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>The ZYTO Hand Cradle was cleared under K111308 with the following intended use: “the measurement of galvanic skin response (GSR).” However, your firm’s promotion of the device represents a major change or modification to its intended use, for which your firm lacks clearance or approval. Thus, although originally classified as Class II under 21 CFR 882.1540, the device does not qualify for the exemption from 510(k) granted in 2019 for that generic type of device (see 84 FR 71794 (December 30, 2019)) because, among other things, the device “is intended for a use different from the intended use of a legally marketed device in that generic type of device.” See 21 CFR 882.9(a).\u003C\u002Fp>\n\n\u003Cp>Further, as we informed you previously, the ZYTO associated proprietary software is a component of the ZYTO Hand Cradle and shares its classification.\u003C\u002Fp>\n\n\u003Cp>In our June 11, 2015, correspondence after the Warning Letter, we stated that per 21 CFR, part 820.3(c), the definition of a component includes software intended to be included as part of a finished, packaged, labeled device. Components of a device are defined as the device itself. The letter further states “…The software, downloaded by end users for the intention of use with your device is considered a component.”\u003C\u002Fp>\n\n\u003Cp>Per our Regulatory Meeting, held August 28, 2015, you were informed again that our review found that your associated proprietary software was intended to be used with the ZYTO Hand Cradle GSR device. You were informed that because the ZYTO Hand Cradle GSR and the software did not function alone but must be used together, the software was a component of the device.\u003C\u002Fp>\n\n\u003Cp>This continues to be the case. For example, your website explains how the ZYTO Hand Cradle GSR and the associated proprietary software function together as follows:\u003C\u002Fp>\n\n\u003Cp>“The ZYTO Hand Cradle measures the user’s galvanic skin response and sends that data directly to the ZYTO software for analysis. The [galvanic skin responses] GSR data is correlated and compared with Virtual Items in the software database.”\u003C\u002Fp>\n\n\u003Cp>“Each Virtual Item represents a different physical item. Every time the software introduces a Virtual Item, a corresponding GSR reading is taken by the Hand Cradle. Each new response is measured and tracked in comparison to the GSR baseline reading.”\u003C\u002Fp>\n\n\u003Cp>Our investigator documented that the virtual items are added to the library in-house using a machine referred to as the “Tower”. Your representative explained that to create a library item, your firm places the item in front of the Tower and the Tower then scans and identifies the item with a generated code from the system which it associates with the energy of that item. This becomes a virtual library item. In addition, your firm’s promotional materials indicate that the hand cradle can now perform this function as well, so that users can add their own virtual items.\u003C\u002Fp>\n\n\u003Cp>Your website further states:\u003C\u002Fp>\n\n\u003Cp>“ZYTO’s proprietary software analyzes GSR data for patterns of coherence—looking for the ways your GSR readings fluctuate or shift in response to each Virtual Item.”\u003C\u002Fp>\n\n\u003Cp>Your proprietary software is a component of the ZYTO Hand Cradle GSR.\u003C\u002Fp>\n\n\u003Cp>Your firm is promoting the ZYTO Hand Cradle GSR and associated proprietary software outside its cleared intended use.\u003C\u002Fp>\n\n\u003Cp>The ZYTO Hand Cradle Galvanic Skin Response System was cleared under K111308 only to measure galvanic skin responses. Despite prior notice from FDA in your 2015 Warning Letter and some corrections made around that time, your firm has added back promotion of the ZYTO Hand Cradle GSR for use in diagnosing diseases or conditions, including determining whether someone responds to a specific allergen, and continues to predict biological responses to a wide range of virtual stimuli including homeopathic nosodes and nutritional supplements.\u003C\u002Fp>\n\n\u003Cp>For example, your current website explains that first the system scans for general categories of “Biomarkers” which might be specific locations or anatomy of the body such as organs, muscles, or bones. Next, there is a subset of “Stressor” virtual items which are scanned for, including heavy metals, bacteria, parasites, viruses, electromagnetic fields, chemicals, allergens, lifestyle choices, and foods.\u003C\u002Fp>\n\n\u003Cp>While a scan may consist of only a stressor Virtual Item scan to reveal which items may warrant further attention, a balancer Virtual Item scan often follows to determine which items bring the stressors into range. The website further states ZYTO software contains thousands of “Balancer” Virtual Items from over 250 health and wellness companies in these categories: supplements, essential oils, homeopathics, herbs, flower essences, or topicals.\u003C\u002Fp>\n\n\u003Cp>Most importantly, your virtual item library identifies items which you describe could be stressors or balancers including, but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Alzheimer’s\u003Cbr>\n• E. coli\u003Cbr>\n• Ebola\u003Cbr>\n• Fibromyalgia\u003Cbr>\n• Flu\u003Cbr>\n• Hepatitis (A, B, C, D, and E)\u003Cbr>\n• Herpes, various forms\u003Cbr>\n• Human immunodeficiency virus (HIV)\u003Cbr>\n• Leukemia, various forms and related nosodes\u003Cbr>\n• Lupus, various forms\u003Cbr>\n• Lymphoma, Melanoma\u003Cbr>\n• Parkinson’s disease\u003Cbr>\n• Staphylococcus aureus\u003Cbr>\n• Zika viruses\u003Cbr>\n• Food allergen’s including but not limited to soy, milk, eggs, peanuts, flaxseed, and fish\u003Cbr>\n• Environmental allergens including but not limited to “Bee Pollen”\u003Cbr>\n• Homeopathic nosodes to above listed disease states, such as but not limited to: asthma, cholera, hepatitis, lupus, infant botulism, scarlet fever, malignant rectal polyps, uterine polyps, leukemia, polio, rabies, and Parkinson’s disease.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. You have added disease claims back to your software library.\u003C\u002Fstrong> The “stressors” identified or diagnosed by the ZYTO Hand cradle and associated proprietary software include diseases and conditions such as Alzheimer’s, HIV, Parkinson’s disease and melanoma, and the identification of these by the device amount to diagnoses. These uses fall outside the device’s cleared intended use to measure galvanic skin response and constitute a major change or modification to the device’s intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm continues to market the ZYTO Hand Cradle GSR to predict biological responses to a range of virtual stimuli, as discussed in your 2015 Warning Letter. \u003C\u002Fstrong>The “balancers” recommended by the software for the “stressors” represent specific treatments, mitigations, or suggestions to prevent such diseases and conditions. You’ve been notified this represents a major change or modification to the device’s intended use for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>The promotion of the ZYTO Hand Cradle GSR and associated proprietary software in examples 1 - 2 above for use in diagnosing a disease or condition, including determining whether someone responds to a specific allergen, and predicting biological responses to a wide range of virtual stimuli, including homeopathic nosodes or nutritional supplements, fall outside the device’s cleared intended use to measure galvanic skin response and constitute major changes or modifications to the device’s intended use.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Quality System Regulations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The December 2022 inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. As noted above, your proprietary software which works with the ZYTO Hand Cradle GSR is a component of the ZYTO Hand Cradle GSR. Thus, it is subject to all applicable regulatory requirements, including design controls.\u003C\u002Fp>\n\n\u003Cp>We received a response from Mr. Ford dated January 5, 2023, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. While reviewing this letter, be aware FDA defines “establish” to include actions to define, document, and implement. The violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to adequately establish procedures for design controls, as required by 21 CFR 820.30.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. You have not conducted design verification and validation testing per the requirements of 21 CFR 820.30(f) and 820.30(g), and your SOP-00302 Design Verification and Validation, rev D, eff 12\u002F14\u002F2020, for the ZYTO Hand Cradle GSR and associated proprietary software, or the device library development processes used in house and by customers.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>SOP-00302 requires you to perform design \u003Cem>verification\u003C\u002Fem> to provide objective evidence that specified requirements have been fulfilled, to confirm that the design output meets the design input requirements, and to document results in the design history file (DHF). It also requires you to perform design \u003Cem>validation\u003C\u002Fem> to establish objective evidence that device specifications conform to user needs and intended use(s). The procedure states you shall include software validation and risk analysis, where appropriate, and activities shall be documented in the DHF.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>i. You failed to verify or validate the ZYTO Hand Cradle GSR and associated proprietary software.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, you provided the Hardware Verification and Validation (TR-00370, Rev. A, eff 06\u002F03\u002F2021) noted in DHF-00664 for the ZYTO Hand Cradle GSR. TR-00370 states these “procedures are not intended to test the engineering of the hand cradle. Instead, they focus on the software’s interactions with the hardware.” TR-00370 defines the testing procedures used to verify the hardware software user interface requirements, as specified in SRS-00288. SRS-00288 includes a \u003Cstrong>(b)(4)\u003C\u002Fstrong> protocol to test the \u003Cstrong>(b)(4)\u003C\u002Fstrong> between the software and ZYTO Hand Cradle GSR. However, your Quality Supervisor stated your firm has no documented evidence to provide to demonstrate this testing was actually performed. She further stated you have no evidence to verify that design outputs meet design inputs. Despite no evidence of conducting this testing, the DHF shows TR-00370 as “Approved” on 6\u002F3\u002F2021.\u003C\u002Fp>\n\n\u003Cp>Your firm’s attorney stated that you have no documented validation of the virtual items in the ZYTO software.\u003C\u002Fp>\n\n\u003Cp>Your firm also received a complaint of an “abnormal” or “empty” scan “where no stressors were found out of range, but many products were recommended for use.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response regarding observation 1 and the completion of the DHF activities and understand that you will review TR-00370 and SRS-00288 to confirm verification and validation that design outputs meet the design inputs to be completed by 6\u002F30\u002F23, subject to “Development availability”. We reviewed your response and determined your response is inadequate, as evidence of corrective actions to this observation were not provided. Additionally, corrective actions were not planned for completion until over six months after the inspection concluded, yet you were notified of this violation both during our August 2015 Regulatory Meeting and again during your 2019 inspection, and at that time you promised corrections.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>ii. You failed to validate the ZYTO Tower or Hand Cradle GSR for addition of virtual library items.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Tower is used in-house for the transmission, interpretation, and creation of virtual library items. This has not been validated. Currently, your firm has directed customers to use the ZYTO Hand Cradle GSR to add new virtual library items for biological preference prediction. We observed your firm’s promotional materials indicate you have replicated the prior functionality of the Tower with what you describe as an antenna inside the ZYTO Hand Cradle GSR. Your website contains videos with instructions (in both the Immunity Biosurvey and the Digestive Biosurvey) on how to use the ZYTO Hand Cradle GSR to perform the same function as the Tower by your clients. This use of the ZYTO Hand Cradle GSR for the transmission, interpretation, and creation of virtual library items has also not been validated.\u003C\u002Fp>\n\n\u003Cp>During our inspection, your firm’s attorney stated you have no documented validation of use of the Tower to identify and add virtual items to the library. He further stated there would be no way to test the process used to input these virtual items.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response specific to the validation of “ZYTO 5 Software and the EVOX phrases” and documentation of virtual items (currently done in house by the Tower) and determined it is inadequate as your recent response states “Documentation for the virtual items in the ZYTO 5 Software and the EVOX phrases is not necessary as the process of creating them is definitional—the unique identifier virtual item name is created \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” We do not agree that documentation demonstrating validation for the virtual items in the ZYTO 5 Software is unnecessary. Medical devices and software controlling them require design validation under 21 CFR Part 820.30.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. You have not conducted design reviews as required by 21 CFR 820.30(e), and your procedure, SOP-00301 Design Control and Project Management, rev K, eff 12\u002F21\u002F2020.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your procedure describes design reviews as a documented, comprehensive, systematic examination of a design to evaluate the adequacy of the design requirements, to evaluate the capability of the design to meet these requirements and to identify problems at appropriate stages of the process. Your procedure also states that these should be documented in the DHF.\u003C\u002Fp>\n\n\u003Cp>The DHF for the ZYTO Hand Cradle GSR, DHF-00664, shows the Design Review is “in process” with no associated file or date. The DHF is signed as approved as of 6\u002F8\u002F2021; however, you do not have a documented design review as required by 21 CFR 820.30(e). You have been marketing this product since at least 2019 with no evidence that this design review requirement has been met.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response and determined your response is inadequate as it does not address why the design review was not completed, why the DHF was signed and approved when the design reviews showed as “In Progress”, and corrective actions are not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019 and promised corrections at that time.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. You failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Corrective and Preventive Actions (CAPA) procedure, SOP-01002, requires assignees to investigate the identified issue(s) to uncover and eliminate potential causes as identified in the CAPA and document their activities. You failed to implement the requirements of your procedure. For example, CAPA records 091719001 and 052720001 were opened based on customer complaints. The related ZYTO Hand Cradle GSRs were replaced, and the records state NCR testing was conducted but neither record shows the cause of the ZYTO Hand Cradle GSR shocking the patient \u002F user or what action should be taken to prevent recurrence. In your uncontrolled testing record titled “Subject Hand Cradle: \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hand Cradle Tested” tied to a related complaint serial number, you confirmed a user was shocked during your own internal testing. Yet still no investigation was performed to see what caused the ZYTO Hand Cradle GSR to shock patients \u002F users. Instead, the record states the customer account was terminated, and therefore no follow up is needed. The other CAPA associated complaint record says the customer was happy with their replacement; however, replacing one ZYTO Hand Cradle GSR with another does not address the need to identify the nonconformity or underlying quality problem causing the ZYTO Hand Cradle GSR to shock patients \u002F users, or the need to identify the action(s) needed to correct and prevent recurrence, which are required by 21 CFR 820.100(a)(2) and (3), respectively.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. You failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Additionally, SOP-01002 requires CAPA investigations to address and monitor the effectiveness of the actions taken. You failed to implement the requirements of your procedure. For example, six CAPA records were opened as a result of past FDA observations in 2019. Despite having dates and initials documented, all six of these are blank or show “ongoing work” in the verification of effectiveness column regarding \u003Cem>what action\u003C\u002Fem> needs to be taken to ensure effectiveness and no adverse effect of corrective action, in accordance with the SOP and 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>We reviewed your response and we cannot determine its adequacy as your corrective actions, including root cause analysis and verification of effectiveness, are in progress and not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately establish procedures for complaint handling per the requirements of 21 CFR Part 820.198, including an evaluation to determine reportability under 21 CFR Part 803 (Medical Device Reporting), and to document complaint investigations or a record including the reason when no investigation is performed.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your SOP-01980, Complaint and MDR System, rev G, eff 8\u002F19\u002F2021, in accordance with 21 CFR 820.198(a)(3), requires an evaluation of complaints to determine whether a medical device report (MDR) is required. Additionally, 21 CFR Part 820.198(b) requires evaluation of complaints to determine whether an investigation is necessary and a record of justification if a complaint does not require investigation.\u003C\u002Fp>\n\n\u003Cp>At least four complaints reviewed during our inspection which were handled using your current complaint handling software and under the current SOP did not include either a documented investigation or a justification for lack thereof and did not include any documented MDR determination. These were complaints of the ZYTO Hand Cradle GSR not scanning, hardware connectivity issues causing the device not to perform scans, and the hand cradle not connecting with some clients which meet both FDA’s definition of a complaint under 21 CFR Part 820.3(b) as well as your procedure’s definition. Additionally, complaints under your previous complaint handling software system related to shocking of patients and users were observed without documented investigations or a written justification.\u003C\u002Fp>\n\n\u003Cp>Section 8.2.2 of the current SOP specifically excludes libraries and biosurveys from the complaint handling process. Since these are functions of the software that controls the ZYTO Hand Cradle GSR, related complaints should be documented, reviewed, and evaluated and, if necessary, investigated per the regulatory requirements set forth in 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response which states you will update procedures to ensure all complaints for the ZYTO Hand Cradle GSR hardware and software will undergo root cause analysis, define types of complaints that should require an MDR Questionnaire, and define instructions on how to do so in your new system. We have concluded that your response is inadequate because your corrective actions do not include a retrospective review of cases outside those identified by our Investigator, and corrective actions are not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019 and promised corrections at that time.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to adequately establish a procedure to ensure DHRs are maintained to demonstrate the device is manufactured in accordance with the DMR, per the requirements of 21 CFR Part 820.184.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your SOP-01840, Device History Record (DHR) Procedure, rev L, eff 6\u002F15\u002F2020, states that samples of labels and labeling will be verified in the approved folder of the Document Management System, but does not require inclusion in the DHR of the primary identification label and labeling used for each production unit or the unique device identifier (UDI), or the location of the label, labeling or UDI. 21 CFR 820.184 requires that the DHR include or refer to the location of these items. All 11 DHRs reviewed during our recent inspection were missing this information.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time as no evidence of corrective actions has been provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to develop, maintain, and implement written labeling procedures to control UDI labeling activities pursuant to 21 CFR 820.120.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your primary label includes an UDI, yet your firm has not established and maintained procedures to control labeling activities to include performing a labeling inspection to ensure the \u003Cem>correct\u003C\u002Fem> UDI is present. Your Quality Supervisor told our investigator that you do not have any UDI procedures and your SOP-01201 Labeling and Packaging Controls, Rev D, eff 12\u002F21\u002F2020, does not include UDI.\u003C\u002Fp>\n\n\u003Cp>We are requesting that you submit to oradevices3firmresponse@fda.hhs.gov on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device quality systems (QS) regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Initial certifications by consultant and establishment – 12\u002F21\u002F2023\u003C\u002Fli>\n\t\u003Cli>Subsequent certifications – 12\u002F23\u002F2024 and 12\u002F22\u002F2025\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. The ZYTO Hand Cradle GSR is adulterated and misbranded, and we request that you immediately cease any marketing of this product and its accessories. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) working days from the date you receive this letter of the specific steps you have taken to correct the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrective action (which must address systemic problems) you have taken. If your planned corrections will occur over time, please include a timetable for implementation of those corrections. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. This letter notifies you of our findings and provides you an opportunity to address the above deficiencies.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS 652316\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violation(s) at your facility. It is your responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violation(s) noted in this letter and in the Inspectional Observations, FDA 483, issued at the closeout of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality assurance systems. Your firm should investigate and determine the causes of the violation(s) and take prompt actions to correct the violation(s) and to bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Nina Mezu‐Nwaba, Deputy Director\u003Cbr>\nOffice of Health Technology 5 – Office of\u003Cbr>\nNeurological and Physical Medical Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh, Program Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\n\u003Cbr>\nCc: Ms. Kami J. Howard, President and CEO\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDr. Vaughn R. Cook\n\nRecipient Title\n\nChairman and Owner\u002FFounder\n\nZYTO Technologies, Inc.\n\n1172 W. 700 N., Suite 300\n\nLindon, UT 84042\n\nUnited States\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS 652316\n\nJune 21, 2023\n\nDear Dr. Cook,\n\nDuring an inspection of your firm located in Lindon, UT on December 5 through 13, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ZYTO Hand Cradle Galvanic Skin Response (GSR) device and associated proprietary software used to scan a patient to identify “stressors” and “balancers.” Your website refers to using the ZYTO as part of a “journey to wellness.\" However, some of the “stressors” identified or diagnosed by the ZYTO Hand cradle and associated proprietary software include diseases and conditions such as Alzheimer’s disease, human immunodeficiency virus (HIV), Parkinson’s disease and melanoma, and some of the “balancers” recommended by the software represent specific treatments or mitigations for a given “stressor.” Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\n\nOur inspection revealed that the ZYTO Hand Cradle GSR and associated proprietary software is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. 352(o), because you did not notify the agency of your intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.\n\nThe ZYTO Hand Cradle was cleared under K111308 with the following intended use: “the measurement of galvanic skin response (GSR).” However, your firm’s promotion of the device represents a major change or modification to its intended use, for which your firm lacks clearance or approval. Thus, although originally classified as Class II under 21 CFR 882.1540, the device does not qualify for the exemption from 510(k) granted in 2019 for that generic type of device (see 84 FR 71794 (December 30, 2019)) because, among other things, the device “is intended for a use different from the intended use of a legally marketed device in that generic type of device.” See 21 CFR 882.9(a).\n\nFurther, as we informed you previously, the ZYTO associated proprietary software is a component of the ZYTO Hand Cradle and shares its classification.\n\nIn our June 11, 2015, correspondence after the Warning Letter, we stated that per 21 CFR, part 820.3(c), the definition of a component includes software intended to be included as part of a finished, packaged, labeled device. Components of a device are defined as the device itself. The letter further states “…The software, downloaded by end users for the intention of use with your device is considered a component.”\n\nPer our Regulatory Meeting, held August 28, 2015, you were informed again that our review found that your associated proprietary software was intended to be used with the ZYTO Hand Cradle GSR device. You were informed that because the ZYTO Hand Cradle GSR and the software did not function alone but must be used together, the software was a component of the device.\n\nThis continues to be the case. For example, your website explains how the ZYTO Hand Cradle GSR and the associated proprietary software function together as follows:\n\n“The ZYTO Hand Cradle measures the user’s galvanic skin response and sends that data directly to the ZYTO software for analysis. The [galvanic skin responses] GSR data is correlated and compared with Virtual Items in the software database.”\n\n“Each Virtual Item represents a different physical item. Every time the software introduces a Virtual Item, a corresponding GSR reading is taken by the Hand Cradle. Each new response is measured and tracked in comparison to the GSR baseline reading.”\n\nOur investigator documented that the virtual items are added to the library in-house using a machine referred to as the “Tower”. Your representative explained that to create a library item, your firm places the item in front of the Tower and the Tower then scans and identifies the item with a generated code from the system which it associates with the energy of that item. This becomes a virtual library item. In addition, your firm’s promotional materials indicate that the hand cradle can now perform this function as well, so that users can add their own virtual items.\n\nYour website further states:\n\n“ZYTO’s proprietary software analyzes GSR data for patterns of coherence—looking for the ways your GSR readings fluctuate or shift in response to each Virtual Item.”\n\nYour proprietary software is a component of the ZYTO Hand Cradle GSR.\n\nYour firm is promoting the ZYTO Hand Cradle GSR and associated proprietary software outside its cleared intended use.\n\nThe ZYTO Hand Cradle Galvanic Skin Response System was cleared under K111308 only to measure galvanic skin responses. Despite prior notice from FDA in your 2015 Warning Letter and some corrections made around that time, your firm has added back promotion of the ZYTO Hand Cradle GSR for use in diagnosing diseases or conditions, including determining whether someone responds to a specific allergen, and continues to predict biological responses to a wide range of virtual stimuli including homeopathic nosodes and nutritional supplements.\n\nFor example, your current website explains that first the system scans for general categories of “Biomarkers” which might be specific locations or anatomy of the body such as organs, muscles, or bones. Next, there is a subset of “Stressor” virtual items which are scanned for, including heavy metals, bacteria, parasites, viruses, electromagnetic fields, chemicals, allergens, lifestyle choices, and foods.\n\nWhile a scan may consist of only a stressor Virtual Item scan to reveal which items may warrant further attention, a balancer Virtual Item scan often follows to determine which items bring the stressors into range. The website further states ZYTO software contains thousands of “Balancer” Virtual Items from over 250 health and wellness companies in these categories: supplements, essential oils, homeopathics, herbs, flower essences, or topicals.\n\nMost importantly, your virtual item library identifies items which you describe could be stressors or balancers including, but not limited to:\n\n• Alzheimer’s\n\n• E. coli\n\n• Ebola\n\n• Fibromyalgia\n\n• Flu\n\n• Hepatitis (A, B, C, D, and E)\n\n• Herpes, various forms\n\n• Human immunodeficiency virus (HIV)\n\n• Leukemia, various forms and related nosodes\n\n• Lupus, various forms\n\n• Lymphoma, Melanoma\n\n• Parkinson’s disease\n\n• Staphylococcus aureus\n\n• Zika viruses\n\n• Food allergen’s including but not limited to soy, milk, eggs, peanuts, flaxseed, and fish\n\n• Environmental allergens including but not limited to “Bee Pollen”\n\n• Homeopathic nosodes to above listed disease states, such as but not limited to: asthma, cholera, hepatitis, lupus, infant botulism, scarlet fever, malignant rectal polyps, uterine polyps, leukemia, polio, rabies, and Parkinson’s disease.\n\n1. You have added disease claims back to your software library. The “stressors” identified or diagnosed by the ZYTO Hand cradle and associated proprietary software include diseases and conditions such as Alzheimer’s, HIV, Parkinson’s disease and melanoma, and the identification of these by the device amount to diagnoses. These uses fall outside the device’s cleared intended use to measure galvanic skin response and constitute a major change or modification to the device’s intended use, for which your firm lacks clearance or approval.\n\n2. Your firm continues to market the ZYTO Hand Cradle GSR to predict biological responses to a range of virtual stimuli, as discussed in your 2015 Warning Letter. The “balancers” recommended by the software for the “stressors” represent specific treatments, mitigations, or suggestions to prevent such diseases and conditions. You’ve been notified this represents a major change or modification to the device’s intended use for which your firm lacks clearance or approval.\n\nThe promotion of the ZYTO Hand Cradle GSR and associated proprietary software in examples 1 - 2 above for use in diagnosing a disease or condition, including determining whether someone responds to a specific allergen, and predicting biological responses to a wide range of virtual stimuli, including homeopathic nosodes or nutritional supplements, fall outside the device’s cleared intended use to measure galvanic skin response and constitute major changes or modifications to the device’s intended use.\n\nObservations Pertaining to Quality System Regulations\n\nThe December 2022 inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. As noted above, your proprietary software which works with the ZYTO Hand Cradle GSR is a component of the ZYTO Hand Cradle GSR. Thus, it is subject to all applicable regulatory requirements, including design controls.\n\nWe received a response from Mr. Ford dated January 5, 2023, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. While reviewing this letter, be aware FDA defines “establish” to include actions to define, document, and implement. The violations include, but are not limited to, the following:\n\n1. Failure to adequately establish procedures for design controls, as required by 21 CFR 820.30.\n\nA. You have not conducted design verification and validation testing per the requirements of 21 CFR 820.30(f) and 820.30(g), and your SOP-00302 Design Verification and Validation, rev D, eff 12\u002F14\u002F2020, for the ZYTO Hand Cradle GSR and associated proprietary software, or the device library development processes used in house and by customers.\n\nSOP-00302 requires you to perform design verification to provide objective evidence that specified requirements have been fulfilled, to confirm that the design output meets the design input requirements, and to document results in the design history file (DHF). It also requires you to perform design validation to establish objective evidence that device specifications conform to user needs and intended use(s). The procedure states you shall include software validation and risk analysis, where appropriate, and activities shall be documented in the DHF.\n\ni. You failed to verify or validate the ZYTO Hand Cradle GSR and associated proprietary software.\n\nDuring our inspection, you provided the Hardware Verification and Validation (TR-00370, Rev. A, eff 06\u002F03\u002F2021) noted in DHF-00664 for the ZYTO Hand Cradle GSR. TR-00370 states these “procedures are not intended to test the engineering of the hand cradle. Instead, they focus on the software’s interactions with the hardware.” TR-00370 defines the testing procedures used to verify the hardware software user interface requirements, as specified in SRS-00288. SRS-00288 includes a (b)(4) protocol to test the (b)(4) between the software and ZYTO Hand Cradle GSR. However, your Quality Supervisor stated your firm has no documented evidence to provide to demonstrate this testing was actually performed. She further stated you have no evidence to verify that design outputs meet design inputs. Despite no evidence of conducting this testing, the DHF shows TR-00370 as “Approved” on 6\u002F3\u002F2021.\n\nYour firm’s attorney stated that you have no documented validation of the virtual items in the ZYTO software.\n\nYour firm also received a complaint of an “abnormal” or “empty” scan “where no stressors were found out of range, but many products were recommended for use.\n\nWe reviewed your response regarding observation 1 and the completion of the DHF activities and understand that you will review TR-00370 and SRS-00288 to confirm verification and validation that design outputs meet the design inputs to be completed by 6\u002F30\u002F23, subject to “Development availability”. We reviewed your response and determined your response is inadequate, as evidence of corrective actions to this observation were not provided. Additionally, corrective actions were not planned for completion until over six months after the inspection concluded, yet you were notified of this violation both during our August 2015 Regulatory Meeting and again during your 2019 inspection, and at that time you promised corrections.\n\nii. You failed to validate the ZYTO Tower or Hand Cradle GSR for addition of virtual library items.\n\nThe Tower is used in-house for the transmission, interpretation, and creation of virtual library items. This has not been validated. Currently, your firm has directed customers to use the ZYTO Hand Cradle GSR to add new virtual library items for biological preference prediction. We observed your firm’s promotional materials indicate you have replicated the prior functionality of the Tower with what you describe as an antenna inside the ZYTO Hand Cradle GSR. Your website contains videos with instructions (in both the Immunity Biosurvey and the Digestive Biosurvey) on how to use the ZYTO Hand Cradle GSR to perform the same function as the Tower by your clients. This use of the ZYTO Hand Cradle GSR for the transmission, interpretation, and creation of virtual library items has also not been validated.\n\nDuring our inspection, your firm’s attorney stated you have no documented validation of use of the Tower to identify and add virtual items to the library. He further stated there would be no way to test the process used to input these virtual items.\n\nWe reviewed your response specific to the validation of “ZYTO 5 Software and the EVOX phrases” and documentation of virtual items (currently done in house by the Tower) and determined it is inadequate as your recent response states “Documentation for the virtual items in the ZYTO 5 Software and the EVOX phrases is not necessary as the process of creating them is definitional—the unique identifier virtual item name is created (b)(4).” We do not agree that documentation demonstrating validation for the virtual items in the ZYTO 5 Software is unnecessary. Medical devices and software controlling them require design validation under 21 CFR Part 820.30.\n\nB. You have not conducted design reviews as required by 21 CFR 820.30(e), and your procedure, SOP-00301 Design Control and Project Management, rev K, eff 12\u002F21\u002F2020.\n\nYour procedure describes design reviews as a documented, comprehensive, systematic examination of a design to evaluate the adequacy of the design requirements, to evaluate the capability of the design to meet these requirements and to identify problems at appropriate stages of the process. Your procedure also states that these should be documented in the DHF.\n\nThe DHF for the ZYTO Hand Cradle GSR, DHF-00664, shows the Design Review is “in process” with no associated file or date. The DHF is signed as approved as of 6\u002F8\u002F2021; however, you do not have a documented design review as required by 21 CFR 820.30(e). You have been marketing this product since at least 2019 with no evidence that this design review requirement has been met.\n\nWe reviewed your response and determined your response is inadequate as it does not address why the design review was not completed, why the DHF was signed and approved when the design reviews showed as “In Progress”, and corrective actions are not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019 and promised corrections at that time.\n\n2. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\n\nA. You failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems.\n\nSpecifically, your Corrective and Preventive Actions (CAPA) procedure, SOP-01002, requires assignees to investigate the identified issue(s) to uncover and eliminate potential causes as identified in the CAPA and document their activities. You failed to implement the requirements of your procedure. For example, CAPA records 091719001 and 052720001 were opened based on customer complaints. The related ZYTO Hand Cradle GSRs were replaced, and the records state NCR testing was conducted but neither record shows the cause of the ZYTO Hand Cradle GSR shocking the patient \u002F user or what action should be taken to prevent recurrence. In your uncontrolled testing record titled “Subject Hand Cradle: (b)(4) Hand Cradle Tested” tied to a related complaint serial number, you confirmed a user was shocked during your own internal testing. Yet still no investigation was performed to see what caused the ZYTO Hand Cradle GSR to shock patients \u002F users. Instead, the record states the customer account was terminated, and therefore no follow up is needed. The other CAPA associated complaint record says the customer was happy with their replacement; however, replacing one ZYTO Hand Cradle GSR with another does not address the need to identify the nonconformity or underlying quality problem causing the ZYTO Hand Cradle GSR to shock patients \u002F users, or the need to identify the action(s) needed to correct and prevent recurrence, which are required by 21 CFR 820.100(a)(2) and (3), respectively.\n\nB. You failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device.\n\nAdditionally, SOP-01002 requires CAPA investigations to address and monitor the effectiveness of the actions taken. You failed to implement the requirements of your procedure. For example, six CAPA records were opened as a result of past FDA observations in 2019. Despite having dates and initials documented, all six of these are blank or show “ongoing work” in the verification of effectiveness column regarding what action needs to be taken to ensure effectiveness and no adverse effect of corrective action, in accordance with the SOP and 21 CFR 820.100(a)(4).\n\nWe reviewed your response and we cannot determine its adequacy as your corrective actions, including root cause analysis and verification of effectiveness, are in progress and not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019.\n\n3. Failure to adequately establish procedures for complaint handling per the requirements of 21 CFR Part 820.198, including an evaluation to determine reportability under 21 CFR Part 803 (Medical Device Reporting), and to document complaint investigations or a record including the reason when no investigation is performed.\n\nSpecifically, your SOP-01980, Complaint and MDR System, rev G, eff 8\u002F19\u002F2021, in accordance with 21 CFR 820.198(a)(3), requires an evaluation of complaints to determine whether a medical device report (MDR) is required. Additionally, 21 CFR Part 820.198(b) requires evaluation of complaints to determine whether an investigation is necessary and a record of justification if a complaint does not require investigation.\n\nAt least four complaints reviewed during our inspection which were handled using your current complaint handling software and under the current SOP did not include either a documented investigation or a justification for lack thereof and did not include any documented MDR determination. These were complaints of the ZYTO Hand Cradle GSR not scanning, hardware connectivity issues causing the device not to perform scans, and the hand cradle not connecting with some clients which meet both FDA’s definition of a complaint under 21 CFR Part 820.3(b) as well as your procedure’s definition. Additionally, complaints under your previous complaint handling software system related to shocking of patients and users were observed without documented investigations or a written justification.\n\nSection 8.2.2 of the current SOP specifically excludes libraries and biosurveys from the complaint handling process. Since these are functions of the software that controls the ZYTO Hand Cradle GSR, related complaints should be documented, reviewed, and evaluated and, if necessary, investigated per the regulatory requirements set forth in 21 CFR 820.198.\n\nWe have reviewed your response which states you will update procedures to ensure all complaints for the ZYTO Hand Cradle GSR hardware and software will undergo root cause analysis, define types of complaints that should require an MDR Questionnaire, and define instructions on how to do so in your new system. We have concluded that your response is inadequate because your corrective actions do not include a retrospective review of cases outside those identified by our Investigator, and corrective actions are not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019 and promised corrections at that time.\n\n4. Failure to adequately establish a procedure to ensure DHRs are maintained to demonstrate the device is manufactured in accordance with the DMR, per the requirements of 21 CFR Part 820.184.\n\nSpecifically, your SOP-01840, Device History Record (DHR) Procedure, rev L, eff 6\u002F15\u002F2020, states that samples of labels and labeling will be verified in the approved folder of the Document Management System, but does not require inclusion in the DHR of the primary identification label and labeling used for each production unit or the unique device identifier (UDI), or the location of the label, labeling or UDI. 21 CFR 820.184 requires that the DHR include or refer to the location of these items. All 11 DHRs reviewed during our recent inspection were missing this information.\n\nThe adequacy of your firm’s response cannot be determined at this time as no evidence of corrective actions has been provided.\n\n5. Failure to develop, maintain, and implement written labeling procedures to control UDI labeling activities pursuant to 21 CFR 820.120.\n\nSpecifically, your primary label includes an UDI, yet your firm has not established and maintained procedures to control labeling activities to include performing a labeling inspection to ensure the correct UDI is present. Your Quality Supervisor told our investigator that you do not have any UDI procedures and your SOP-01201 Labeling and Packaging Controls, Rev D, eff 12\u002F21\u002F2020, does not include UDI.\n\nWe are requesting that you submit to oradevices3firmresponse@fda.hhs.gov on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device quality systems (QS) regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\n\nInitial certifications by consultant and establishment – 12\u002F21\u002F2023\n\nSubsequent certifications – 12\u002F23\u002F2024 and 12\u002F22\u002F2025\n\nYour firm should take prompt action to address any violations identified in this letter. The ZYTO Hand Cradle GSR is adulterated and misbranded, and we request that you immediately cease any marketing of this product and its accessories. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen (15) working days from the date you receive this letter of the specific steps you have taken to correct the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrective action (which must address systemic problems) you have taken. If your planned corrections will occur over time, please include a timetable for implementation of those corrections. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. This letter notifies you of our findings and provides you an opportunity to address the above deficiencies.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS 652316 when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violation(s) at your facility. It is your responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violation(s) noted in this letter and in the Inspectional Observations, FDA 483, issued at the closeout of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality assurance systems. Your firm should investigate and determine the causes of the violation(s) and take prompt actions to correct the violation(s) and to bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Nina Mezu‐Nwaba, Deputy Director\n\nOffice of Health Technology 5 – Office of\n\nNeurological and Physical Medical Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh, Program Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nCc: Ms. Kami J. Howard, President and CEO","ZYTO Technologies, Inc.","zyto-technologies-inc-652316-06212023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyto-technologies-inc-652316-06212023","2026-10-26T08:10:40.338776+00:00","2023-07-11","652316","Division of Medical Device and Radiological Health Operations West","Dr. Vaughn R. Cook","2026-08-20T00:55:45.601+00:00","2023-06-21",{"id":309,"raw":310,"subject":83,"body_html":314,"body_text":315,"firm_name":316,"letter_id":317,"created_at":66,"fei_number":19,"letter_url":318,"updated_at":319,"action_type":22,"case_status":23,"posted_date":320,"marcs_cms_no":321,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":322,"body_fetched_at":323,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":320,"medical_device_id":19,"response_letter_date":19},2092,[311,312,313,82,83,13,13,13],"\u003Ctime datetime=\"2023-05-25T13:20:00Z\">05\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-25T04:00:00Z\">05\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-innokin-technology-co-ltd-657347-05252023\">Shenzhen Innokin Technology Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tao Cui\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Shenzhen Innokin Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@innokin.com\"> sales@innokin.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:marketing@innokin.com\"> marketing@innokin.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@innokin.com\"> support@innokin.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@innokin.com\"> info@innokin.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 25, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Tao Cui:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.innokin.com, and additional information, and determined that electronic nicotine delivery system (ENDS) products are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)), and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.innokin.com, and additional information, revealed that you manufacture and deliver ENDS products without a marketing authorization order. Specifically, Shenzhen Innokin Technology Co., Ltd. distributes the products, including those listed below, in the United States to retailers listed on https:\u002F\u002Fwww.innokin.com. Shenzhen Innokin Technology Co., Ltd. owns and operates the website https:\u002F\u002Fwww.innokin.com, which identifies retailers that sell those products and directs consumers to those retailers. Such retailers, which are found in the “US Authorized Distributors” webpage of https:\u002F\u002Fwww.innokin.com, include MadVapes (https:\u002F\u002Fmadvapes.com). ENDS products offered for sale or distribution within the United States on https:\u002F\u002Fmadvapes.com include: Esco Bars H2O 6000 – Disposable – Mango Lassi and Esco Bars H20 6000 – Disposable – Strawberry Milkshake.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm delivers new tobacco products lacking premarket authorization for introduction into interstate commerce in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring the tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301916, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Pastel Cartel LLC and American Vape Company, LLC\u003Cbr>\nAttn: Darrell Suriff\u003Cbr>\n13326 Immanuel Road\u003Cbr>\nPflugerville, TX 78660\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>MadVapes\u003Cbr>\n130 Oak Park Dr, Suite A\u003Cbr>\nMooresville, NC 28115\u003Cbr>\nsupport@madvapes.com\u003C\u002Fp>\n\n\u003Cp>Nice Line Inc.\u003Cbr>\n19120 The Glebe Lane\u003Cbr>\nCharles City, VA 23030\u003C\u002Fp>\n\n\u003Cp>Alibaba Cloud Computing (Beijing) Co., Ltd.\u003Cbr>\nDomainAbuse@service@aliyun.com\u003C\u002Fp>\n\n\u003Cp>HubSpot, Inc.\u003Cbr>\nabuse@hubspot.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nTao Cui\n\nShenzhen Innokin Technology Co., Ltd.\n\nChina\n\n(b)(6)\n\nsales@innokin.com\n\nmarketing@innokin.com\n\nsupport@innokin.com\n\ninfo@innokin.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 25, 2023\n\nWARNING LETTER\n\nDear Tao Cui:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.innokin.com, and additional information, and determined that electronic nicotine delivery system (ENDS) products are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)), and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.innokin.com, and additional information, revealed that you manufacture and deliver ENDS products without a marketing authorization order. Specifically, Shenzhen Innokin Technology Co., Ltd. distributes the products, including those listed below, in the United States to retailers listed on https:\u002F\u002Fwww.innokin.com. Shenzhen Innokin Technology Co., Ltd. owns and operates the website https:\u002F\u002Fwww.innokin.com, which identifies retailers that sell those products and directs consumers to those retailers. Such retailers, which are found in the “US Authorized Distributors” webpage of https:\u002F\u002Fwww.innokin.com, include MadVapes (https:\u002F\u002Fmadvapes.com). ENDS products offered for sale or distribution within the United States on https:\u002F\u002Fmadvapes.com include: Esco Bars H2O 6000 – Disposable – Mango Lassi and Esco Bars H20 6000 – Disposable – Strawberry Milkshake.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, these products are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm delivers new tobacco products lacking premarket authorization for introduction into interstate commerce in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring the tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301916, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nPastel Cartel LLC and American Vape Company, LLC\n\nAttn: Darrell Suriff\n\n13326 Immanuel Road\n\nPflugerville, TX 78660\n\n(b)(6)\n\nMadVapes\n\n130 Oak Park Dr, Suite A\n\nMooresville, NC 28115\n\nsupport@madvapes.com\n\nNice Line Inc.\n\n19120 The Glebe Lane\n\nCharles City, VA 23030\n\nAlibaba Cloud Computing (Beijing) Co., Ltd.\n\nDomainAbuse@service@aliyun.com\n\nHubSpot, Inc.\n\nabuse@hubspot.com","Shenzhen Innokin Technology Co., Ltd.","shenzhen-innokin-technology-co-ltd-657347-05252023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-innokin-technology-co-ltd-657347-05252023","2026-10-26T08:09:56.523417+00:00","2023-05-25","657347","Tao Cui","2026-08-20T01:06:10.108+00:00",{"id":325,"raw":326,"subject":83,"body_html":328,"body_text":329,"firm_name":330,"letter_id":331,"created_at":66,"fei_number":19,"letter_url":332,"updated_at":333,"action_type":22,"case_status":23,"posted_date":206,"marcs_cms_no":334,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":19,"body_fetched_at":335,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":206,"medical_device_id":19,"response_letter_date":19},2346,[197,198,327,82,83,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-quawins-technology-co-ltd-645113-11162022\">Shenzhen Quawins Technology Co., Ltd\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Shenzhen Quawins Technology Co., Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@quawins.com\"> info@quawins.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:customerservice@quawins.com\"> customerservice@quawins.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 16, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.quawins.com and determined that the electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.quawins.com revealed that you manufacture and offer for sale or distribution to customers in the United States the ENDS products without a marketing authorization order, including: Quawins VFUN Disposable Kit with Rainbow Flash Light, Quawins VFUN PLUS D1 Disposable Kit 3500 Puffs, Quawins VFUN D2 Disposable Kit 1000 Puffs, and Quawins Cocktail D1 DV Panda 3000 Puffs Dual Flavor Disposable Kit.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds your products particularly concerning because the product labeling and\u002For advertising for Quawins VFUN Disposable Kit with Rainbow Flash Light, Quawins VFUN PLUS D1 Disposable Kit 3500 Puffs, Quawins VFUN D2 Disposable Kit 1000 Puffs, and Quawins Cocktail D1 DV Panda 3000 Puffs Dual Flavor Disposable Kit (see Exhibits A) are likely to promote use of the products by youth by imitating children’s products and\u002For featuring youth-appealing cartoons (see Exhibits B). Further, the packaging for the Quawins VFUN Disposable Kit with Rainbow Flash Light and Quawins VFUN D2 Disposable Kit 1000 Puffs are likely to promote the use of the product by youth because they help conceal the nature of the products as a tobacco products from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645113%20Glow%20Stick.PNG\" alt=\"Glow Sticks\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645113.png\" alt=\"BabyBus\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645113%20Glow%20Sticks.PNG\" alt=\"Glow Sticks\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645113%20BabyBus_0.PNG\" alt=\"BabyBusPink\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201872, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Alibaba Cloud Computing (Beijing) Co., Ltd\u003Cbr>\nDomainAbuse@service.aliyum.com\u003C\u002Fp>\n\n\u003Cp>Alibaba (Alicloud-US)\u003Cbr>\nintl-abuse@list.alibaba-inc.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nShenzhen Quawins Technology Co., Ltd\n\nChina\n\ninfo@quawins.com\n\ncustomerservice@quawins.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 16, 2022\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.quawins.com and determined that the electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.quawins.com revealed that you manufacture and offer for sale or distribution to customers in the United States the ENDS products without a marketing authorization order, including: Quawins VFUN Disposable Kit with Rainbow Flash Light, Quawins VFUN PLUS D1 Disposable Kit 3500 Puffs, Quawins VFUN D2 Disposable Kit 1000 Puffs, and Quawins Cocktail D1 DV Panda 3000 Puffs Dual Flavor Disposable Kit.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nAdditional Considerations\n\nFDA finds your products particularly concerning because the product labeling and\u002For advertising for Quawins VFUN Disposable Kit with Rainbow Flash Light, Quawins VFUN PLUS D1 Disposable Kit 3500 Puffs, Quawins VFUN D2 Disposable Kit 1000 Puffs, and Quawins Cocktail D1 DV Panda 3000 Puffs Dual Flavor Disposable Kit (see Exhibits A) are likely to promote use of the products by youth by imitating children’s products and\u002For featuring youth-appealing cartoons (see Exhibits B). Further, the packaging for the Quawins VFUN Disposable Kit with Rainbow Flash Light and Quawins VFUN D2 Disposable Kit 1000 Puffs are likely to promote the use of the product by youth because they help conceal the nature of the products as a tobacco products from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nIt is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201872, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nAlibaba Cloud Computing (Beijing) Co., Ltd\n\nDomainAbuse@service.aliyum.com\n\nAlibaba (Alicloud-US)\n\nintl-abuse@list.alibaba-inc.com","Shenzhen Quawins Technology Co., Ltd","shenzhen-quawins-technology-co-ltd-645113-11162022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-quawins-technology-co-ltd-645113-11162022","2026-10-26T08:09:56.653758+00:00","645113","2026-08-20T01:26:21.733+00:00",{"id":337,"raw":338,"subject":256,"body_html":343,"body_text":344,"firm_name":345,"letter_id":346,"created_at":347,"fei_number":19,"letter_url":348,"updated_at":349,"action_type":22,"case_status":23,"posted_date":350,"marcs_cms_no":351,"product_type":265,"closeout_date":19,"issuing_office":342,"recipient_name":352,"body_fetched_at":353,"delivery_method":354,"recipient_title":19,"reference_number":19,"action_taken_date":355,"medical_device_id":19,"response_letter_date":19},3550,[339,340,341,342,256,13,13,13],"\u003Ctime datetime=\"2021-02-09T14:20:00Z\">02\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-03T05:00:00Z\">02\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshangrao-chunyu-technology-co-ltd-610194-02032021\">ShangRao Chunyu Technology Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Daniel Suer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ShangRao Chunyu Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Xuri Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shangrao Economic-Technical Development Area\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shangrao Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangxi Sheng\u003C\u002Fspan>, \u003Cspan>334100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-24\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 3, 2021\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Suer:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as Instant – Hand Sanitizer – Moisturizing. This drug product was declared to be manufactured at your facility, Shangrao Chunyu Technology Co., Ltd., FEI 3015958566, at Xuri Zone, Shangrao Economic-Technical Development Area, Shangrao, Jiangxi 334100, China. Following an attempt to import Instant – Hand Sanitizer – Moisturizing into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Instant – Hand Sanitizer – Moisturizing, declared to be manufactured at your facility, is labeled to contain 75% of the active ingredient alcohol ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of only 58% ethanol volume\u002Fvolume. This hand sanitizer drug product is adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its label.\u003C\u002Fp>\n\n\u003Cp>CDC recommends\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>On September 8, 2020, FDA held a teleconference with you and Pragmatic Compliance, LLC, your registered U.S. Agent. We requested additional information concerning your CGMP operations, including test methods for your finished product. In your response, you provided your test method for release of finished hand sanitizer products. The method you submitted uses a \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;that is unsuitable for the testing of finished hand sanitizers that contain materials other than ethanol and water in their \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of this unsuitable device to test your finished hand sanitizer products violates CGMP requirements (see 21 CFR 211.160(b)(requiring the use of scientifically sound and appropriate test procedures to, among other things, assure that drug products conform to appropriate standards of identity, strength, quality, and purity).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 75% ethanol, in fact contained 58% ethanol.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• For all batches distributed to the U.S., provide a third-party analysis using validated test methods for ethanol content. For out-of-specification (OOS) batches, provide your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003Cbr>\n• A complete, comprehensive, and independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n\u003Cbr>\nThe subpotency of a drug product declared as manufactured at your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.2\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on November 6, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3015958566 and ATTN: Bryce Hammer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nJerry Doane\u003Cbr>\nPragmatic Compliance LLC\u003Cbr>\n15815 SW 11th Court Rd\u003Cbr>\nOcala, FL 34473-8916\u003C\u002Fp>\n\n\u003Cp>__________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of a hand sanitizer product declared as manufactured at your facility, a review of the drug product’s labeling further indicates that the product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Daniel Suer\n\nRecipient Title\n\nCEO\n\nShangRao Chunyu Technology Co., Ltd.\n\nXuri Zone\n\nShangrao Economic-Technical Development Area\n\nShangrao Shi\n\nJiangxi Sheng, 334100\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-24\n\nFebruary 3, 2021\n\nDear Mr. Suer:\n\nYour firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as Instant – Hand Sanitizer – Moisturizing. This drug product was declared to be manufactured at your facility, Shangrao Chunyu Technology Co., Ltd., FEI 3015958566, at Xuri Zone, Shangrao Economic-Technical Development Area, Shangrao, Jiangxi 334100, China. Following an attempt to import Instant – Hand Sanitizer – Moisturizing into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nAdulteration Violation\n\nInstant – Hand Sanitizer – Moisturizing, declared to be manufactured at your facility, is labeled to contain 75% of the active ingredient alcohol ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of only 58% ethanol volume\u002Fvolume. This hand sanitizer drug product is adulterated under section 501(c) of the FD&C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its label.\n\nCDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOn September 8, 2020, FDA held a teleconference with you and Pragmatic Compliance, LLC, your registered U.S. Agent. We requested additional information concerning your CGMP operations, including test methods for your finished product. In your response, you provided your test method for release of finished hand sanitizer products. The method you submitted uses a (b)(4) that is unsuitable for the testing of finished hand sanitizers that contain materials other than ethanol and water in their (b)(4). The use of this unsuitable device to test your finished hand sanitizer products violates CGMP requirements (see 21 CFR 211.160(b)(requiring the use of scientifically sound and appropriate test procedures to, among other things, assure that drug products conform to appropriate standards of identity, strength, quality, and purity).\n\nIn response to this letter, provide the following:\n\n• A detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 75% ethanol, in fact contained 58% ethanol.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• For all batches distributed to the U.S., provide a third-party analysis using validated test methods for ethanol content. For out-of-specification (OOS) batches, provide your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\n• A complete, comprehensive, and independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nThe subpotency of a drug product declared as manufactured at your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on November 6, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3015958566 and ATTN: Bryce Hammer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent\n\nJerry Doane\n\nPragmatic Compliance LLC\n\n15815 SW 11th Court Rd\n\nOcala, FL 34473-8916\n\n__________________________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of a hand sanitizer product declared as manufactured at your facility, a review of the drug product’s labeling further indicates that the product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","ShangRao Chunyu Technology Co., Ltd.","shangrao-chunyu-technology-co-ltd-610194-02032021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshangrao-chunyu-technology-co-ltd-610194-02032021","2026-10-26T08:09:55.989565+00:00","2021-02-09","610194","Mr. Daniel Suer","2026-08-20T03:24:38.691+00:00","VIA UPS","2021-02-03",{"id":357,"raw":358,"subject":363,"body_html":364,"body_text":365,"firm_name":366,"letter_id":367,"created_at":368,"fei_number":19,"letter_url":369,"updated_at":370,"action_type":22,"case_status":23,"posted_date":371,"marcs_cms_no":372,"product_type":265,"closeout_date":19,"issuing_office":362,"recipient_name":373,"body_fetched_at":374,"delivery_method":375,"recipient_title":19,"reference_number":376,"action_taken_date":377,"medical_device_id":19,"response_letter_date":19},22201,[359,360,361,362,363,13,13,13],"\u003Ctime datetime=\"2026-11-10T05:00:00Z\">11\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-29T04:00:00Z\">10\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchongqing-qiancan-technology-co-ltd-736416-10292026\">Chongqing Qiancan Technology Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-14\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wenjuan Li\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Sales Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chongqing Qiancan Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9-13, No. 8 Auxiliary, No. 505, Shangmao M. Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Duzhou SubDistrict\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Changshou Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chongqing Shi\u003C\u002Fspan>, \u003Cspan>400000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 29, 2026\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-14\u003C\u002Fp>\u003Cp>To Wenjuan Li:\u003C\u002Fp>\u003Cp>This warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>Your facility, Chongqing Qiancan Technology Co., Ltd. (hereafter CQT), FDA Establishment Identifier (FEI) # 3040333997 at 9-13, No. 8 Auxiliary, No. 505, Shangmao M. Road, Duzhou SubDistrict, Changshou District, Chongqing is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>A review of import records showed multiple shipments of API intended for prescription compounding into the U.S., which declared CQT as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\u003C\u002Fp>\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as having been manufactured at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Refusal to Provide Records\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 17, 2026, FDA sent an electronic records request to the contact email address on file in your registration. Your firm de-registered and discontinued your drug listing on June 29, 2026, one day prior to your reply on June 30, 2026, in which you stated that your firm was unable to meet FDA requirements. The requested records were never provided despite APIs manufactured by your firm being imported to the U.S. market and still being within expiry.\u003C\u002Fp>\u003Cp>Notably, your firm re-registered on July 13, 2026.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure the drugs you manufacture meet U.S. standards prior to distributing them into the U.S. supply chain.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 26, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>Until FDA is able to confirm your compliance with Current Good Manufacturing Practice and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at CQT, located at 9-13, No. 8 Auxiliary, No. 505, Shangmao M. Road, Duzhou SubDistrict, Changshou District, Chongqing coming into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\u003Cp>In response to this letter, you may submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3040333997 and ATTN: Marva Taylor in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: U.S. agent\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-14\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nWenjuan Li\n\nRecipient Title\n\nSales Director\n\nChongqing Qiancan Technology Co., Ltd.\n\n9-13, No. 8 Auxiliary, No. 505, Shangmao M. Road\n\nDuzhou SubDistrict\n\nChangshou Qu\n\nChongqing Shi, 400000\n\nChina\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 29, 2026\nWARNING LETTER\nReference number: 320-27-14\nTo Wenjuan Li:\nThis warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\nYour facility, Chongqing Qiancan Technology Co., Ltd. (hereafter CQT), FDA Establishment Identifier (FEI) # 3040333997 at 9-13, No. 8 Auxiliary, No. 505, Shangmao M. Road, Duzhou SubDistrict, Changshou District, Chongqing is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\nA review of import records showed multiple shipments of API intended for prescription compounding into the U.S., which declared CQT as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as having been manufactured at your facility.\nRefusal to Provide Records\nOn June 17, 2026, FDA sent an electronic records request to the contact email address on file in your registration. Your firm de-registered and discontinued your drug listing on June 29, 2026, one day prior to your reply on June 30, 2026, in which you stated that your firm was unable to meet FDA requirements. The requested records were never provided despite APIs manufactured by your firm being imported to the U.S. market and still being within expiry.\nNotably, your firm re-registered on July 13, 2026.\nIt is your responsibility to ensure the drugs you manufacture meet U.S. standards prior to distributing them into the U.S. supply chain.\nFDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 26, 2026.\nConclusion\nThe violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\nUntil FDA is able to confirm your compliance with Current Good Manufacturing Practice and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at CQT, located at 9-13, No. 8 Auxiliary, No. 505, Shangmao M. Road, Duzhou SubDistrict, Changshou District, Chongqing coming into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\nIn response to this letter, you may submit a request to schedule an FDA inspection.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3040333997 and ATTN: Marva Taylor in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: U.S. agent\n(b)(4)","Chongqing Qiancan Technology Co., Ltd.","chongqing-qiancan-technology-co-ltd-736416-10292026","2026-11-17T01:02:03.701861+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchongqing-qiancan-technology-co-ltd-736416-10292026","2026-11-17T01:02:19.806892+00:00","2026-11-10","736416","Wenjuan Li","2026-11-17T01:02:19.615+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-14","2026-10-29",{"id":379,"raw":380,"subject":384,"body_html":385,"body_text":386,"firm_name":387,"letter_id":388,"created_at":151,"fei_number":19,"letter_url":389,"updated_at":390,"action_type":22,"case_status":23,"posted_date":391,"marcs_cms_no":392,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":393,"body_fetched_at":394,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":395,"medical_device_id":19,"response_letter_date":19},1564,[381,382,383,11,384,13,13,13],"\u003Ctime datetime=\"2024-03-12T13:20:00Z\">03\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-26T05:00:00Z\">01\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnobles-medical-technology-ii-inc-673465-01262024\">Nobles Medical Technology II, Inc.\u003C\u002Fa>","Investigational Review Board (IRB)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anthony A. Nobles, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nobles Medical Technology II, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17072 Newhope Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fountain Valley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92708\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:anobles@noblesmedical.com\"> anobles@noblesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 26, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Nobles:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at Nobles Medical Technology II, Inc. from October 16, 2023, to October 20, 2023, by investigators from the FDA’s Office of Bioresearch Monitoring Operations (OBIMO). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch EL versus FDA approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent ischemic stroke,” for NobleStitch EL, Investigational Device Exemption (IDE), G180296, complied with applicable federal regulations. The NobleStitch EL is a device as that term is defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited.\u003C\u002Fp>\n\n\u003Cp>The inspection was conducted under a program designed to ensure that data and information contained in requests for IDEs, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\n\n\u003Cp>Our review of the inspection report prepared by the OBIMO revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions, which concerns requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an Inspectional Observations Form FDA-483 for your review and discussed the observations listed on the form with you. To date, your firm has not submitted a written response. The deviations noted on the Form FDA-483 and our subsequent review of the inspection report, are discussed below:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to ensure proper monitoring and Institutional Review Board (IRB) review and approval [21 CFR 812.40].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for providing investigators with the information they need to conduct the investigation properly and for ensuring proper monitoring of the investigation. You are also responsible for ensuring that IRB review and approval are obtained and that the IRB and FDA are promptly informed of significant new information about an investigation. Examples of your failure include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>a. You failed to provide investigators with necessary information to properly conduct the study, including but not limited to, signed protocols, investigational brochures, and labeling.\u003C\u002Fp>\n\n\u003Cp>b. You failed to ensure proper monitoring of the study. Examples include, but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Lack of a written monitoring plan and procedures describing how you will monitor the investigation, including how to handle protocol deviations and investigator noncompliance.\u003C\u002Fli>\n\t\u003Cli>Site monitoring reports do not include the documents reviewed, associated findings, and communications with site personnel, including whether your site monitoring included a comparison of source documents with Case Report Forms (CRFs), an essential component of a monitoring plan to ensure data integrity.\u003C\u002Fli>\n\t\u003Cli>Additionally, you failed to secure investigator signatures on CRFs in a timely manner per the Investigator Agreement Section 10.1 (Trial Documentation). For example, Investigator \u003Cstrong>(b)(6)\u003C\u002Fstrong> signed four CRFs eight to twelve months after their monitoring visits, and Investigators \u003Cstrong>(b)(6)\u003C\u002Fstrong> and \u003Cstrong>(b)(6)\u003C\u002Fstrong> did not sign nine and two CRFs, respectively, for monitoring visits to their sites.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>c. You failed to provide documentation of IRB approvals and continuing review for site \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and IRB approval for sites \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the protocol (versions 5 and 6) and the Amplatzer and NobleStitch CRFs.\u003C\u002Fp>\n\n\u003Cp>Proper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your failure to ensure that IRB review and approval was obtained at least annually, delays, or prevents the IRB from considering any changes in the research or research-related events and determining whether the human subject protection measures are adequate or need to be changed. Lastly, inadequate oversight of investigator activities can also significantly impact conduct of the study and therefore, the reliability of data generated in the study as well as the safety of study participants.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to select qualified investigators and monitors by training and experience for conducting of a study [812.43(a) and (d)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for selecting qualified investigators and monitors. Examples of your failure include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>a. You failed to ensure that clinical investigators were qualified by training and experience to conduct the study. During the inspection, you did not provide documentation, such as a curriculum vitae, to show that the clinical investigators were qualified to conduct this study.\u003C\u002Fp>\n\n\u003Cp>b. You did not provide documentation to support that you have the proper training and experience to appropriately monitor the study.\u003C\u002Fp>\n\n\u003Cp>The selection of qualified investigators and monitors is essential to ensure subjects’ safety and that your study is conducted properly in accordance with Good Clinical Practices.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to obtain a signed agreement from each participating investigator that includes a statement of the investigator’s commitment to conduct an investigation in accordance with the agreement, investigational plan, applicable FDA regulations, conditions of approval imposed by the reviewing IRB and conditions of approval imposed by the FDA [21 CFR 812.43(c)(4)(i)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for obtaining from each participating investigator a signed agreement that includes a statement of the investigator's commitment to conduct the investigation in accordance with the agreement, the investigational plan, and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB or FDA.\u003C\u002Fp>\n\n\u003Cp>While signed agreements were obtained of participating clinical investigators, they lack a statement of the investigator’s commitment to supervise all testing of the device involving human subjects. Obtaining signed agreements is important for ensuring that investigators participating in the clinical study are accountable for the conduct of the study.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to obtain from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement [21 CFR 812.43(c)(5)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor you are responsible for obtaining from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement.\u003C\u002Fp>\n\n\u003Cp>You failed to obtain a signed agreement that includes sufficient accurate financial disclosure information from each participating investigator. Specifically, you did not provide financial disclosure records for any site during your inspection. Obtaining accurate financial disclosure information is important for ensuring that there is no financial bias by any of your clinical investigators that may impact clinical study data.\u003C\u002Fp>\n\n\u003Cp>In addition to the above objectionable conditions found during the inspection of your U.S. sites, there were similar observations noted for your site in Italy, which is your largest enrolling site. These observations include inadequate study protocols, lack of investigator agreements, inadequate informed consent, inadequate adverse event reporting, inadequate investigational device tracking, and inadequate monitoring.\u003C\u002Fp>\n\n\u003Cp>All of these failures raise significant concerns regarding whether your study will yield credible and accurate data and whether the rights, safety and well-being of subjects are adequately protected. The consequences of these failures are evidenced by the decision to suspend your study and the numerous cycles of review of your annual reports for the IDE, where discrepant and unclear information has been provided regarding fundamental aspects of your study (e.g., reviewing IRBs and sites and numbers of enrolled\u002Fimplanted subjects) as well as safety and effectiveness information.\u003C\u002Fp>\n\n\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\n\n\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\u003C\u002Fp>\n\n\u003Cp>Your response should reference “CTS# G180296\u002FE003” and be sent via email to: Albert.Rodriguez@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>A copy of this letter has been sent to FDA’s OBIMO West via email ORABIMOW.Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\n\n\u003Cp>The Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, you may contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Soma Kalb, PhD\u003Cbr>\nDirector\u003Cbr>\nDivision of Clinical Policy and Quality\u003Cbr>\nOffice of Clinical Evidence &amp; Analysis\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAnthony A. Nobles, PhD\n\nRecipient Title\n\nChairman and CEO\n\nNobles Medical Technology II, Inc.\n\n17072 Newhope Street\n\nFountain Valley, CA 92708\n\nUnited States\n\nanobles@noblesmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nJanuary 26, 2024\n\nDear Dr. Nobles:\n\nThis Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at Nobles Medical Technology II, Inc. from October 16, 2023, to October 20, 2023, by investigators from the FDA’s Office of Bioresearch Monitoring Operations (OBIMO). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch EL versus FDA approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent ischemic stroke,” for NobleStitch EL, Investigational Device Exemption (IDE), G180296, complied with applicable federal regulations. The NobleStitch EL is a device as that term is defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited.\n\nThe inspection was conducted under a program designed to ensure that data and information contained in requests for IDEs, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\n\nOur review of the inspection report prepared by the OBIMO revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions, which concerns requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an Inspectional Observations Form FDA-483 for your review and discussed the observations listed on the form with you. To date, your firm has not submitted a written response. The deviations noted on the Form FDA-483 and our subsequent review of the inspection report, are discussed below:\n\n1. Failure to ensure proper monitoring and Institutional Review Board (IRB) review and approval [21 CFR 812.40].\n\nAs a sponsor, you are responsible for providing investigators with the information they need to conduct the investigation properly and for ensuring proper monitoring of the investigation. You are also responsible for ensuring that IRB review and approval are obtained and that the IRB and FDA are promptly informed of significant new information about an investigation. Examples of your failure include, but are not limited to, the following:\n\na. You failed to provide investigators with necessary information to properly conduct the study, including but not limited to, signed protocols, investigational brochures, and labeling.\n\nb. You failed to ensure proper monitoring of the study. Examples include, but are not limited to:\n\nLack of a written monitoring plan and procedures describing how you will monitor the investigation, including how to handle protocol deviations and investigator noncompliance.\n\nSite monitoring reports do not include the documents reviewed, associated findings, and communications with site personnel, including whether your site monitoring included a comparison of source documents with Case Report Forms (CRFs), an essential component of a monitoring plan to ensure data integrity.\n\nAdditionally, you failed to secure investigator signatures on CRFs in a timely manner per the Investigator Agreement Section 10.1 (Trial Documentation). For example, Investigator (b)(6) signed four CRFs eight to twelve months after their monitoring visits, and Investigators (b)(6) and (b)(6) did not sign nine and two CRFs, respectively, for monitoring visits to their sites.\n\nc. You failed to provide documentation of IRB approvals and continuing review for site (b)(4) and IRB approval for sites (b)(4) and (b)(4) for the protocol (versions 5 and 6) and the Amplatzer and NobleStitch CRFs.\n\nProper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\n\nFurthermore, your failure to ensure that IRB review and approval was obtained at least annually, delays, or prevents the IRB from considering any changes in the research or research-related events and determining whether the human subject protection measures are adequate or need to be changed. Lastly, inadequate oversight of investigator activities can also significantly impact conduct of the study and therefore, the reliability of data generated in the study as well as the safety of study participants.\n\n2. Failure to select qualified investigators and monitors by training and experience for conducting of a study [812.43(a) and (d)].\n\nAs a sponsor, you are responsible for selecting qualified investigators and monitors. Examples of your failure include, but are not limited to, the following:\n\na. You failed to ensure that clinical investigators were qualified by training and experience to conduct the study. During the inspection, you did not provide documentation, such as a curriculum vitae, to show that the clinical investigators were qualified to conduct this study.\n\nb. You did not provide documentation to support that you have the proper training and experience to appropriately monitor the study.\n\nThe selection of qualified investigators and monitors is essential to ensure subjects’ safety and that your study is conducted properly in accordance with Good Clinical Practices.\n\n3. Failure to obtain a signed agreement from each participating investigator that includes a statement of the investigator’s commitment to conduct an investigation in accordance with the agreement, investigational plan, applicable FDA regulations, conditions of approval imposed by the reviewing IRB and conditions of approval imposed by the FDA [21 CFR 812.43(c)(4)(i)].\n\nAs a sponsor, you are responsible for obtaining from each participating investigator a signed agreement that includes a statement of the investigator's commitment to conduct the investigation in accordance with the agreement, the investigational plan, and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB or FDA.\n\nWhile signed agreements were obtained of participating clinical investigators, they lack a statement of the investigator’s commitment to supervise all testing of the device involving human subjects. Obtaining signed agreements is important for ensuring that investigators participating in the clinical study are accountable for the conduct of the study.\n\n4. Failure to obtain from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement [21 CFR 812.43(c)(5)].\n\nAs a sponsor you are responsible for obtaining from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement.\n\nYou failed to obtain a signed agreement that includes sufficient accurate financial disclosure information from each participating investigator. Specifically, you did not provide financial disclosure records for any site during your inspection. Obtaining accurate financial disclosure information is important for ensuring that there is no financial bias by any of your clinical investigators that may impact clinical study data.\n\nIn addition to the above objectionable conditions found during the inspection of your U.S. sites, there were similar observations noted for your site in Italy, which is your largest enrolling site. These observations include inadequate study protocols, lack of investigator agreements, inadequate informed consent, inadequate adverse event reporting, inadequate investigational device tracking, and inadequate monitoring.\n\nAll of these failures raise significant concerns regarding whether your study will yield credible and accurate data and whether the rights, safety and well-being of subjects are adequately protected. The consequences of these failures are evidenced by the decision to suspend your study and the numerous cycles of review of your annual reports for the IDE, where discrepant and unclear information has been provided regarding fundamental aspects of your study (e.g., reviewing IRBs and sites and numbers of enrolled\u002Fimplanted subjects) as well as safety and effectiveness information.\n\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\n\nWithin 15 working days of receiving this letter, please provide documentation of the corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\n\nYour response should reference “CTS# G180296\u002FE003” and be sent via email to: Albert.Rodriguez@fda.hhs.gov.\n\nA copy of this letter has been sent to FDA’s OBIMO West via email ORABIMOW.Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\n\nThe Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn.\n\nIf you have any questions, you may contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\n\nSincerely yours,\n\n\u002FS\u002F\n\nSoma Kalb, PhD\n\nDirector\n\nDivision of Clinical Policy and Quality\n\nOffice of Clinical Evidence & Analysis\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Nobles Medical Technology II, Inc.","nobles-medical-technology-ii-inc-673465-01262024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnobles-medical-technology-ii-inc-673465-01262024","2026-10-26T08:09:34.338448+00:00","2024-03-12","673465","Anthony A. Nobles, PhD","2026-08-20T00:14:37.004+00:00","2024-01-26",41,{"510k":398,"classification":399,"enforcement":400,"event":401,"event_backfill":402,"pma":403,"warning_letter":404},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]